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CD47+ EXOSOMES FACILITATE EFFECTIVE TARGETING OF ONCOGENIC 
KRAS IN PANCREATIC CANCER 
 
 
Sushrut D. Kamerkar, BS 
Advisory Professor: Raghu Kalluri, MD, Ph.D. 
 
Despite the current standard of care, the prognosis for patients with 
pancreatic ductal adenocarcinoma (PDAC) remains dismal. Genetic analyses of 
PDAC show that mutations in the GTPase KRAS are encountered in the majority 
of patients that present with the disease, and are key drivers of cancer initiation, 
progression and metastasis. However, while it is recognized that the Ras 
mediated signaling pathway is a key mediator of PDAC progression, a direct and 
specific targeting of Ras has been elusive. Therefore, due to the indisputable 
evidence for the causal functional role of RAS in the biology of PDAC, new 
approaches to specifically and efficiently target it must be explored.  
 Currently, many different strategies to target oncogenic Ras, including 
RNA interference, are being explored. However, a major hurdle in employing 
specific RNAi constructs to inhibit Ras is the lack of an optimal delivery system. 
Therefore, we probed whether exosomes could function as an efficient carrier of 
RNAi molecules. Exosomes are nano-sized extracellular vesicles (40-150nm) 
with a membrane lipid bilayer that are released by all cells of the body and 
efficiently enter other cells. Therefore exosomes derived from normal fibroblast-
like mesenchymal cells were engineered to carry RNA interference molecules to 
specifically target oncogenic KRASG12D, a mutation identified in about 50% of 
   xiii 
patients with pancreatic cancer. Compared to liposomes, exosomes containing 
siRNA or shRNA specific to KrasG12D mRNA (iExosomes) targeted oncogenic 
Kras with an enhanced efficacy. iExosomes treatment suppressed tumor growth 
in multiple pre-established orthotopic human pancreatic cancer models, 
genetically engineered mouse models (GEMMs), as well as in a patient derived 
xenograft (PDX) model of pancreatic cancer, and significantly increased their 
overall survival. In addition we demonstrate that the enhanced efficacy 
iExosomes is in part due to enhanced survival of exosomes in the circulation, as 
compared to liposomes, which is mediated by CD47, a widely expressed integrin 
associated transmembrane protein found on exosomes. We also reveal the role 
of macropinocytosis in aiding the entry of exosomes into oncogenic Ras mutant 
pancreatic cancer cells. Overall, our results inform on a novel approach of direct 
and specific targeting of oncogenic Kras in tumors using iExosomes. 
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Chapter 1 
Background and Significance 
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Pancreatic Cancer: 
In the United States in 2016, pancreatic cancer ranked fourth among all 
cancer related deaths10. Approximately 85% of pancreatic cancers are classified 
as exocrine tumors, with the vast majority of them being adenocarcinomas, which 
have a ductal morphology. The remaining minority is made up of pancreatic 
neuroendocrine tumors, acinar cell-carcinomas’ and seruos cystadenomas, all of 
which usually show a slower rate of growth as compared to exocrine tumors5. 
Due to a dearth of early screening tools and treatment options, it was estimated 
that of the 53,070 patients that present with pancreatic cancer in the clinic, about 
41,780 would succumb to the disease10. The 5-year survival rate for patients with 
pancreatic cancer is less than 5%4. The incidence of pancreatic adenocarcinoma 
in the world is higher in developed countries, and therefore the incidence of 
PDAC ranges from 1 to 10 cases per 100,000 people, which makes it's the 8th 
leading cause of cancer death in men, and the 9th in women11. The causal factors 
in pancreatic cancer remain unknown, however, there are several environmental 
Fig 1: Schematic representation 
of the risk factors and inherited 
syndrome associated with 
pancreatic cancer - Reproduced 
with permission from (Ryan, D. 
P., Hong, T. S. & Bardeesy, N. 
Pancreatic adenocarcinoma. 
The New England journal of 
medicine 371, 2140-2141, 
doi:10.1056/NEJMc1412266) 
Copyright Massachesuets 
Medical Society11 
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factors that increase the risk and have been implicated in the disease (Fig 1). 
This is however a disease that is more often than not associated with age, with 
the median age for diagnosis being 71 years5,11. Tobacco use and smoking has 
been seen to contribute to a higher risk of pancreatic cancer, with the risk of 
pancreatic cancer in smokers being 2.5 to 3.6 times more that in non smokers4,12. 
In addition, there is also an increased risk among patients with a known family 
history of pancreatic adenocarcinoma11,13.  
Amongst patients that present with pancreatic cancer in the clinic, a 
majority, that is about 60-70% of them have tumors in the head of the pancreas, 
whereas the remaining 25% of tumors are located in the body and tail. The 
symptoms related to pancreatic adenocarcinoma are often dull, deep upper 
abdominal pain, weight loss, and asthenia. Half of the patients also present with 
diabetes, whereas Jaundice is found to occur in most patients that present with 
PDAC in the head of the pancreas. Manifestations such as increased abdominal 
girth, deep and superficial venous thrombosis, panniculitis and gastric outlet 
obstruction are less common4. Physically; temporal wasting, jaundice and ascites 
are signs of pancreatic cancer whereas some mild abnormalities in liver-function 
tests, anemia and hyperglycemia may be found in blood tests. To evaluate the 
presence of a tumor, multiphase multidetector helical compound tomography 
(CT) is usually the preferred imagining modality of choice. In general, this method 
usually confirms pancreatic tumor mass and the possibility of surgical 
resectibility14. With the recent interest in serum biomarkers, there has been a 
vast increase in the analysis and discovery of new and early biomarkers for 
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pancreatic adenocarcinoma. However, to date, carbohydrate antigen 19-9 (CA 
19-9) has been the only biomarker that has been observed to be useful in the 
clinic for detection and therapy monitoring, as well as detecting recurrence of the 
tumor after resection or treatment4,15-17. This method however does have certain 
failings and limitations: it is not specific for pancreatic cancer, and other diseases 
and conditions such as cholestasis may show upregulated levels of CA 19-9 in 
the serum. In addition, about 10% of patients may show undetectable levels of 
CA 19-9, despite the presence of pancreatic tumors, due to an absence of Lewis 
antigen a or b4.  
 
Staging and Histopathology of Pancreatic Cancer: 
The American Joint Committee of Cancer tumor-node-metastasis 
classification has staged pancreatic cancer into four main stages, based on the 
assessment of resectibility of the tumor: T1, T2 and T3 tumors are resectable; 
however T4 tumors, which involve the superior mesenteric artery or celiac axis 
are classified as unresectable. It is also based on metastasis, in which late stage 
Fig legend 
Fig 2: Schematic representing the current staging of pancreatic cancer - 
Reproduced with permission from (Hidalgo, M. Pancreatic cancer. The New 
England journal of medicine 362, 1605-1617, doi:10.1056/NEJMra0901557 
(2010)) Copyright Massachesuets Medical Society4 
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pancreatic tumors show secondary tumors in primarily the liver, lungs and 
abdomen (Fig 2). Approximately 70% of patients who present with pancreatic 
adenocarcinoma die from extensive metastatic disease to these sites4,11. 
Several studies have come up with a common consensus regarding the 
precursor lesions in ductal adenocarcinoma: mucinous cystic neoplasms 
(MCNs), intraductal papillary mucinous neoplasms (IPMNs) and pancreatic 
intraepithelial neoplasia (PanINs)18-20. In light of recent molecular analyses, 
PanINs have been observed to be the most frequent and well-characterized 
precursor lesion20,21. These are defined as “ neoplastic epithelial proliferations in 
the small caliber pancreatic ducts.” Depending on the degree of architectural and 
nuclear atypia present, PanINs are classified into PanIN-1, PanIN-2 and PanIN-3 
Fig 3: Ductal reprogramming and development from PanIN to PDAC in 
pancreatic cancer - Reproduced with permission from  (Morris, J. P. t., Wang, 
S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental 
biology of pancreatic ductal adenocarcinoma. Nature reviews. Cancer 10, 683-
695, doi:10.1038/nrc2899 (2010))6. License number: 4098981342522 
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lesions. There is a gradual genetic progression from PanIN-1, which shows 
elongated cells and mucin production, to PanIN-2, which shows nuclear 
abnormalities, to PanIN-3, which shows severe nuclear atypia, and budding into 
lumen, to finally invasive adenocarcinoma which shows invasive growth and 
marked stromal reaction (Fig 3)5,20,21. This progression is mediated by initially 
Kras mutation, and a subsequent loss of function of several other genes such as 
CDKN2A, SMAD4 and TP535,22,23. More recently, a low grade (PanIN-1 and 
PanIN-2) and high grade (PanIN-3) classification has taken precedence, due to 
the fact that the latter lesions have the most potential for cancer progression, and 
therefore should be the objects for evaluating early detection in ductal 
adenocarcinoma24,25. 
 
 
 
 
Fig 4: Genetic progression and histology of pancreatic ductal adenocarcinoma - 
Reproduced with permission from (Bardeesy, N. & DePinho, R. A. Pancreatic 
cancer biology and genetics. Nature reviews. Cancer 2, 897-909, 
doi:10.1038/nrc949 (2002))5. License number: 4096620202688 
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Molecular Genetics of Pancreatic Cancer: 
 Over the years in the field of pancreatic cancer, there has been a gradual 
increase in the understanding that pancreatic adenocarcinoma is a cancer of 
inherited and somatic mutations. There is an order of specific and signature 
mutations that defines the cancer, and is associated with certain neoplastic 
stages5,26. 
 
 
KRAS: 
About 90-95% of the patients that present with pancreatic 
adenocarcinoma in the clinic have activating mutations in the KRAS 
oncogene, making it the most common genetic abnormality in pancreatic 
cancer26,27. It is also the earliest genetic alteration, occurring in the pre-
neoplastic lesions, and increasing in frequency with disease progression, 
demonstrable in approximately 36%, 44% and 87% of adenocarcinoma 
associated PanIN-1A, 1B and 2/3 lesions respectively19,26. Mutations in 
the GTPase KRAS initiates cell survival, cell proliferation, cytoskeletal 
remodeling and invasion, among others26,28,29. Binding of growth factor 
ligands to the growth factor receptor as well as various other stimuli 
results in the activation of the Kras protein. In an active state, Kras is 
bound to GTP, and is inactivated by guanosine-triphosphatase activating 
proteins that initiate GTP hydrolysis to GDP, that eventually results in the 
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attenuation of Kras signaling26. An activating mutation in Kras essentially 
prevents the GTP to GDP hydrolysis, impairing the GTPase activity, and 
resulting in Kras being constitutively active26,30. Activation of this GTPase 
leads to the downstream effector pathways such as the RAF/MEK/MAPK 
and PI3K/PTEN/AKT pathways being stimulated. Genetic studies have 
shown that the MAPK pathway is arguably the most important and critical 
mediator of oncogenic KRAS induced mitogenic effects, and its need for 
Kras driven PDAC tumor maintenance25. A plethora of drugs and small 
molecule inhibitors have been evaluated to target this pathway in 
oncogenic Kras mutant cancers, however results have been mixed in that 
regard7. The PI3K pathway, among others, has also been shown to be 
promoted by activation of Kras, and promote tumor growth in PDAC, as 
well as other cancers, and targeting this pathway with small molecule 
inhibitors has been shown to have some efficacy in treating Kras mutant 
cancers25,31,32. The most common occurring Kras mutations in pancreatic 
adenocarcinoma are at codon 12, of which G12D is the most frequent, 
followed by G12V. Mutations at G13 and Q61 have also been observed, 
however, they are not as common, and may be associated with a better 
prognosis33,34. 
 
CDKN2A/p16: 
 A loss of CDKN2A function occurs in about 80-95% of all 
pancreatic adenocarcinomas, and occurs by mutation, deletion or 
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promoter hypermethylation26,35. CDKN2A tumor suppressor locus at 9q21 
encodes INK4A and ARF, both of which are tumor suppressors, and 
therefore a homozygous deletion (40% of cases) results in the disruption 
of both the retinoblastoma and p53 tumor suppression pathways5,36. A 
loss of INK4A is usually observed only in the latter stages of pancreatic 
adenocarcinomas. Due to it belonging to the cyclin-dependent kinase 
(CDK) inhibitor family, a loss of CDKN2A function results in inhibition of 
cell cycle progression through the G1-S checkpoint26. 
 
TP53: 
The TP53 tumor suppressor is mutated in approximately 50-75% of 
pancreatic adenocarcinomas, and is inactivated by missense alterations of 
the DNA binding domain37,38. These mutations are generally found in late 
stage PanIN lesions that have undergone severe dysplasia. The function 
of the p53 protein is to induce apoptosis and regulate the G1-S cell cycle 
checkpoint. Therefore, in pancreatic adenocarcinoma, a loss of p53 
facilitates the survival of a cell despite DNA damage, which leads to the 
rampant genetic instability and accumulation of mutations seen in this 
disease39. 
 
SMAD4: 
 SMAD4 or DPC4 is another important gene that is deleted in about 
55% of all pancreatic adenocarcinomas40. The Smad4 protein encodes a 
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critical transcriptional regulator in the transforming growth factor β (TGF-β) 
pathway, which has severe growth inhibitory effects by regulating the 
expression of various target genes26,41. Therefore in a pancreatic 
adenocarcinoma cell, a loss of Smad4 provides a selective growth 
advantage by abrogating the Smad-dependent TGF-β signaling26,41. A loss 
of Smad4 has seen to be observed almost exclusively in later stage PanIN 
lesions (PanIN-3), as well as being a diagnostic marker for decreased 
survival and suspected metastases in clinical patients42.  
 
Kras in Pancreatic Cancer: 
The Kras oncogene, which is a 21kDa small GTPase, shuttles between an 
inactive GDP bound state, and an active GTP bound state43. The exchange from 
an inactive to active state, to exchange GDP for GTP is aided by guanine 
nucleotide exchange factors (GEFs). Additionally, inactivation of GTP bound 
Kras is mediated by GTPase-activating proteins (GAPs).  An activating point 
mutation in Kras results in the blocking of the interaction between Kras and 
GAPs, thereby inducing Kras to be constitutively active, and activating all the 
downstream effector pathways such as the MEK/ERK and AKT/PI3K pathways 
that are involved in cell cycle progression, proliferation, migration, invasion, and 
metastasis44.  
The frequency of RAS mutations in various cancers is not equally 
distributed. In general, throughout all types of cancers, KRAS is the most 
frequently mutated isoform, making up 86% of all RAS driven cancers, followed 
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by NRAS (11%) and HRAS (3%)7. In pancreatic cancer in particular, there is 
almost a 100% frequency of KRAS mutations among RAS driven gene 
mutations7. As mentioned earlier, almost all patients that present with pancreatic 
adenocarcinoma in the clinic have a Kras mutation. It is also the earliest genetic 
alteration, occurring in the pre-neoplastic lesions, and increasing in frequency 
with disease progression27. Recent studies and mouse models have investigated 
the role of Kras addiction in pancreatic adenocarcinoma, and have impressively 
shown that dampening oncogenic Kras inhibits tumor progression, despite the 
presence of other genetic defects45,46.  
 Activating Kras missense mutations result from a single amino acid 
substitution, and in PDAC, the most frequent mutations are primarily at G12 (94-
98%), followed by G13 and Q61 at much lower frequencies7. At G12, among the 
eight different amino acid substitutions that have been identified, the most 
frequent and pre dominant mutation is a single amino acid substitution from 
glycine to aspartic acid (G12D-51%). The next frequent mutation in PDAC is a 
glycine to valine substitution (G12V-30%) (Fig 5). Mutations at G13 and Q61 also 
result in constitutive activation, those, however are not as common and may also 
be associated with a better prognosis in patients5,7.  
   12 
 
 
Until recently, there were contradictory reports regarding the prognostic 
value of Kras in pancreatic cancer. Earlier reports did not seem to find any 
correlation between harboring an activating Kras mutation, and survival rates in 
patients47,48. Recently, however, studies have indeed described a worse 
prognosis for patients that harbor a Kras mutation in both resectable and 
unresectable adenocarcinoma cases49. In additions, studies have also revealed a 
difference in aggressiveness of the cancer, depending on the particular type of 
Kras mutation. For example, Medarde et al in their extensive review of Kras 
isoforms have stated that tumors harboring a G12V of G12S mutation in 
Fig 5: Frequency and distribution of RAS mutations in human cancers - 
Reproduced with permission from (Cox, A. D., Fesik, S. W., Kimmelman, A. C., 
Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission possible? Nature 
reviews. Drug discovery 13, 828-851, doi:10.1038/nrd4389 (2014))7. License 
number: 4099030094849 
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pancreatic adenocarcinoma reportedly had better survival rates than tumors 
bearing a G12R or G12A mutation49-51.  
 
Kras Pathway Analyses: 
GTP bound RAS is capable of binding to effector enzymes, thereby 
activating them, and controlling cell cycle progression, survival and 
proliferation52. Over 20 effector pathways that are comprised of regulators of 
other GTPases or kinases have been identified as being activated by Kras53,54.  
The protein serine/ threonine kinase RAF was the first effector of RAS to 
be characterized, and is still intensely studied to date. When RAS is GTP bound 
and constitutively active, it binds to the three related RAF proteins: c-RAF1, 
BRAF and ARAF, thereby activating them55,56. This binding and activation causes 
RAF to be localized to the cell membrane, which is important for its activation52. 
Therefore, once RAF is activated, it phosphorylates and activates the mitogen-
activated protein kinase kinases 1 and 2 (MEK1 and MEK2). These in turn are 
capable of phosphorylating and activating the mitogen-activated protein kinases 
(MAPKs) extracellular regulated kinases 1 and 2 (ERK 1 and ERK2). Therefore, 
due to the activation of these important transcriptional regulators, cell cycle 
proteins such as D-type cyclins are expressed, which in turn aids the cell in 
progressing through the cell cycle, specifically the G1 phase. Activation of RAF 
therefore helps the cells progress through the cell cycle, consequently helping 
the cell divide and proliferate57,58. 
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Another important pathway downstream of RAS involved in tumor 
formation is the PI3K/PDK1/AKT pathway. Once RAS is GTP bound, it can 
directly interact with phosphatidylinositol-3-kinases (PI3K), which leads to the 
phosphorylation of phosphatidylinositol-4,5-bisphosphate (PtfIns(4,5)P2), which in 
turn binds to a number of proteins, and results in the activation of PDK1. PDK1 
plays an important role in the activation of protein kinases from the AGC family, 
including AKT. AKT therefore phosphorylates various downstream cellular 
proteins, which subsequently leads to the inhibition of several tumor suppressors, 
such as p27, p53 and BCL-2. Both AKT and PDK1 also play a strong role in anti-
apoptotic function by phosphorylating various other oncogenic downstream 
targets, subsequently leading to cell survival, cell cycle progression, cell growth, 
cell migration and transcription52,59,60. 
A third well-studied pathway downstream of RAS is the 
RALGDS/RAL/PLD pathway. This pathway, along with the PI3K/AKT pathway, 
contributes to the inhibition of the FoxO family, which is implicated in promoting 
cell cycle arrest through the induction of KIP1 (a cyclin-dependent kinase) as well 
as apoptosis52,61. 
Therefore, constitutively active RAS can promote tumor initiation and 
progression by the combined action of these various downstream effector 
pathways. It can result in increased proliferation due to the induction of multiple 
cell cycle regulators and inactivation of various cell cycle inhibitors, inhibition of 
apoptotic pathways, as well as playing an important role in cell survival, cell 
migration, transcription, cell cytoskeleton and cell invasion52. 
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Biology of Kras in Pancreatic Cancer: 
 Studies have shown in detail how constitutive activation of RAS fuels cell 
proliferation. Once GTP bound and activated, the signals generated result in the 
upregulation of a multitude of transcription factors that are involved in cell cycle 
progression and entry44 (Fig 6). These may include the leucine zipper protein 
JUN, nuclear factor κB (NF-κB), FOS, activating transcription factor 2 (ATF2), 
among others. Cyclin D1 is then in turn, triggered by these factors, which results 
in increased cell proliferation62,63. Cyclin D1 is therefore extremely crucial in RAS 
induced transformation. In addition, there are other RAS induced mechanisms 
that result in the cell transforming into a hyperproliferative states. Activated RAS 
can also deregulate anti growth signaling pathways by suppressing cyclin 
dependent kinase inhibitors (CKIs) such as p27 and p21, which ultimately results 
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in cell cycle progression as well44,64,65.  
 A disruption of the cells apoptosis machinery is a defining feature of 
cancer cells. Constitutively active RAS initiates both the PI3K and RAF 
pathways, and these pathways are known to upregulate anti-apoptotic and 
downregulate pro-apoptotic molecules and mediators66,67. The PI3K pathway 
downregulates the pro-apoptotic protein BCL-1 homologous antagonist/killer 
(BAK1), as well as increasing the levels of IAPs by activating NF- κB44. The RAF 
pathway on the other hand downregulates the pro-apoptotic repressor PAR4, 
and upregulates the anti apoptotic protein BCL-2. In addition, various studies 
have revealed that both these pathways play a major role in mediating the 
phosphorylation of pro-apoptotic BCL-2 associated agonist of cell death 
(BAD)44,68, resulting in oncogenic RAS driven cells being in a constant state of 
pro-survival. 
 Another key feature of oncogenic RAS is the ability to change the 
metabolic programming of the cell to sustain unrestricted tumor growth25,45,69. 
The Warburg effect plays a crucial role in PDAC, and oncogenic KRAS is 
involved in rewiring glucose metabolism by inducing glucose uptake, thereby 
enhancing glycolysis25,70. This is achieved in part, due to the upregulation of 
various crucial glycolytic enzymes such as glucose transporter type 1 (GLUT1) 
that confers the cell with an increased capacity to take up glucose71. Oncogenic 
Fig 6: RAS signaling pathway depicting the multiple downstream effector 
pathways - Reproduced with permission from (Berndt, N., Hamilton, A. D. & 
Sebti, S. M. Targeting protein prenylation for cancer therapy. Nature reviews. 
Cancer 11, 775-791, doi:10.1038/nrc3151 (2011))2. License number: 
4099020608432 
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RAS also increases the metabolic reprogramming of a cell by upregulating HIF 
1α. This is achieved by the activation and upregulation of the MAPK and PI3K 
effector pathways, which in turn leads to the stimulation of mTOR, and 
subsequently mTOR mediated translation of HIF 1α72. This also results in an 
increase in the transport and capture of glucose44. Lastly, constitutive oncogenic 
RAS can also channel glycolysis intermediates through the non-oxidative arm of 
the pentose phosphate pathway (PPP).  
 
Targeting Oncogenic Kras: 
A question that is extremely imperative in terms of drug development for 
oncogenic Kras is whether pancreatic cancer cells completely retain dependence 
on Kras for growth and proliferation, and recent studies have shown that that 
certainly seems to be the case73. Genetic ablation of oncogenic Kras from the 
tumors of genetically engineered mouse models driven by Kras showed 
impressive and dramatic regression of the primary tumors, confirming the 
dependence of the tumors on oncogenic Kras45. Therefore, due to surmounting 
evidence suggesting the dependency of pancreatic cancer cells to oncogenic 
Kras, there is little doubt as to why Kras might be a viable therapeutic target. 
However, because the frequency of mutation of each Ras isoform is different in 
different cancers, therapeutic approaches will need to be tailored towards the 
specific mutations, and possibly a combination of various Kras targeting drugs 
will need to be used. 
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To be able to target Kras, it is important to understand the molecular 
characteristics and mechanisms of the molecule. Ras is a small GTPase that 
generally circulates between an active GTP bound state, and an inactive GDP 
bound state. The GDP bound inactive state is partly facilitated by the GTPase 
activating proteins (GAPs). Therefore, when Ras is mutated, impaired GAP 
stimulation results in the formation of constitutively active GTP bound Ras7. 
Another important component of Ras that can be used as an Achilles’ heel is its 
association with the inner face of the plasma membrane74. This results in the 
addition of a C15 farnesyl isoprenoid lipid to its carboxy-terminal CAAX motif7, 
whose tetrapeptide sequence alone is sufficient enough to inhibit 
farnesyltransferase (FTase) activity. A third key component of Ras function is the 
activation of effector pathways and proteins that transmit signals downstream of 
mutant Ras (Fig 7).  So far, at least 11 different and distinct classes of Ras 
effector pathways have been identified, of which at least 4 have established 
cancer-driving roles75. Therefore, efforts have also focused on targeting the 
downstream effector signaling pathways of Ras as well.  
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As mentioned above, post translation, Kras is farnesylated, which allows it 
to be associated with the inner face of the plasma membrane. Here, Kras is 
activated by gunanine nucleotide factors (GEFs), which help in Kras binding to 
GTP, thereby activating it76. Therefore in view of these post translational 
modifications of Kras, Farnesyltransferase inhibitors (FTIs) were tested pre 
clinically, and when they showed significant efficacy, were then tested in the 
clinic as Lonafarnib and Tipifarnib76. These have however proven to be 
unsuccessful77. Studies into the mechanism of failure attributed it to the various 
differences between the three Ras proteins. The initial pre clinical trials of FTIs 
were performed on Hras-dependent tumors76. However, in comparison to Hras, 
Fig 7: Recent experimental approaches and methods to discover and develop 
inhibitors against oncogenic RAS - Reproduced with permission from (Cox, A. 
D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the 
undruggable RAS: Mission possible? Nature reviews. Drug discovery 13, 828-
851, doi:10.1038/nrd4389 (2014))7. License number: 4099030094849 
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Kras is geranyl-geranylated upon inhibition of farnesyltransferase, which provides 
it with an escape mechanism, thereby allowing it to associate with the membrane 
and activate the downstream effector proteins and pathways78. This failure 
prompted many groups to explore various other strategies of inhibiting Kras, one 
of which was preventing Kras from reaching the membrane. One such inhibitor, 
Deltarasin, which binds to the farnesyl-binding pocket of PDEδ, was extensively 
researched79. The translocation of Kras to the membrane is aided by PDEδ, 
which interacts with farnesylated Kras. Therefore Deltarasin essentially allows for 
the farnesylation of Kras, but prevents it from binding to the membrane. Another 
molecule being investigated is Salirasib, which blocks Kras activity by dislodging 
the farnesylated protein from the membrane76,80. Both have shown encouraging 
pre clinical potential, but need to be extensively evaluated clinically.  
 There have also been efforts to inhibit the interaction between Kras and its 
Ras-GEFs, the most important of which is SOS. One group has designed a small 
molecule that interferes with this Ras-SOS interaction, thereby blocking the 
exchange of GDP to GTP, and blocking the activation of Kras81. 
 As previously stated, there are atleast 11 Kras effector pathways, out of 
which at least 4 of them have established cancer-driving roles7. Therefore, since 
directly targeting Kras has proven to be extremely difficult, the most favored 
method recently has been to target the downstream effector and signaling 
pathways. The two pathways that have been studied the most in terms of 
mechanism and as therapeutic targets are the RAF/MEK/ERK pathway, and the 
PI3K/AKT/mTOR pathway. THE RAF/MEK/ERK pathway is a complex cascade, 
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with multiple inputs and outputs, as well as feed-forward and feed-back 
mechanisms. At least 11 pharmocological inhibitors of RAF kinases haven been 
evaluated in clinical trials, with four of them being approved for clinical use by the 
US Food and Drug Administration (FDA)7. Sorafenib for example has 
 
 
 
shown anti tumor benefits due to its ability to block tyrosine kinases that are 
involved in tumor angiogenesis82. However, with vemurafenib and dabrafenib, 
Fig 8: Recent drugs and inhibitors targeting the downstream effector pathways 
of RAS. Reproduced with permission from (Cox, A. D., Fesik, S. W., 
Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission 
possible? Nature reviews. Drug discovery 13, 828-851, doi:10.1038/nrd4389 
(2014))7. License number: 4099030094849 
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both of which are RAF inhibtors, a paradoxical activation of ERK was observed, 
instead of inactivation, leading to the increased research in understanding the 
basic mechanisms of this pathway7. In addition, at least 15 MEK inhibitors have 
reached the clinic. However, even though these inhibitors have been effective 
against BRAF mutant melanoma, they have only been partially effective in Kras 
mutant cancers, mouse models and cell lines7,83. Similarly, three ERK inhibitors 
have been evaluated in clinical trials. However, similar to MEK inhibitors, ERK 
inhibitors block ERK feed back mechanisms, leading to the enhanced MEK 
activation. Similarly, inhibitors for both PI3K and AKT have been developed and 
investigated thoroughly. Due to having several isoforms, inhibition of PI3K is 
complicated76. However, preliminary preclinical studies in mouse models have 
shown reduced cell proliferation and tumor growth on PI3K inhibition84. These 
results however were not consistent across all preclinical models of pancreatic 
cancer. Quantitatively, about 53 inhibitors of PI3K/AKT/mTOR are under 
investigation in clinical trials7. They have however shown disappointing results 
when used as monotherapies7. Therefore, although downstream effector 
signaling inhibition has shown to be the most promising outlet for targeting Kras, 
several challenges still remain (Fig 8). Firstly, compensatory mechanisms and 
feed back loops are activated rigorously when one certain effector pathway is 
inhibited. Secondly, due to these compensatory mechanisms, combinations are 
expanded to target more effector pathways at once, thereby drastically 
increasing normal cell toxicity and possibly causing a loss of the therapeutic 
window7.  
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Direct Targeting of Kras: 
 Identifying agents or compounds that directly bind to Kras and block it has 
been a goal for researchers for many years now. Although the surface of Ras 
contains very few, if any, binding pockets, there have been a few compounds 
that have shown limited yet encouraging efficacy73,85,86. The Shokat group have 
discovered a compound that binds specifically to the G12C allele of Kras, and 
this has indeed encouraged efforts to discover compounds that will bind only to 
the mutant allele specifically87. In this regard, the G12D allele for Kras is the most 
attractive, since it is the most common mutant allele in all Kras driven cancers.  
 Recently, in view of directly targeting Kras, there has been an interest in 
designing and using siRNA to specifically target only the mutant alleles of Kras. 
For example, using siRNA directed at Kras enclosed in nanoparticles, and in 
combination with siRNA targeting PI3K, Yuan et al showed an efficient 
regression of tumors88. Xue and colleagues observed that a combination of 
siRNA targeting Kras and miR-34A showed an efficient stagnation of lung tumor 
growth in vivo89. Finally, Khavelevsky et al showed that siRNA targeting the 
G12D allele using miniature biodegradable polymeric matrices in the pancreas 
were effective in treating mice with pancreatic cancer90. These studies are indeed 
encouraging, and may suggest that siRNA targeted therapies against Kras in the 
clinic may be attainable in the very near future. A major advantage of siRNA is 
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the capability to target the mutant alleles and isoforms specifically, as well as 
using combinations to target different genes simultaneously.  
 
 
Issues with Delivery of siRNA: 
However, delivering the siRNA molecules in vivo has been a major issue. 
Naked siRNA gets degraded almost immediately within the circulation, and 
therefore it is imperative to enclose the siRNA molecules within nanoparticles, 
such as liposomes. There are however multiple problems and issues with 
nanoparticles such as liposomes that have been observed over the years. A very 
early problem associated with liposomes was the difficulty in retaining the drugs 
or molecules within the liposome interior, which would drastically decrease the 
efficiency of loading91,92. In addition, exposure to serum proteins was also shown 
to affect liposomal drug release91,93. Drug release is an imperative therapeutic 
characteristic of nanoparticles, including liposomes. The drug or molecules 
enclosed inside liposomes will only become bioavailable when they are released, 
and therefore the drug must be delivered to the site of disease, become 
bioavailable to the target cells by being released at a sufficient rate for a 
sufficient period within the therapeutic window. This was not the case for 
liposomes94,95. Another major problem faced by liposomes and nanoparticles 
alike is their rapid clearance from the circulation by monocytes and phagocytes, 
and predominantly to the liver and spleen91,96. Opsonization of these particles by 
serum proteins also results in an accumulation in the liver and spleen91. This 
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rapid uptake of liposomes and nanoparticles therefore significantly reduced their 
distribution to other organs and tissues, and increased the toxicity in the liver and 
spleen91. A third significant problem with liposomal drug delivery is the passage 
of the molecules across the cell membranes to intracellular sites of action. Many 
types of liposomes cannot gain access to intracellular sites of action due to not 
being able to cross the cell membranes, and hence need to be modified 
extensively to fulfill this property91.  
Therefore, in view of these multiple and significant problems of delivery 
siRNA molecules to cells and organs of interest, it is imperative to discover and 
evaluate new avenues of drug delivery. Properties that need to be looked into 
while evaluating new drug delivery systems include a high and very efficient drug 
release rate, low clearance from the circulation in vivo, low toxicity when injected 
at high concentrations, and being able to bind to and enter cell membranes 
efficiently. 
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Introduction to Exosomes:  
Exosomes are 40-150nm nano-vesicles that are secreted by all cells in the 
body97,98. Since they are released by all cells in the body, exosomes are also 
associated with several types of extracellular fluid, including blood, urine, sperm, 
saliva and cerebrospinal fluid, to name a few99,100. Exosomes are of endocytic 
origin, and initially, it was thought that these nano/extracellular vesicles (EVs) 
were formed to recycle proteins, nucleic acid from the cell to potentially modulate 
extracellular signaling98. Exosomes are now widely known to serve as vehicles 
for a multitude of cargo from the cell101,102. Because they reflect the phenotypic 
state of the cells that they are released from, exosomes are highly 
heterogeneous97. Therefore, much like the cells they come from, exosomes are 
composed of a lipid bilayer containing cholesterol, sphingolipids, 
phosphoglycerides and ceramides; express a variety of proteins and receptors 
on the surface; as well as containing nucleic acids such as DNA, RNA, mRNA, 
miRNA and various types of proteins within the membrane103,104. 
 
Biogenesis of Exosomes (Fig 9):  
 The first step of biogenesis of exosomes involves the formation of 
endocytic vesicles from the plasma membrane by the process of invagination, to 
create multivesicular bodies (MVBs)99,105. The endocytic vesicles initially, called 
as early endosome, subsequently mature to give rise to the late endosomes, and 
undergo inward budding to form intraluminal vesicles (ILVs). The accumulation of 
these ILVs is known as MVBs102. The release of these MVBs can be either 
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dependent on endosomal sorting complexes required for transport (ESCRT) or 
ESCRT independent106. In brief, the ESCRT consists of ESCRT-0, ESCRT-I, 
ESCRT-II, ESCRT-III, which are four multiprotein complexes, and this complex, 
when recruited, sorts multiple selected proteins into ILVs107. Consequently, after 
the loading of proteins, secretion of exosomes is dependent on the fusion of 
MVBs with the plasma membrane99. This process is dependent on multiple Rab 
GTPase proteins, such as RAB27A, RAB27B, RAB35 and RAB1199,108. This 
process of exosomal biogenesis separates exosomes from EVs such as 
apoptotic bodies or necrotic blebs, that emerge by the process of outward 
budding from the plasma membrane109. This biogenesis is observed in all types 
of cells, including immune cells, mesenchymal stem cells, fibroblasts and 
epithelial cells97. The rate of biogenesis of these exosomes is however unknown, 
and can change according to the cell type, as well as the physiological condition 
of the cell. 
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Characterization of Exosomes (Fig 10): 
 After being released from cells, exosomes contain the ability to fuse with 
the plasma membrane of other recipient cells, and release their cargo. 
Additionally, the proteins expressed on the surface of exosomes may also play a 
role in aiding exosomes bind to certain cell surface receptors to induce 
intracellular signaling1,110. Therefore, the contents both within and on an 
exosomes are imperative in defining the characteristics of it. 
 As mentioned earlier, the surface of exosomes is constituted of a lipid 
bilayer that includes cholesterol, sphingomyelin, phosphatidylserine and fatty 
acids1,97. As far as proteins are concerned, the surface of exosomes contains 
Fig 9: Schematic representation of the biogenesis of exosomes within a cell - 
Reproduced with permission from (Kowal, J., Tkach, M. & Thery, C. 
Biogenesis and secretion of exosomes. Current opinion in cell biology 29, 116-
125, doi:10.1016/j.ceb.2014.05.004 (2014))8. License number: 
4099020867212 
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multiple families of proteins, such as the tetraspanins (CD63, CD9, CD81), heat 
shock proteins (HSP70, HSP90) as well as certain fusion proteins (flotillin, 
annexin) and lysosomal proteins (Lamp2b)1,98. Exosomes are also enriched in 
proteins that are involved in membrane transport and fusion, such as the Rab 
GTPase proteins, annexins, as well as proteins involved in exosome biogenesis 
(TSG101, ALIX and ESCRT proteins)97. More recently, the tetraspanins, which 
include CD9, CD63, CD81, have received high attention due to that fact that they 
have been widely used as exosomes specific markers99. Since exosomes are a 
vastly hetereogenous population, the possibility of discovering only one specific 
protein as an exosome specific marker is extremely low, and therefore a panel of 
proteins such as the tetraspanins is needed to specifically identify exosomes111.  
 In addition to what is observed on the surface of exosomes, Valadi et al 
were the first to discover the presence of RNA within exosomes that were initially 
derived from human and mouse mast cells104. The first classes of nucleic acids to 
be identified within exosomes were mRNA and miRNA97,112,113. Subsequently 
after these discoveries, other RNA sub types, including viral RNA, long 
noncoding RNAs (lncRNAs) and transfer RNAs (tRNA) were identified in 
exosomes112. One of the most interesting observations to come out of these 
discoveries was the fact that these different types of RNAs, including miRNAs 
and lncRNAs were functional, and are exported out of a cell and subsequently 
have an impact on gene expression in distant recipient cells1. The presence of 
small fragments of single stranded DNA, as well as fragments larger than 10kb, 
were discovered in exosomes by multiple groups103,114. 
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 Given that exosomes are secreted, and therefore can be isolated from all 
types of cells, are involved in pathobiological mechanisms, and extensively 
participate in cell to cell communication, there has been a vast increase in 
Fig 10: Schematic representation of an exosome - Reproduced with 
permission from (Colombo, M., Raposo, G. & Thery, C. Biogenesis, secretion, 
and intercellular interactions of exosomes and other extracellular vesicles. 
Annu Rev Cell Dev Biol 30, 255-289, doi:10.1146/annurev-cellbio-101512-
122326 (2014))1.  
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interest of utilizing exosomes in both diagnostics, and as drug delivery vehicles in 
therapy. 
 
Exosomes as Drug Delivery Vehicles: 
 The most widely used and preferred drug delivery system currently are 
liposomes, as well as polymeric nanoparticles, to a lesser extent. Liposomes are 
synthetically made vesicles that are composed of a phospholipid membrane, that 
can be assembled into various shapes and sizes102,115. Polymeric nanoparticles 
on the other hand help in the encapsulation or attachment of drug molecules116. 
However, as stated earlier, liposomes have multiple issues relating to drug 
delivery, such as the inability to evade the immune system, low circulation time in 
vivo, and significantly high toxicity due to accumulation in the liver. Polymeric 
nanoparticles have also been observed to have several biocompatibility 
issues102. Therefore, recently, exosomes have emerged as a possible answer to 
these nanoparticle drug delivery issues. Exosomes, which are the body’s natural 
delivery system for mRNA, miRNA and DNA, also possess several inherent 
desirable features of a drug delivery system. The intrinsic ability to target, bind to, 
and enter cells, as well as long circulation time, ability to evade the immune 
system and generating low toxicity are some of the features that exosomes 
possess. Therefore, assuming that the drug/cargo is efficiently loaded in 
exosomes, these intrinsic properties make exosomes a possible superior choice 
as a drug delivery vehicle.  
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 An important requirement of exosomal drug delivery is the optimal choice 
of cell type from which exosomes are isolated from. The cells should produce 
exosomes at a relatively high rate, produce exosomes that are completely devoid 
of any immunologically stimulating activity that may induce an inflammatory 
response, as well as producing exosomes that are stable in the circulation due to 
the presence of proteins that aid in evading the hosts immune system99.  
 Another distinct property that exosomes intrinsically have is the ability to 
cross the blood brain barrier (BBB). Around 98% of central nervous system drugs 
cannot cross the blood brain barrier, and therefore fail when the experiments are 
transferred from concept to clinical trials117. Therefore exosomes can be tailored 
to cross the blood brain barrier, thereby increasing the efficiency of drug 
distribution to the brain. In addition, drug delivery vehicles such as liposomes and 
other polymeric nanoparticles have been shown to undergo rapid clearance by 
the mononuclear phagocyte system118. More recently, in regards to synthetically 
made liposomes and other nanoparticles, polyethylene glycol (PEG) has been 
introduced to potentially decrease the amount of phagocytosis by monocytes. 
This however has introduced a reduced interaction between the nanoparticles 
and target cells, thereby considerably decreasing the efficiency of drug 
distribution to the target cells119,120. Exosomes, on the other hand, are naturally 
known to escape phagocytosis and opsonization, thereby increasing the potential 
distribution of drugs or small molecules to the target cells. A major difference 
also, between synthetically prepared liposomes and exosomes is the complex 
surface composition. In exosomes in particular, the surface consists of an array 
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of various membrane proteins and lipids. Therefore, the presence of such 
membrane proteins and complex lipid bilayer composition results in an efficient 
receptor-ligand mediated binding of exosomes to it’s recipient cells, and is not 
observed in liposomes or other polymeric nanoparticles99,121. 
 Due to the aforementioned advantages of exosomes as compared to 
liposomes and other nanoparticles, there have been a few studies in recent years 
that have utilized exosomes in drug delivery. Sun et al utilized exosomes to form 
complexes with curcumin to enhance the delivery of curcumin to treat an 
inflammatory disease122. Some chemotherapeutic agents that have a low 
solubility and high toxicity, such as doxorubicin, have been encapsulated in 
exosomes and shown decent anti tumor effects in breast cancer, both in vitro and 
in vivo123. Blaskovich et al loaded the STAT3 inhibitor JSI-124 in exosomes, and 
showed anti tumor efficacy in a murine GBM model124.  
 The variety of chemotherapeutic cargo’s loaded into exosomes has 
displayed the evidence that exosomes can be potentially used as drug delivery 
vehicles. However, exosomes, which are innate carriers of mRNA and miRNA, 
can be used to deliver other types of molecules as well, particularly interfering 
RNAs. Recently, there have been a few studies that have looked into loading 
siRNA and miRNA into exosomes, albeit with the caveat that the studies haven’t 
been too exhaustive in terms of in vivo experiments and relevance. Exosomes 
derived from cells were shown to specifically knockdown MAPK1 using a siRNA 
specific to that gene in vitro125. Shtam et al used a siRNA targeting RAD51 and 
RAD52 to induce an efficient knockdown using exosomes, thereby decreasing 
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the proliferation and viability of fibrosarcoma cells126. Alvarez-Erviti et al 
downregulated the Alzheimer’s disease associated gene (BACE-1), and targeted 
delivery via exosomes to the brain120. 
  
Therefore, as seen by the recent research and interest, exosomes have 
the potential to be utilized as drug delivery vehicles. Many drug candidates, 
especially nucleic acids, are highly unstable in an in vivo environment, and get 
degraded at a high rate. Using exosomes allows for utilizing the cell’s natural 
transport system, to potentially allow for the transport of these anti cancer 
agents. Due to their inherent small size (80-150nm), as well as the natural 
expression of various proteins and lipids on the surface, exosomes can avoid 
phagocytosis and degradation, as well as survive in the circulation for extended 
periods of time, as compared to liposomes or other nanoparticles used for drug 
delivery. In addition, exosomes can potentially deliver their cargo in the 
cytoplasm directly, by potentially being able to avoid the endosomal and 
lysosomal degradation pathways within a cell102. Avoiding the endosomal 
pathway may then potentially lead to increasing the transfection efficiency of its 
RNAi cargo102. However, exhaustive studies into the role of proteins on 
exosomes, for conferring advantages such as immune evasion and efficient 
entry, need to be performed. 
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Introduction to CD47: 
 One of the advantages of exosomes put forward is the ability to avoid 
immune evasion and opsonization. Unlike liposomes and other synthetic drug 
nanoparticle carriers, exosomes contain many transmembrane and membrane 
anchored proteins that likely enhance endocytosis and facilitate direct fusion with 
the plasma membrane of the recipient cells, but also aid in immune evasion by 
being able to escape phagocytosis127,128. 
 One such protein that is highly involved in the evasion of phagocytosis is 
CD47. Originally named integrin associated protein (IAP), CD47 is a cell surface 
protein that is in the immunoglobulin family, and is essentially expressed by 
virtually all types of cells in the body129,130. It is a 50kDa protein, which is fairly 
well conserved between multiple species, having about 70% similarity in the 
amino acid sequence between human, rat or mouse131. CD47 was initially 
identified as a tumor antigen on ovarian cancer in human, and subsequently, it 
has been found to be expressed on multiple cancer types such as non-Hodgkins 
lymphoma, acute lymphoblastic leukemia, bladder cancer, as well as several 
other types of solid tumors132. CD47 has been shown to be implicated in various 
processes, such as axon development, t-cell activation, as well as cell 
migration132. However, the most widely studied property of CD47 is the ability to 
bind to SIRPα on macrophages and dendritic cells, thereby initiating a signaling 
cascade that results in the inhibition of phagocytosis133. 
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CD47-SIRPα Mediated Evasion of Phagocytosis: 
 Macrophages and monocytes, as well as other immunological phagocytes 
must be prevented from phagocytizing other healthy cells to maintain 
homeostasis and tissue integrity134. One of the ways cells maintain this 
homeostasis and evade phagocytosis is by the interaction between CD47 and 
signal regulatory protein α (SIRPα)132,135. The mechanism between CD47 and 
SIRPα, was first reported by Oldenborg et al. With various red blood cell 
transfusion experiments, this group was the first to demonstrate that WT mice 
rapidly cleared and eliminated syngeneic CD47 null RBCs134. They isolated fresh 
erythrocytes from the blood of CD47 deficient mice, and transfused them back in 
wild type mice. These erythrocytes were observed to have a significantly reduced 
half-life of less than 24 hours, as compared to the average life131span of murine 
erythrocytes, which is between 45-60 days. Others then showed later, that 
platelets, hematopoietic cells, and lymphocytes were also phagocytosed in the 
absence of CD47-SIRPα interaction136,137.  
 CD47 has been shown to be a ligand for SIRPα138. SIRPα (also known as 
CD172a) was the first member to be identified from the SIRP family of proteins, 
which belong to the Ig family of cell surface glycoproteins139. Most primary 
macrophages and macrophage cell lines, as well as monocytes, dendritic cell 
and granulocytes highly express SIRPα131. Therefore, this interaction between 
CD47 and SIRPα serves as an inhibitory signaling regulator between ‘self-cells’ 
and macrophages and monocytes140. Once CD47 has been extracellularly ligated 
to SIRPα, the expression of tyrosine phosphorylation in the cytoplasmic domain 
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immunoreceptor tyrosine based inhibition motif (ITIM) is increased by SIRPα, 
which leads to SH2-containing tyrosine phosphatase (SHP1/2) being activated. 
Inhibitory signaling events are then mediated via protein dephosphorylation, 
which finally results in CD47-SIRPα mediated inhibition of phagocytosis (Don’t 
eat me signal)134 (Fig 11). Indeed, conversely, it has been demonstrated that in 
apoptotic cells, CD47 is downregulated or redistributed, thereby failing to bind to 
SIRPα, and undergoing phagocytosis3. For example, ageing erythrocytes in the 
circulation significantly lose their CD47 expression, and are subsequently cleared 
by splenic macrophages130. 
 
 
 
Fig 11: Representation of the interaction between CD47 and SIRPα to 
activate the ‘don’t eat me’ signal - Reproduced with permission from 
(Takizawa, H. & Manz, M. G. Macrophage tolerance: CD47-SIRP-alpha-
mediated signals matter. Nature immunology 8, 1287-1289, 
doi:10.1038/ni1207-1287 (2007))3. License number: 4099021338997 
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Role of CD47 in Cancer: 
 As mentioned earlier, CD47 is highly expressed on all types of cancer 
cells, while its main function is to bind to SIRPα, thereby initiating the ‘don't eat 
me’ signal, and evading phagocytosis. According to Willingham et al, CD47 is 
expressed highly on most, if not all, human cancer cells. They have 
demonstrated CD47 to be a unique cell surface marker that is expressed on all 
cancer cell types. Increased expression of CD47 in patient samples inversely 
correlates with patient survival133.  
 Therefore interest in targeting this interaction has lead to various efforts to 
target CD47-SIRPα interaction, principally by monoclonal blocking antibodies 
against CD47132. Efforts, led by the Weissmann group, have demonstrated anti 
CD47 antibodies to have pre-clinical anti tumor activity both in vitro and in vivo. 
Robust anti tumor activity has been seen in mice engrafted with primary human 
AMM and ALL cells, as well as in bladder cancer and breast cancer 
settings141,142. Anti CD47 antibodies block the binding of CD47 on cancer cells to 
SIRPα, thereby enabling the rapid phagocytosis of tumor cells. Various studies 
have shown that incubation of tumor cells with anti-CD47 blocking monoclonal 
antibodies (B6H12) lead to efficient phagocytosis of those cells, whereas non-
blocking (2D3) antibodies had no effect, whatsoever141,142. Conversely, SIRPα 
can also be targeted by blocking antibodies, which similarly inhibit the binding of 
CD47 with SIRPα, thereby allowing for rapid phagocytosis. Indeed, SIRPα 
antibodies have shown anti tumor properties142. 
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CD47 on Exosomes: 
 Therefore, it is evident, that CD47 is imperative for immune evasion of 
cells from phagocytosis by macrophages and monocytes. Since CD47 is 
expressed on the surface of most cells, it is not surprising to observe the 
presence of CD47 on the surface of most exosomes as well143,144. In this regard, 
exosomes have been well known to avoid opsonization and evade the immune 
system. 
 The distinction between self and non-self is extremely imperative for an 
organism to successfully eliminate foreign pathogens while preserving healthy 
host cells131. According to Oldenborg, a system based on ‘foreign or non-self’, 
can be circumvented by a defense system with broad recognition, combined with 
specific molecules that mark tissues or cells as ‘self’. Therefore, recognition of 
‘self’ by the host will result in the inhibition of activation of the innate immune 
system, while recognition of ‘foreign, or missing-self’ will result in the activation of 
an innate immune response. Therefore, a system in which the host 
cells/exosomes express the ‘self’ marker not present in foreign cells/exosomes, 
could easily make the distinction between self and foreign. Therefore, innate 
immune cells such as macrophages and monocytes would only need to look for 
the ‘self’ marker to release the cells/exosomes, whereas a lack of ‘self’ marker 
would result in the destruction of that cell/exosome. There would therefore only 
be a need for a few recognition markers of self, instead of foreign specific 
markers131. That is what makes CD47 an attractive target for experiments in both 
exosomes and cells. 
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Introduction to Macropinocytosis: 
 As mentioned earlier, exosomes have the potential to be utilized as drug 
delivery vehicles. Using exosomes allows for utilizing the cell’s natural transport 
system, to potentially allow for the transport of these anti cancer agents. The 
interaction between an exosome and tumor cells plays an important part in 
exosomal drug delivery. Recently, endocytosis has been reported to be an 
important pathway that is involved in uptake of exosomes. Tetraspanins such as 
CD9 and CD81, which are highly expressed on exosomes, have been shown to 
be ligands for their endocytic pathways9,145. These ligand-receptor interactions 
subsequently lead to uptake of exosomes. However, mechanisms pertaining to 
the cellular entry of exosomes, especially in a cancer cell setting, still need to be 
elucidated in more detail. 
 Macropinocytosis, which was first described in 1931, is a clathrin 
independent endocytic pathway146. Macropinocytosis involves actin 
reorganization, ruffling of the plasma membrane, as well as engulfment of large 
volumes of extracellular fluid147 (Fig 12). It is usually a signal dependent process, 
that occurs due to stimulation of growth factors such as epidermal growth factor 
(EGF) and macrophage colony stimulating factor 1 (CSF-1), among others146. In 
addition, oncogenic Kras has been shown to play a key role in macropinocytosis 
of pancreatic cancer cells. Commisso et al, by comparing cell lines that harbor a 
Kras mutation (MIA PaCa-2) with lines that do not harbor a mutation (BxPC-3), 
have demonstrated that increased levels of macropinocytosis is attributed to 
cancer cells that express oncogenic Kras, both in vitro and in vivo148. Therefore, 
   41 
since a majority of cells in pancreatic cancer harbor a Kras mutation, the amount 
of macropinosomes observed in pancreatic cancer cells is significantly higher, as 
compared to other types of tumors that do not harbor a mutation in Kras. 
 
 
 
Endocytic pathways such as clathrin-mediated endocytosis, have a severe size 
limitation for their cellular uptake, which is approximately 100nm149. Therefore, 
since exosomes are similar in size, the efficiency of cellular entry of exosomes by 
Fig 12: Macropinocytosis of exosomes, displaying actin reorganization and 
membrane ruffling - Reproduced with permission from (Nakase, I., Kobayashi, 
N. B., Takatani-Nakase, T. & Yoshida, T. Active macropinocytosis induction by 
stimulation of epidermal growth factor receptor and oncogenic Ras expression 
potentiates cellular uptake efficacy of exosomes. Scientific reports 5, 10300, 
doi:10.1038/srep10300 (2015))9. 
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clathrin-mediated endocytosis is low9. Macropinosomes however, have been 
shown to uptake large volumes of extracellular fluid (upto 1µm), which in turn 
may increase the efficiency of exosomal entry into cells9. In addition, recent 
experiments have demonstrated that phosphatidyserine, which is present on the 
surface of exosomes, has the ability to activate macropinocytosis in microglia150. 
Therefore, the process of macropinocytosis may serve as a mechanism for 
increased exosomal entry, especially in pancreatic cancer cells. 
 
  
Here, we hypothesize that exosomes can be an optimal drug delivery 
vehicle as compared to liposomes. Additionally, loading exosomes with 
oncogenic Kras specific RNAi would circumvent the problem of toxicity 
associated with current Kras targeting strategies. We plan to test the efficacy of 
treatment by utilizing multiple orthotopic and genetically engineered mouse 
models. In addition, several groups have demonstrated an increased half-life of 
exosomes in the circulation. Therefore, we hypothesize that the potential 
increased efficiency seen by exosomes in drug delivery is due to the presence of 
CD47 ‘don’t eat me’ mechanism, as well as a macropinocytosis driven increased 
entry into pancreas tumor cells. 
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Methods: 
Cell culture 
Human foreskin fibroblast (BJ), Capan-1, MIA PaCa-2 cells were cultured in 
DMEM supplemented with 10% exosomes depleted FBS and 1% penicillin-
streptomycin. Panc-1, BxPC-3, and T3M4 cells were cultured in RPMI 10% FBS 
and 1% penicillin-streptomycin. All the cells lines were from American Type 
Culture Collection-ATCC. Luciferase expressing Panc-1 and BxPC-3 cells 
(expressing a CMV promoter 5’ to the firefly luciferase protein) were gifts from Dr. 
Thiruvengadam Arumugam, UT MDACC. KPC-689 cancer cell line was 
established from the pancreas tumors of Pdx1cre/+;LSL-KRasG12D/+;LSL-
Trp53R172H/+ mice (KPC) mice151. KPC689 cells were engineered to stably 
express GFP and luciferase following infection with F-Luc-GFP lentivirus (Capital 
Biosciences). C57BL/6 wild type (WT) fibroblasts were isolated from the ears of 
C57BL/6 mice by mincing the isolated ears in DMEM supplemented with 
collagenase type 4 (400 units/ml) and incubating overnight. The next day the 
cells and tissue pieces were washed with DMEM supplemented with 20% FBS 
and 1% penicillin-streptomycin and expanded in this media. For exosomes 
collection, the cells were cultured using exosomes-depleted FBS. The same 
procedure was performed on the CD47 knockout mice (B6.129S7-Cd47tm1Fpl/J) 
mice and C57BL/6 mice to generate ear and tail fibroblast lines.  For 
overexpression of CD47 on BJ fibroblasts, transfections were performed using 
Lipofectamine 2000 reagent (Invitrogen) with pCMV6-AC-GFP CD47 plasmid 
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(Origene, MG204706), after which exosomes were isolated using the standard 
protocol described below.  
 
Isolation and purification of exosomes 
Exosomes were purified by differential centrifugation processes, as described 
previously120,152-154. Exosomes-depleted FBS was prepared as follows: the FBS 
is filtered using a 100nm filter, then ultracentrifuged for 16 hours, and then 
filtered again using a 100nm filter. Supernatant was collected from cells that were 
cultured in media containing exosomes-depleted FBS for 48 hours, and was 
subsequently subjected to sequential centrifugation steps for 800g for 5 minutes, 
and 2,000g for 10 minutes. This resulting supernatant was then filtered using 0.2 
μm filters, and a pellet was recovered at 100,000g in a SW 32 Ti rotor after 2 
hours of ultracentrifugation (Beckman). The supernatant was aspirated and the 
pellet was resuspended in PBS and subsequently ultra-centrifuged at 100,000g 
for another 2 hours. The purified exosomes were then analyzed and used for 
experimental procedures. For treatment of exosomes with proteinase K, purified 
exosomes were incubated (37°C, 30 minutes) with 50mg/mL of proteinase K 
(Sigma-Aldrich,dissolved in RNase-free water) followed by heat inactivation 
(60°C, 20 minutes). For RNase treatment, purified exosomes were incubated 
(37°C, 30 minutes) with 2 mg/mL of protease-free RNase A (Thermo Scientific) 
followed by addition of 10X concentrated RNase inhibitor (Ambion). These 
exosomes were then subsequently used for FACS analysis, in vitro assays and 
treatment of tumor bearing mice, as described below. 
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Sucrose gradient155 
Sucrose density gradients were performed to characterize the exosomes. 
Exosomes were resuspended in 2 mL of HEPES/sucrose stock solution (2.5 M 
sucrose, 20 mM HEPES/NaOH solution, pH 7.4). For the “Bottom-Up” sucrose 
gradient separation, the exosomes suspension was overlaid by a linear sucrose 
gradient (2.0-0.25M sucrose, 20mM HEPES/NaOH, pH 7.4) in a SW41 tube 
(Beckman, 11mL). Additionally, for the “Top-Down” sucrose gradient separation, 
exosomes were resuspended in 1mL of 0.25M sucrose, and the suspension was 
overlaid on top of the linear sucrose gradient. The gradients were ultracentrifuged 
for 16 hours at 210,000g at 4°C. Gradient fractions of 1 mL were collected from 
top to bottom and the densities of each fractions were evaluated using a 
refractometer. The exosomes pellets were then washed in PBS followed by a 
second step of ultracentrifugation at 150,000g at 4°C for 2 hours. The exosomes 
pellets or liposomes were resuspended in 200 μl of PBS and loaded onto a black 
96-welled microplate to detect the Alexa fluor 647 (AF647) fluorophore-tagged 
siRNA contained in them using a fluorescence detection plate reader. A 
microplate containing 200 μl of PBS was used for background readings. The 
detection of the fluorescence of Alexa-Fluor 647 fluorophore is depicted as the 
ratio of fluorescent intensity of the sucrose gradient layer wells over the 
fluorescent intensity of PBS (negative control) containing wells.  The sucrose 
gradient experiments were also performed loading siKrasG12D iLiposomes and 
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electroporated siKrasG12D siRNA. A total of three independent repeats were 
performed and all experiments showed consistent results. 
 
Electroporation of exosomes and liposomes 
109 number of total exosomes (measured by Nanosight analysis) and 1 μg of 
siRNA or shRNA were mixed in 400 μl of electroporation buffer (1.15mM 
potassium phosphate pH 7.2, 25mM potassium chloride, 21% Optiprep). These 
exosomes were electroporated using a single 4 mm cuvette using a Gene Pulser 
Xcell Electroporation System (BioRad, catalog number 165-2081), as previously 
described120,154. The cuvette electrode plates are made of aluminum that allows 
for a uniform pulse delivery to the entire system. Briefly, after adding 400 μl of the 
RNAi-exosomes mixture to the cuvette, it was electroporated at 400V, 125μF and 
∞ ohms, and the cuvette was immediately transferred to ice. Of note, when 
injecting multiple mice or using more than 109 exosomes and 1 μg of siRNA, a 
master mix of exosomes and siRNA is prepared in the electroporation buffer, and 
400 μl of the mixture is aliquoted into each cuvette prior to electroporation. A 
similar procedure was performed using liposomes (100 nm, purchased from 
Encapsula Nano Sciences). After electroporation, exosomes were washed with 
PBS, as described above. After the wash, the exosomes are resuspended in 
PBS, and kept on ice and injected into the mice immediately. Following this wash 
step, the mice were dosed with, conservatively, 108 iExosomes per injection in 
100 μl PBS volume. This dosage represents approximately 0.15 to 0.20 μg of 
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exosomes protein, and mice thus received approximately 0.15-0.20 μg of 
exosomes protein every 48 hours. For in vitro transfection, exosomes and 
liposomes were electroporated and washed with PBS as described above, and 
200,000 cells in a 6 well plate were treated with exosomes and liposomes for the 
indicated time as described for each assay and subsequently washed with PBS 
and used for further analysis. The siRNA sequence 
(GTTGGAGCTGATGGCGTAGTT) reflects a G to A nucleotide deviation from the 
wild-type Kras gene sequence (bold) to specifically target the Glycine to 
Aspartate amino acid substitution (KrasG12D) and include a TT nucleotide 
overhang to promote silencing efficiency, as described previously156-158. The 
central position of the nucleotide deviant in this KrasG12D siRNA enhances its 
specificity against the wild-type mRNA sequence. This was also labeled with an 
Alexa fluor 647 (AF647) fluorophore at the 3’ end on the sense strand to track its 
delivery. The siRNA was obtained from Qiagen (Cat. No.1027424). All Stars 
Negative siRNA (Scrambled siRNA) (1027287) was obtained from Qiagen. The 
siRNA sequences were also tagged with Alexa fluor 647. A second scrambled 
siRNA control was used (target sequence: AATTCTCCGAACGTGTCACGT) and 
the results were consistent with the scrambled siRNA from Qiagen. The KrasG12D 
shRNA sequence used was 
5’CCGGGTTGGAGCTGATGGCGTAGTTCTCGAGCTACGCCATCAGCTCCAAC
TTTTTT-3’, and was flanked with Age1 and EcoR1 sequences to allow for 
cloning into the pLKO.1 vector, according to manufacturers protocol (Addgene). 
The shRNA sequence reflects a G to A nucleotide deviation from the wild type 
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Kras gene sequence (bold) so that to specifically target the Glycine to Aspartate 
amino acid substitution in the KrasG12D mutation. Scrambled pLKO.1 shRNA was 
obtained from Addgene. For experiments performed on siRNA electroporated 
without exosomes, 1 μg of siRNA was added to 400 μl of electroporation buffer, 
and electroporated as described above. This mixture was then ultracentrifuged 
for 2 hours at 100,000g either by itself, or after it was mixed with 109 exosomes 
(RT and 37°C, in PBS for 30 minutes), and then used for further downstream 
assays. Notably, freshly prepared exosomes were used for every single assay 
reported in this manuscript, in both in vivo and in vitro experiments. 
 
Immunogold Labeling and Electron Microscopy 
Fixed specimens at an optimal concentration were placed onto a 300 mesh 
carbon/formvar coated grids and allowed to absorb to the formvar for a minimum 
of 1 minute. For immunogold staining the grids were placed into a blocking buffer 
for a block/permeabilization step for 1 hour. Without rinsing, the grids were 
immediately placed into the primary antibody at the appropriate dilution overnight 
at 4°C (monoclonal anti-CD9 1:10, Abcam). As controls, some grids were not 
exposed to the primary antibody. The next day, all of the grids were rinsed with 
PBS then floated on drops of the appropriate secondary antibody attached with 
10nm gold particles (AURION, Hatfield, PA) for 2 hours at room temperature. 
Grids were rinsed with PBS and were placed in 2.5% Glutaraldehyde in 0.1M 
phosphate buffer for 15 minutes. After rinsing in PBS and distilled water the grids 
were allowed to dry and stained for contrast using uranyl acetate. The samples 
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were viewed with a Tecnai Bio Twin transmission electron microscope (FEI, 
Hillsboro, OR) and images were taken with an AMT CCD Camera (Advanced 
Microscopy Techniques, Danvers, MA).  
 
Flow cytometry analyses of exosomes 
Exosomes from BJ Fibroblasts, BJ Fibroblasts over-expressing CD47, CD47 
knockout mouse ear fibroblasts and WT-C57BL/6 mouse ear fibroblasts were 
isolated as described above and resuspended in 200 μL of PBS. 
Aldehyde/sulfate beads (10 μL, Life Technologies) were added to the solution 
and beads and exosomes mixture allowed to mix using a benchtop rotator for 15 
minutes at room temperature. PBS (600 μL) was then added to the solution and 
mixing was continued overnight at 4°C. 1M Glycine (400 μL) was added and 
mixing was continued for 1 hour at room temperature. The mixture was then spun 
down at 12,000rpm at RT for 1 minute. The precipitate was then resuspended in 
100 μL of 10% BSA in PBS, and mixed for 45 minutes at room temperature. The 
mixture was spun down at 12,000rpm for 1 minute at RT and the supernatant 
aspirated. The beads with the exosomes attached (pellet) were then 
resuspended in 40 μL of 2% BSA in PBS, and split equally into two tubes: one for 
staining for CD47, CD63 or CD81, the other for control (secondary antibody only). 
The exosomes bound to beads were then incubated with 1μL of anti-CD47 
antibody (for mouse: BD biosciences, catalog no. 556045; for human:  
eBiosciences, catalog no. 14-0479) or 3μL of anti-CD63 (for mouse: Santa Cruz 
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Biotech catalog no. SC-31211; for human: BD biosciences, catalog no. 556019) 
or anti CD-81 antibody (for human: BD Biosciences, catalog no. 555675) in 20 μL 
volume, and mixed at RT for 30 minutes. The mixture was then centrifuged at 
12,000 rpm for 1 minute at RT, the supernatant aspirated, and the pellet 
resuspended in 20 μL of 2% BSA in PBS. Secondary antibodies were then added 
and the samples were mixed at RT for 1 hour. The samples were then 
centrifuged at 12,000 rpm for 1 minute at RT, supernatant aspirated, and pellet 
resuspended in 200 μL of 2% BSA in PBS. The exosomes bound to the beads 
were washed three times with 2% BSA in PBS. CD47, CD63 and CD81 detection 
on the beads was analyzed using the LSR Fortessa X-20 cell analyzer. 
 
Flow cytometry analysis for exosomes and liposomes biodistribution 
Exosomes and liposomes were labeled with PKH67 (Invitrogen) according to 
the manufacturer’s protocol. Alternatively, the exosomes and liposomes were 
electroporated with AF-647 tagged RNAi prior to injection in mice. These were 
then injected i.p. into C57BL/6 or Nude mice. Plasma was then obtained from 
these mice at the listed time points following injection of either exosomes or 
liposomes. The plasma was then diluted in 11 mL PBS and filtered through a 
0.2 μm pore filter. Subsequently, the samples were then ultracentrifuged 
overnight at 150,000g at 4°C. The pellet was then washed with PBS, and 
followed by a second step of ultracentrifugation at 150,000g for 2 hours at 4°C. 
The samples were then resuspended in 200 μL of PBS. Aldehyde/sulfate beads 
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(10 μL, Life Technologies) were added to the solution and the beads and 
exosomes/liposomes mixture was allowed to mix using a benchtop rotator for 15 
minutes at room temperature. PBS (600 μL) was then added to the solution and 
mixing was continued overnight at 4°C. 1M Glycine (400 μL) was added and 
mixing was continued for 1 hour at room temperature. The mixture was then spun 
down at 12,000rpm at RT for 1 minute, supernatant aspirated, and pellet 
resuspended in 200 μL of 2% BSA in PBS. The exosomes/liposomes bound to 
the beads were washed three times with 2% BSA in PBS. FITC or APC+ beads 
were analyzed using the LSR Fortessa X-20 cell analyzer.  
 
Flow cytometry analysis for binding efficiency of CD47 neutralizing 
antibody on exosomes 
Exosomes from BJ fibroblasts were isolated as described above, and then 
incubated with 10μg/mL of anti-CD47 neutralizing monoclonal antibody (Bio-
Xcell, B6H12 or 2D3 antibodies, as specified) for 1 hour at either room 
temperature or 37°C, or overnight at 4°C, and then bound to aldehyde sulfate 
beads as described above. 1M Glycine (400 μL) was added and mixing was 
continued for 1 hour at room temperature. The mixture was then spun down at 
12,000rpm at RT for 1 minute. The samples were washed with 2% BSA, and 
secondary antibody (Alexa 488) was then added and the samples were mixed at 
RT for 1 hour. The samples were then centrifuged at 12,000 rpm for 1 minute at 
RT, supernatant aspirated, and pellet resuspended in 200 μL of 2% BSA in PBS. 
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The exosomes bound to the beads were washed three times with 2% BSA in 
PBS. Alexa 488 positive beads were then analyzed using the LSR Fortessa X-20 
cell analyzer. 
 
Flow cytometry analysis for comparison of binding efficiency of 
exosomes and liposomes to aldyhyde sulfate beads 
Exosomes and liposomes were electroporated with A647 siRNA as described 
above. The samples were then resuspended in 200 μL of PBS. Aldehyde/sulfate 
beads (10 μL, Life Technologies) were added to the solution and the beads and 
exosomes/liposomes mixture was allowed to mix using a benchtop rotator for 15 
minutes at room temperature. PBS (600 μL) was then added to the solution and 
mixing was continued overnight at 4°C. 1M Glycine (400 μL) was added and 
mixing was continued for 1 hour at room temperature. The mixture was then spun 
down at 12,000rpm at RT for 1 minute, supernatant aspirated, and pellet 
resuspended in 200 μL of 2% BSA in PBS. The exosomes/liposomes bound to 
the beads were washed three times with 2% BSA in PBS. A647+ beads were 
analyzed using the LSR Fortessa X-20 cell analyzer.  
 
Visualization of exosomes biodistribution in the tissue 
Exosomes were labeled with PKH67 (Invitrogen) according to the 
manufacturer’s protocol. Alternatively, the exosomes were electroporated with 
AF647 tagged RNAi prior to injection in mice. These were then injected i.p. into 
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C57BL/6 mice. The specific organs were obtained from these mice at the listed 
times post injection and then were frozen. Sectioned tissue was stained with 
DAPI nuclear stain, and images were then captured using Zeiss Observer Z1 
inverted microscope. Images were quantified by counting the number of nuclei 
that had PKH67 labeled/AF647 labeled exosomes surrounding it (PKH67/AF647 
positive cells) and divided by the total number of nuclei, in five random visual 
fields per organ (400x). For evaluation of the entry of exosomes in the various 
pancreas structures, exosomes electroporated with AF647 tagged siRNA were 
injected i.p into 26-day old KTC mice. The pancreas of these mice were then 
harvested 24 hours later, mounted in O.C.T. compound and frozen. Sectioned 
tissue was stained with DAPI nuclear stain, and the images were then captured 
using Zeiss Observer Z1 inverted microscope. Images were quantified by 
counting the number of nuclei within a particular structure (Islet, Acinus, Duct, 
CAF, Tumor) that had AF647 labeled exosomes surrounding it (AF647 positive 
cells) and dividing by the total number of nuclei within that structure (400x). 
 
Real-time PCR Analyses 
Cells were incubated with iExosomes for 3 hours, after which RNA was retro-
transcribed with MultiScribe Reverse Transcriptase (Applied Biosystems) and 
oligo-d(T) primers following total RNA purification with Trizol (Invitrogen), 
according to the manufacturer’s directions. Real-time PCR analyses were 
performed on an ABI PRISM 7300HT Sequence Detection System Instrument 
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using SYBR Green Master Mix (Applied Biosystems).  The transcripts of interest 
were normalized to 18S transcript levels. Primers for KrasG12D were designed as 
described in159, KrasG12C/V were designed as described in152, and Kras WT 
primers were designed as described in160. Each reaction included three technical 
replicates, which were averaged to define one biological replicate. The 
experiments were repeated three times on distinct days and each experiment 
defined a biological replicate. Statistical analyses were performed on dCt of 
biological replicates (mice or independent experiments) and the results 
expressed as relative fold change. Primer sequences were: 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
KRASG12D(hu) ACTTGTGGTAGTTGGAGCAGA TTGGATCATATTCGTCCACAA 
KRASG12D(Mo) ACTTGTGGTGGTTGGAGCAGC TAGGGTCATACTCATCCACAA 
KRASWT(hu) ATTGTGAATGTTGGTGT GAAGGTCTCAACTGAAATT 
18S  GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
KRASG12V/C (Hu) ACTTGTGGTAGTTGGAGCAGT TTGGATCATATTCGTCCACAA 
 
In some experiments, the exosomes were subjected to a variety of treatments as 
described below, prior to treatment of Panc-1 cells: 
siKrasG12D iExo: Panc-1 cells treated with siKrasG12D iExo (BJ derived 
exosomes). 
Media Exo: FBS-depleted culture medium was incubated without cells for 48hrs 
at 37°C, and then processed as to collect exosomes. The ultracentrifuged pellet 
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was electroporated with siKrasG12D iExo as performed in the siKrasG12D iExo 
group. 
siRNA: Panc-1 cells treated with siKrasG12D siRNA (no exosomes, no 
electroporation). 
siRNA (E): Panc-1 cells treated with siKrasG12D siRNA that was electroporated 
(‘E’). 
Exo (E): Panc-1 cells treated with just BJ derived exosomes were electroporated 
(‘E’) without siKrasG12D. 
siRNA + Exo: Panc-1 cells treated with BJ derived exosomes and siKrasG12D 
added to the wells of cells concurrently.  
siRNA (E) + Exo: Panc-1 cells treated with BJ derived exosomes that were mixed 
with electroporated siKrasG12D.  
siRNA + Exo (E): Panc-1 cells treated with electroporated BJ derived exosomes 
that were mixed with siKrasG12D.  
siRNA (E) + Exo (E): Panc-1 cells treated with electroporated BJ derived 
exosomes that were mixed with electroporated siKrasG12D.  
Scramble iExo: Panc-1 cells treated with BJ derived exosomes that were 
electroporated with siScramble siRNA (from Qiagen, as described above).  
Scramble (2) iExo: Panc-1 cells treated with BJ derived exosomes that were 
electroporated with a distinct siScramble siRNA (target sequence: 
AATTCTCCGAACGTGTCACGT)   
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MTT, TUNEL and flow cytometry apoptosis assay 
Panc-1, BxPC-3, Capan-1 and MIA PaCa-2 cells were seeded in a 96-well plate 
(1,000 cells/well) and allowed to seed for 24 hours, after which they were treated 
with exosomes electroporated with KrasG12D siRNA, KrasG12D shRNA, scrambled 
siRNA, scrambled shRNA, PBS or non-electroporated control exosomes. 
Treatment was given only once at the beginning, post seeding of cells. 
Subsequently, every 24 hours, MTT reagent (tetrazole, Sigma Aldrich) was 
added to the cell culture media for 3 hours at 37°C. The supernatant was then 
discarded, cells washed with PBS, and lysed with dimethyl sulfoxide to dissolve 
the formazan product. Absorbance was measured at an optical density of 562 nm 
in a spectrophotometric plate reader. In these MTT experiments, each treatment 
(e.g. iExosomes) were aliquoted into 5 partitions, and each partition was used to 
treat 3 wells of cells. The triplicate wells were averaged to define n=1 partition 
and each treatment thus totaled n=5 partitions. The MTT assay for Panc-1 and 
BXPC-3 was repeated again under the exact same conditions, as an 
independent experiment. For TUNEL assay, cells were treated with iExosomes 
for 24 hours, and apoptosis measurement by TUNEL was assessed using the In 
Situ Cell Death Kit, TMR red (Roche), according to the manufacturer’s directions. 
The cells were fixed with 4% PFA at room temperature for 20 minutes, and 
SYTOX green nucleic acid stain (Invitrogen, 1:10,000 in PBS for 10 minutes at 
room temperature) or DAPI were used to delineate the nuclei. Images were taken 
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by Zeiss LSM 510 confocal microscope, quantified by counting the number of 
cells with TUNEL positivity per visual field (400x), and the results were expressed 
as the percentage of cells with positive label out of the total number of cells 
counted per visual field. The TUNEL assay was repeated again under the exact 
same conditions, as an independent experiment. For flow cytometry analysis of 
apoptosis in Panc-1 cells, Panc-1 cells were treated with iExosomes or scramble 
iExosomes for 24 hours, and apoptosis and dead cells were measured by 
LIVE/DEAD fixable aqua (ThermoFisher, L34957) and propidium idodide (5 μL of 
a 50μg/ml stock solution per reaction (from BD Biosciences, 556547), according 
to the manufacturers instructions. This was then analyzed by using the LSR 
Fortessa X-20 cell analyzer. 
 
Visualization and quantification of Alexa Fluor 647/CM-Dil in cells treated 
with exosomes or liposomes 
Exosomes isolated from BJ fibroblasts, CD47 knockout fibroblasts, and WT 
C57BL/6 fibroblasts were electroporated with Alexa fluor 647 tagged siRNA and 
treated with PBS, proteinase K, or trypsin (Life Technologies, 10X, 15 minutes at 
room temperature and ultracentrifuged with PBS for 2 hours at 4°C), were 
washed with PBS for 2 hours, and then added to Panc-1 cells cultures on glass 
coverslips for 3 hours. For staining of exosomes with CM-Dil dye (ThermoFisher), 
isolated exosomes were resuspended in 1 mL PBS, and 2 μL (1:500) of CM-Dil 
dye was added, after which the mixture was incubated at 37°C for 5 minutes, and 
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then at 4°C for 10 minutes. This was then ultracentrifuged with PBS for 2 hours, 
and then added to Panc-1 and BxPC-3 cells on glass coverslips for 3 hours.  The 
cells were then fixed by washing with cold PBS and incubating with 4% PFA at 
room temperature for 20 minutes. The cells were then washed with PBS, 
incubated with 0.05% Triton X for 10 minutes, washed with PBS and stained with 
Sytox green nuclear stain (Invitrogen) or DAPI. The coverslips were then 
mounted on to glass slides with mounting media. Accumulation of Alexa Fluor 
647/CM-Dil was visualized using Zeiss Observer Z1 inverted microscope. The 
number of cells with Alexa Fluor 647/CM-Dil labels was counted per visual field 
(x400) and the results were expressed as the percentage of cells with positive 
label out of the total number of cells counted per visual field. 
 
Quantification of Loading Efficiency within Exosomes/Liposomes by RT-
PCR 
109 exosomes or liposomes were electroporated with 1 µg siRNA as described 
above.  When stated, the electroporated exosomes/liposomes were proteinase K 
treated and RNAse A treated (as described above). Specifically, when both 
treatments were required, they were performed sequentially. The samples were 
first proteinase K (PK) treated, the PK was inactivated, then the samples were 
washed with PBS and spun down using ultracentrifugation. The resuspended, 
PK-treated exosomes were then RNAse A treated, then the RNAse was 
inactivated, and the exosomes were washed with PBS and spun down using 
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ultracentrifugation.  We also treated exosomes with 1% Triton X-100 prior to 
RNAse A treatment. Briefly, exosomes were subjected to treatment with 1% 
Triton X-100 for 30 minutes at 37°C, after which RNAase A was added. One 
microgram of siRNA was used as input, and 1 µg siRNA was also used for 
RNAse A treatment following an identical procedure as listed above. Control 
exosomes consisted in non-electroporated exosomes. All samples were mixed 
with 500 µl of TRIzol reagent, and 200 µl of chloroform was added to the 
mixtures. The aqueous phase was recovered following 15 minutes of 
centrifugation at 10,000g at 4°C. The aqueous phase, 200 µl for each sample, 
was then mixed with 250 µl of 100% ethanol and bound to filters provided in the 
Total Exosomes RNA and Protein Isolation Kit (Invitrogen, catalog number 
4478545). The protocol to purify the RNA was then followed according to the 
manufacturer’s directions. A total of 100 µl of eluted RNA for each sample was 
obtained. The Custom TaqMan® Small RNA Assay kit was purchased (Applied 
Biosystems) to specifically detect the sense strand of the KrasG12D siRNA and the 
manufacturer’s protocol was followed, using 5 µl of RNA template for the reverse 
transcription (RT) reaction, and 1.33 µl of 1:1000 diluted RT reaction product for 
the qPCR. The reactions were also performed by diluting the electroporated 
exosomes 1:1000 prior to proceeding with the described treatments (using 106 
exosomes), in which case the RT reaction product was not diluted. The RNA was 
extracted as described above, RT reaction performed as described above, and 
1.33 µl of the RT reaction product was used for the pPCR. qPCRs were run with 
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technical duplicates. The RT reaction product of the siRNA input sample was 
also further diluted 1:2 and 1:4 fold to establish a standard curve. No template 
control were included in the qPCR reaction and showed no detectable signal. 
Each exosomes and liposomes samples was prepared in triplicates, consisting in 
3 independent preparations of exosomes/liposomes electroporation, washes, and 
RNA extractions. The average 1/Ct and standard deviation of the 3 independent 
experiments is presented.  
 
Protein identification by nano Liquid Chromatography coupled to tandem 
Mass Spectrometry (LC-MS/MS) analysis 
Exosomes extraction was performed by ultracentrifugation (Beckman Optima XE 
100) 100,000g, overnight, 4ºC, followed by two washing steps with NaCl 0.9% 
(saline). Protein extraction was done using a solution of 8M/2.5% SDS-Urea 
(Sigma), cComplete (Roche) and PMSF (Sigma), for 30 minutes on ice followed 
by centrifugation 17,000g for 30 minutes. Proteins were present in the 
supernatant. T3M4 CD24+CD44+ derived exosomes protein was precipitated 
using methanol/chlorophorm methodology and quantified with PIERCE 660nm. A 
total of 40 µg of protein was used for the analysis. The sample digestion was 
performed overnight using trypsin solution. The digestion product was purified 
with SEP-PAK C18 cartridge. For the analysis, 1 µg of peptides were subjected 
to nano liquid chromatography (Eksigent Technologies nanoLC Ultra 1D plus, AB 
SCIEX, Foster City, CA) coupled to high-speed Triple TOF 5600 mass 
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spectrometer (AB SCIEX, Foster City, CA) with a Nanospray III source (1 
technical replicate). The mass spectrometry data obtained was analyzed using 
Mascot Server v. 2.5.0 (Matrix Science, London, UK) as search engine against 
Homo sapiens database (including also the decoy database). The confidence 
interval for protein identification was set to ≥ 95% (p<0.05) and only peptides with 
an individual ion score above the 1% False Discovery Rates (FDR) threshold 
were considered correctly identified. 
 
 
 
Western Blot  
To deduce the protein levels in cell lysates after 24 hours of treatment with 
exosomes, Panc-1 cells were homogenized in RIPA lysis buffer and protein 
lysates were normalized using Bicinchoninic Acid (BCA) protein assay kit (Pierce, 
Thermo Fisher Scientific). Twenty micrograms of protein lysates were loaded 
onto acrylamide gels for electrophoretic separation of proteins under denaturing 
conditions and transferred onto PVDF membranes (ImmobilonP) by wet 
electrophoretic transfer. The membranes were then blocked for 1 hour at room 
temperature with 5% non-fat dry milk in PBS with 0.05% Tween-20, and 
incubated overnight at 4°C with the following primary antibodies: anti-rabbit p-
Erk-p44/p42 MAPK (Erk1/2) (Thr202/Tyr 204) (Cell Signaling, 4376, 1:1,000), 
anti-rabbit Vinculin (Abcam, 129002, 1:10,000). Secondary antibodies were 
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incubated for 1 hour at room temperature. Washes after antibody incubations 
were done with an orbital shaker, three times at 15 min intervals, with PBS 
containing with 0.05% Tween-20. Membranes were developed with 
chemiluminescent reagents from Pierce, according to the manufacturer’s 
directions. The quantifications were performed on two independent experiments 
(n=2). Western blots were quantified by ImageJ software, wherein the p-ERK 
peak intensity values were normalized to those of vinculin, in each blot. 
 
 
 
RAS Binding Assay 
Lysates from cells treated with iExosomes and controls were isolated according 
to the manufacturers instructions (Cytoskeleton, BK008), and subsequently the 
GTP bound vs. GDP bound RAS activity in Panc-1 and BxPC-3 cells was 
measured using the Ras pulldown activation assay kit (Cytoskeleton, BK008), 
and using western blotting as the final readout. 
 
Mice  
Female athymic nu/nu mice (Charles Rivers) between 4 to 6 weeks of age were 
housed in individually ventilated cages on a 12 hours light-dark cycle at 21 to 
23ºC and 40% to 60% humidity. Mice were allowed free access to an irradiated 
diet and sterilized water. Under general anesthesia, Panc-1, BxPC-3 (106 cells in 
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10μl PBS) or KPC689 cells (5x105 cells in PBS) were injected into the tail of the 
pancreas using a 27-gauge syringe. For detection of luciferase expression, the 
mice were injected i.p. with 100mg/kg of body weight of luciferin (200 μl of 
10mg/ml luciferin in PBS) 12-15 minutes before imaging, anesthetized with 
isofluorane, and imaged using IVIS (Xenogen Spectrum). For tumor burden 
analyses, Living Image version 4.4 (Caliper Life Sciences) was used to quantify 
all tumors. A circular region of interest (ROI) around the pancreas and tumor was 
set within the same experimental groups. In addition, exposure conditions (time, 
aperture, stage position, binning) were kept identical for all measurements within 
each experiment. Tumor measurements for average radiance (p/sec/cm2/sr) or 
total flux (wherever mentioned, p/sec) were obtained under the same conditions 
for all experimental groups. All IVIS imaging analyses were ascertained by two 
independent experimentalists, one of which was blinded to the treatment groups. 
The mice were imaged regularly and randomly divided into groups for treatments. 
The mice were monitored for sign of distress daily, and two of the 3 
experimentalists monitoring health status were blinded to the treatment groups. 
Mice received 108 exosomes or liposomes i.p. in 100 μl volume of PBS every 
other day. Exosomes or liposomes were electroporated with 1 μg of siRNA 
(Alexa 647 tagged siRNA), or shRNA, or were pre-treated with proteinase K 
and/or RNase A as described above, or were mixed with electroporated siRNA 
(RT and 37°C), and washed with PBS prior to injection. When using KTC 
(Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2Lox/Lox)161 genetically engineered mice, exosomes 
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treatment was initiated at 18 (early) or 33 (late) days of age. For exosomes 
biodistribution studies, adult C57BL/6 mice were injected i.p. with exosomes 
labeled with PKH67 (Invitrogen) or exosomes electroporated with AF647. For the 
KPC689 orthotopic study, 5x105 of KPC689 cells were injected orthotopically in 
the tail of the pancreas of adult C57BL/6 mice (Jackson Laboratory). These mice 
were then imaged by IVIS or by Magnetic Resonance Imagining (MRI) 20 days 
post tumor cell induction. Treatment with exosomes (siKrasG12D iExo and 
siScramble iExo) was started on day 16 (early) and day 32 (late)-post tumor cell 
induction, and continued every other day. Another MRI was additionally 
performed on 48 days post tumor cell induction. MRI was performed and 
analyzed as previously described151. For experiments aimed to neutralize CD47, 
10μg/mL of anti-CD47 neutralizing monoclonal antibody (Bio-Xcell, B6H12 or 
2D3 antibodies, as specified) was incubated with either exosomes or liposomes 
for 1 hour at room temperature, washed with PBS by ultracentrifugation as 
described above, and injected into the mice. Treatment with both CD47 
monoclonal antibody and iExosomes/iLiposomes along with controls was 
performed every other day. Treatment of KPC (Pdx1cre/+;LSL-KRasG12D/+;LSL-
Trp53R172H/+) was started when the mice reached a 100 days of age. Due to the 
variability of the model, the mice were subjected to MRI to determine baseline 
tumor size, and subsequently grouped into siKrasG12D iExo or siScrbl iExo 
groups.  For gemcitabine studies, a 50mg/kg dosage, administered every 48 
hours intraperitoneally was used. At time of necropsy or euthanasia, gross 
observation of the metastatic burden and measure of primary tumor burden was 
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performed in a blinded fashion: the experimentalist performing the tissue 
collection, recording of disease burden and metastasis, was blinded to the 
treatment group. Blood urea nitrogen (BUN), aspartate transaminase (AST) and 
alanine transaminase (ALT) analyses were performed using plasma (collected 
using heparin) and BioAssay Systems blood chemistry assay kits (catalog DIUR-
100, EASTR-100 EALT-100 respectively), following the manufacturer’s 
specifications. All animal procedures were reviewed and approved by the 
Institute for Animal Care and Use Committee at UT MDACC. 
 
Histological analyses 
Tissues were fixed in formalin and processed for paraffin embedding. Tissue 
sections of 5 μm thickness were cut and stained for haematoxylin and eosin 
(H&E) and Masson’s trichrome (MTS) (Leica). For histopathological scoring, H&E 
stained slides were scored based on the morphological stages of pancreas 
cancer: normal, pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal 
adenocarcinoma (PDAC). For each tissue section, a percentage score for each 
of the three stages (Normal, PanIN, PDAC) were performed in a blinded fashion. 
Specifically, at least two (three in some experiments) experimentalists evaluated 
the slides. They each performed their analyses independently from one another, 
and one of the two, or two of the three, experimentalists were blinded to the 
treatment groups. All three experimentalists returned identical conclusions and 
the scores were averaged for each stages for each mouse. Note that while small 
foci of cancer cells can be seen in the shKrasG12D iExo treated pancreas, the vast 
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majority of the pancreas was histologically unremarkable. For the analysis of 
fibrosis in mice, six 200x visual fields were randomly selected for each MTS 
stained pancreas section and fibrosis was quantified using a grid intersection 
analysis with Adobe Photoshop. For each image evaluated, a grid of a 100 
squares was overlapped on each picture, and each intersection was counted for 
blue (fibrotic area) and purple/red (non-fibrotic area). A percentage score was 
then obtained for each tissue section. Tissue sections were also subjected to 
antigen retrieval (15 minutes in 10nM citrate buffer at pH6 and 98°C) prior to 
immunostaining. The tissue sections were incubated with 4% CWFS gelatin 
(Aurion) in either TBS or PBS, 1 hour prior to overnight incubation with the 
primary antibodies. The following primary antibodies were used for staining: anti-
rabbit p-Erk-p44/p42 MAPK (Erk1/2) (Thr202/Tyr 204) (IHC, Cell Signaling, 4376, 
1:400), anti-rabbit p-AKT-Anti AKT1 (phospho S473) (IHC, Abcam, ab81283, 
1:100), anti-rabbit Ki-67 (IHC, Thermo Scientific, RM-9106-S, 1:400) and 
conjugated anti-actin α-SMA-Cy3 (IF, Sigma, C6198, 1:100). For CK19 p-ERK 
co-staining, the primary antibodies used were anti-rabbit CK19 (IF, Abcam, 
52625) and anti-rabbit p-ERK p44/p42 MAPK (Erk1/2) (IF, Cell Signaling, 4370). 
For IHC, the sections were incubated with biotinylated goat anti-rabbit and 
streptavidin HRP (Biocare Medical), each for 10 minutes, and counterstained with 
haematoxylin. DAB positivity was analyzed. Note that the quantification was 
performed on measurably smaller tumor areas in the siKrasG12D iExo treated 
group compared to large tumor area in control group. This was performed on at 
least five, and up to eight 200x pictures per tissue section, and an average of 
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relative percent positive score was obtained for each tissue section. Ki-67 
staining was quantified by counting the number of positively stained nuclei, per 
visual field (400x), whereas p-Erk, p-AKT, and α-SMA staining was quantified 
with ImageJ to define a positively stained area, which was then expressed as a 
percentage of positively stained area to the total image area.  Quantification of 
CK19 and p-ERK co-immunolabels was performed on 8 random 400x images per 
tissue section, and inserted into FIJI by Image J co-localization software. TUNEL 
assay was performed using the In situ cell death detection kit, TMR Red (Roche), 
according to the manufacturer’s directions. Alexa fluor 647 was detected on 
frozen tissue sections by staining the nuclei of the tissue with SYTOX green 
(1:10,000 in PBS for 10 minutes). Images were taken by Zeiss LSM 510 confocal 
microscope, and quantified by counting the number of cells with TUNEL positivity 
per visual field (400x) and the results were expressed as the percentage of cells 
with positive label out of the total number of cells counted per visual field. PKH67 
labeled exosomes or AF647 electroporated exosomes were also injected into 
mice 3 hours prior to euthanasia, and the pancreas were fixed, processed and 
sectioned as described above. Sections were mounted on slides, the nuclei 
stained with DAPI, and the pancreas sections imaged using the Zeiss Observer 
Z1 inverted microscope. PKH67 /AF647 positive cells were counted in each 400x 
visual field and differentiated according to tumor or normal peritumoral cells 
based on nuclear staining characteristics. For the exosomes biodistribution 
studies, the number of PKH67 positive cells was counted in each 400x visual 
   69 
field in the brain, G.I. Tract, kidney, liver, lung, pancreas and spleen. The results 
were expressed as the percentage of cells with positive label out of the total 
number of cells counted per visual field. For pancreas structure quantification, the 
number of AF647 positive cells was counted in each 400x visual field in the 
pancreas, and the results were expressed as the percentage of cells with positive 
label out of the total number of cells counted per visual field. Representative 
pictures of the structures were taken accordingly. For Kras staining, pancreas 
tumor, liver, lung, kidney, spleen and heart, 5 μm thick sections from formalin 
fixed, paraffin embedded tissues were processed for antigen retrieval (2 repeats 
of 15 minutes microwave based antigen retrieval using sodium citrate buffer 
(10mM sodium citrate, 0.05% Tween 20, pH 6.0)), then incubated at room 
temperature for 15 minutes with 3% H2O2 in methanol. The sections were 
washed in TBS, blocked with Rodent Block M solution (Biocare) for 30-45 
minutes at room temperature, then incubated with 1:10 dilution of Kras antibody 
(ThermoFisher, 414700, clone 9.13) in 3% BSA containing PBS diluent, overnight 
at 4°C or at room temperature for 4 hours. The slides were then processed for 
secondary antibody application and DAB based development using Biocare’s 
MACH 4 universal HRP-polymer reagents, according to the manufacturer’s 
recommendation. Analyses for comparative DAB positivity was performed using 
ImageJ software by designing a macros to define a positively stained area, which 
was then expressed as a percentage of positively stained area to the total image 
area. Each organ had a unique macros programmed for quantification. 
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Quantification of the number of exosomes from the plasma of mice 
CD47 knockout mice (CD47 k/o) vs. WT C57BL/6 mice were retro-orbitally bled 
using heparin and the plasma was isolated. 300 μl of plasma per mouse was 
then diluted in 11 mL PBS and filtered through a 0.2 μm pore filter. 
Subsequently, the samples were then ultracentrifuged overnight at 150,000g at 
4°C. The pellet was then washed with PBS, and followed by a second step of 
ultracentrifugation at 150,000g for 2 hours at 4°C, after which the total number of 
exosomes in the plasma of the mice was measured by NanoSightTM analysis. 
 
Macrophage clearance 
Immunocompetent C57BL/6 mice between the ages of 10 and 14 weeks were 
injected i.p. with either exosomes or liposomes containing Alexa fluor 647 tagged 
siRNA. The blood of these mice was collected 3 hours post injection and 
processed for flow cytometry analyses. Red blood cells were depleted using ACK 
lysis buffer (Invitrogen), and the peripheral cells were blocked with FC block 
(1:1000, BD Pharmingen), stained with Live/Dead Aqua dye (1:200, Life 
technologies, 405nm) anti-CD11b (1:200, BD Pharmingen, PerCP/Cye 5.5) and 
anti CD172a (1:200, BD Pharmingen, FITC) antibodies for 30 minutes, washed 
with PBS, and analyzed using the LSR Fortessa X-20 cell analyzer (UT MDACC 
flow cytometry core facility). Immunocompetent C57BL/6 mice were also i.p. 
injected with exosomes that were electroporated with Alexa fluor 647-tagged 
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siRNA and incubated with 10μg/mL of CD47 neutralizing monoclonal antibody 
(Bio-Xcell, B6H12 or 2D3 antibodies) for 1 hour at RT. The blood of these mice 
was collected 3 hours post injection and processed for flow cytometry analyses 
as described above.   
 
Macropinosome visualization and quantification148 
Fifty thousand cells (Panc-1 and BxPC-3) were seeded onto glass coverslips, 
and 24 hours after seeding the cells, they were serum starved for 18 hours. For 
5-(N-ethyl-N-isopropyl) amiloride (EIPA, Sigma Aldrich) treatment, cells were pre-
treated with 5µM, 25µM or 75µM EIPA for 30 minutes at 37°C. DMSO was used 
as a vehicle. Cells were then incubated with exosomes or liposomes, labeled with 
PKH67 (Sigma Aldrich) for 3 hours at 37°C. Macropinosomes were detected 
using a high molecular mass TMR-dextran (Invitrogen), wherein TMR dextran is 
added to the serum free media at a concentration of 1mg/mL for 30 minutes at 
37°C. At the end of the incubation period, cells were rinsed 5 times with cold PBS 
and fixed with 4% PFA. Cells were then stained with DAPI nuclear stain, and 
then coverslips were mounted onto the slides. Images were then captured using 
Zeiss Observer Z1 inverted microscope, and at least three fields from atleast 
three to five separate wells were randomly selected across each sample, and 
analyzed using the ‘Analyze Particles’ feature on Image J, according to 
Commisso C. and colleagues148. The particle density was then expressed as the 
relative number of macropinosomes. Briefly, the ‘macropinocytic index’ was 
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computed by determining the total macropinosome area in relation to the total 
cell area for each field, and then determining the average across all fields. A 
detailed protocol to analyze and calculate the amount of macropinocytosis within 
a sample is listed in148. A similar quantification was performed using PKH67 label 
and the result was expressed as the relative number of exosomes or liposomes. 
The macropinocytosis assay was repeated again as an independent experiment. 
 
Statistical analyses 
Statistical analyses used are detailed in the figure legends.  One-way ANOVA or 
unpaired two tailed student’s t test were used to establish statistical significance 
using GraphPad Prism (GraphPad Software). For survival analyses, Kaplan-
Meier plots were drawn and statistical differences evaluated using the Log-rank 
(Mantel-Cox) test. A P value < 0.05 was considered statistically significant.  
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Chapter 3: iExosomes specifically target KrasG12D expression and induce 
apoptosis of pancreas cancer cells  
 As mentioned above, targeting the mutant allele of Kras has been an 
issue, as well as using an efficient drug delivery system that does not cause any 
overt toxicity, enters the target cells and releases cargo efficiently, as well as 
remaining in the circulation of a longer period of time, as compared to other 
nanoparticles. We therefore explored the idea of designing RNAi constructs that 
were specific only towards the KrasG12D mutant allele, and would not target the 
WT allele, as described previously88,90.  
Therefore, to address the problem of targeting only the mutant allele of 
Kras, as well as utilizing an efficient drug delivery method, we initially isolated 
exosomes from non-tumerigenic human foreskin fibroblast cells by 
ultracentrifugation. The purity and homogeneity (40-150 nm diameter particles) of 
the exosomes collected using ultracentrifugation methodology were validated by 
nanoparticle tracking analysis (NanoSightTM; R Fig. 1A), transmission electron 
microscopy and CD9 immunogold labeling, which is a protein that is well 
established in literature to be found on the surface of exosomes derived from 
most types of cells (R Fig. 1B). In addition, as a drug delivery comparative 
measure, we analyzed 100nm liposomes by nanoparticle tracking analysis, as 
well as for using them in further experiments downstream to compare the efficacy 
of RNAi loading and delivery efficiency (R Fig. 1A). 
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 Furthermore, after characterizing the exosomes isolated from fibroblast 
cells, we designed RNAi (both siRNA and shRNA) that was specific towards the 
G12D allele, which targeted the GGT to GAT single base amino acid substitution. 
The siRNA also had an Alexa 647 fluorophore attached to the sense strand. Both 
the siRNA and shRNA were packaged inside exosomes by the process of an 
optimized electroporation protocol (see methods) (hereafter referred to as 
iExosomes) (R Fig. 2A). To indeed confirm the presence of the RNA cargo within 
exosomes, we electroporated exosomes with the fluorophore tagged siRNA and 
ran them through a continuous sucrose gradient, after which each 1mL gradient 
was ran through a spectrophotometer to detect the AF647 fluorophore. 
Exosomes were loaded from the bottom (Bottom-Up) as well as from the top 
(Top-Down) (See methods). Liposomes electroporated with the AF647 siRNA as 
well as just electroporated siRNA were ran as controls under the same 
conditions. Fractionation using sucrose gradient and spectrophotometric 
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detection of Alexa-Fluor 647 indicated the detection of the AF647-tagged siRNA 
electroporated into exosomes and liposomes, whereas electroporated siRNA 
without exosomes did not accumulate in sucrose gradient fractions 
characteristics of exosomes (R Fig. 2B-C). Consistent findings were noted in 
both “Bottom-Up” and “Top-Down” methods.  
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 After confirming the presence of KrasG12D RNAi within exosomes, we 
wanted to evaluate the efficiency of loading within exosomes by our optimized 
electroporation methods. Previous studies have established variable loading 
efficiencies by electroporation154,162. Therefore, in order to evaulate our loading 
efficiency, we used the Custom TaqMan® Small RNA Assay kit (Applied 
Biosystems) that specifically detects either the sense or anti sense strand of the 
KrasG12D siRNA. Therefore, we then measured the amount of siRNA in 
iExosomes vs iLiposomes by quantitative PCR. Control exosomes (no KrasG12D 
siRNA) and siScramble siRNA PCR amplification did not yield any detectable Ct 
values, supporting the specificity of the PCR assay for KrasG12D siRNA 
quantification (R Fig. 3A). We observed that the efficiency of loading with 
exosomes was high, consistent, and similar to the loading within liposomes (R 
Fig. 3A). We also noted that while RNAse A digested the naked siRNA, the 
siRNA electroporated into exosomes or liposomes was protected from digestion 
(R Fig. 3A). In contrast, treatment of iExosomes with RNAase A in the presence 
of detergent (Triton X-100) resulted in the digestion of the siRNA, whereas 
RNAase A or detergent alone did not result in siRNA digestion (R Fig. 3B). 
R Fig 2: Sucrose gradient of iExosomes (A) Schematic representation of electroporation of 
RNAi into exosomes. The RNAi in the representation is tagged with Alexa fluor 647 (AF647). (B) 
Schematic and fluorescence intensity plot of sucrose gradient layers (from the “Bottom-Up” 
method) containing BJ fibroblast exosomes electroporated with Alexa Fluor 647 (AF647) tagged 
siRNA, liposomes electroporated with Alexa Fluor 647 (AF647) tagged siRNA, and electroporated 
Alexa Fluor 647 (AF67) tagged siRNA. The detection of the fluorescence of Alexa-Fluor 647 
fluorophore is depicted as the ratio of fluorescent intensity of the sucrose gradient layer wells over 
the fluorescent intensity of PBS (negative control) containing wells. (C) Schematic and 
fluorescence intensity plot of sucrose gradient layers (from the “Top-Down” method) containing BJ 
fibroblast exosomes electroporated with Alexa Fluor 647 (AF647) tagged siRNA, liposomes 
electroporated with Alexa Fluor 647 (AF647) tagged siRNA, and electroporated Alexa Fluor 647 
(AF67) tagged siRNA. The detection of the fluorescence of Alexa-Fluor 647 fluorophore is 
depicted as the ratio of fluorescent intensity of the sucrose gradient layer wells over the 
fluorescent intensity of PBS (negative control) containing wells. 
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These results indicated that the majority of siRNA in the iExosomes and 
iLiposomes was contained within the particles, rather than on the outside. 
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 After confirming high loading efficiency of KrasG12D RNAi within the 
exosomes by electroporation, we sought out to evaluate the effect of iExosomes 
on pancreatic cancer cells bearing a KrasG12D mutation. Therefore, after 
generating iExosomes (si/shKrasG12D iExo) and iLiposomes (si/shKrasG12D iLipo), 
as well as scrambled siRNA and shRNA containing exosomes and liposomes, 
we subjected Panc-1 cells (that harbor a KrasG12D mutation) to the above 
mentioned treatments. siKrasG12D and shKrasG12D containing exosomes 
treatment reduced KrasG12D mRNA levels (~70% and ~50% reduction, 
respectively) in Panc-1 human pancreatic cells compared to siScrbl/shScrbl 
exosomes or non-electroporated (control, without RNAi payloads) exosomes (R 
Fig. 4A). Liposomes containing siKrasG12D and shKrasG12D also reduced KrasG12D 
mRNA levels (~20%) in Panc-1 cells compared to control liposomes (R Fig. 4A), 
however the efficacy of downregulation was significantly lower as compared to 
iExosomes. In addition, for quantitative measurements, we observed that 
iExosomes showed efficacy at ~400 iExosomes per cell dosage after 3 hours of 
incubation. Increasing iExosomes concentration (~700 iExosomes per cell 
dosage) did not result in superior efficacy in suppressing KrasG12D transcript level 
(R Fig. 4B). Therefore we used a dosage of ~400 iExosomes per cell in all 
R Fig 3: Loading efficiency of siRNA in exosomes (A-B) 1/Ct values from RT-PCR analysis 
of exosomes and liposomes under the listed conditions, to determine the loading efficiency of 
siRNA within the exosomes and liposomes, as well as confirming the presence of the siRNA 
within the exosomes. Standards (siKrasG12D, 1:2 and 1:4 dilution): n=1, experimental groups: 
n=3 independent experiments. Please see methods for detailed description of experimental 
groups. The data is presented as the mean +/- SEM. 
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subsequent in vitro studies. Similar to what we saw with iExosomes, increasing 
the concentration of iLiposomes (up to 100-fold more than iExosomes) or 
increasing their incubation time (from 3 hours to 24 hours) with Panc-1 cells did 
not improve iLiposomes efficacy to target KrasG12D mRNA (R Fig. 4C). Notably, 
electroporated siRNA without exosomes, or exosomes mixed with siRNA at room 
temperature or 37°C did not significantly reduce KrasG12D levels in Panc-1 cells(R 
Fig. 4D). Additionally, a combination of electroporated/non-electroporated siRNA 
mixed with electroporated/non-electroporated exosomes (a detailed list of groups 
is described in the methods) also did not reduce KrasG12D levels as well, 
confirming our protocol optimization in engineering iExosomes to target 
oncogenic Kras expression (R Fig. 4E). 
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After confirming efficient downregulation of KrasG12D at the mRNA level, 
we wanted to evaluate and confirm the efficiency of downregulation at the protein 
level. Since there are no antibodies specific to the mutant alleles of Kras, we 
observed the levels of phosphorylated ERK in Panc-1 cells post treatment and 
incubation with iExosomes and iLiposomes. Oncogenic Kras suppression in 
Panc-1 cells treated with iExosomes was associated with robust decrease in 
phosphorylated-ERK protein levels while iLiposomes treatment showed marginal 
reduction in phosphorylated-ERK protein levels (R Fig. 5 A). In addition, we used 
a Ras activation assay to to evaluate the expression of active GTP bound Ras in 
cells treated with iExosomes. The assay uses the Ras Binding Domain (RBD) 
region of the Raf kinase, which is a Ras effector protein. The RBD protein motif 
 R Fig 4: iExosomes attenuate KrasG12D expression (A) Real time PCR analyses of KRASG12D 
transcript levels in Panc-1 cells (n=3 independent experiments) treated for 3 hours with siKrasG12D, 
shKrasG12D, siScrbl or shScrbl containing exosomes (iExo) or liposomes (iLipo), or non-
electroporated exosomes (empty cargo, control Exo). The fold change is represented relative to the 
expression of untreated Panc-1 cells (Control), arbitrarily set to 1. (B) Real time PCR analyses of 
KRASG12D transcript levels in Panc-1 cells treated for 3 hours with siKrasG12D or shKrasG12D iExo and 
with increased concentration of exosomes (700 exos per cell compared to 400 exos per cell), n=3 
independent experiments. The experiments with 400 exos per cell is the same data that is also 
presented in A. (C) Real time PCR analyses of KRASG12D transcript levels in Panc-1 cells treated for 
3 hours with siKrasG12D or shKrasG12D iLipo, siScrbl or shScrbl iLipo with increasing concentrations of 
liposomes (1x, 10x, 100x) as well as increased treatment time of Panc-1 cells (24 hours). The fold 
change is represented relative to the expression of untreated Panc-1 cells (control), which was 
arbitrarily set to 1. In all groups, n=3 independent experiments. (D) Real time PCR analyses of 
KRASG12D transcript levels in Panc-1 cells treated for 3 hours with the listed groups. The fold change 
is represented relative to the expression of untreated Panc-1 cells (control), which was arbitrarily set 
to 1. In all groups, n=3 independent experiments. (E) Real time PCR analyses of KRASG12D 
transcript levels in Panc-1 cells treated for 3 hours with the listed groups. The fold change is 
represented relative to the expression of untreated Panc-1 cells (control), which was arbitrarily set to 
1. In all groups, n=3 independent experiments. The data is presented as the mean ± SEM. Unless 
otherwise stated, one-way ANOVA was used to determine statistical significance. * p<0.05, ** p< 
0.01, *** p<0.001, **** p<0.0001. 
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binds specifically to the GTP bound form of Ras, which is ‘pulled-down’ by 
sepharose beads in the assay, and therefore allows the user to quantify the 
amount of active GTP bound Ras. Therefore, as expected, we observed a 
significant decrease in the expression of active GTP bound Ras in Panc-1 cells 
treated with iExosomes. Conversely, BXPC-3 cells (which do not harbor a 
KrasG12D mutation) were used as a control. These cells were subjected to 
iExosomes treatment under the exact same conditions, and showed no change 
in Ras expression (R Fig. 5 B). 
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 R Fig 5: iExosomes attenuate KrasG12D expression (A) Western blotting for phosphorylated ERK 
(p-ERK) and Vinculin (loading control) of lysates from untreated Panc-1 (Control) lysates and lysates 
from Panc-1 cells treated with siKrasG12D or shKrasG12D containing iExo, Panc-1 cells treated with 
siKrasG12D containing iLipo, and untreated Panc-1 (Control) lysates. (B) RAS pull-down assay in 
Panc-1 and BxPC-3 cells treated with siKrasG12D iExosomes, depicting the expression of active GTP 
bound RAS. 
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 After confirming that iExosomes induce efficient downregulation of 
KrasG12D at both the mRNA and protein level, we evaluated the effect of 
downregulating oncogenic Kras via iExosomes on both proliferation and 
apoptosis. We observed by MTT assay that suppression of oncogenic Kras and 
downstream signaling significantly impaired proliferation (R Fig. 6 A). 
Significantly high apoptosis levels were also detected in Panc-1 cells post 
incubation of iExosomes, with both TUNEL assay, and flow cytometry detecting 
propidium iodide and LIVE/DEAD fixable aqua (R Fig. 6 B-C). As mentioned 
above, specificity in targeting only the oncogenic allele of Kras is extremely 
imperative. Therefore, to address this issue, we treated three other cell lines that 
do not harbor a KrasG12D mutation to evaluate whether iExosomes treatment on 
these cells lines would induce any changes in either proliferation or their 
respective Kras allele expression. We observed that iExosomes treatment was 
specific to cancer cells with KrasG12D mutation. BxPC-3 (KrasWT), Capan-1 
(KrasG12V), and MIA PaCa-2 (KrasG12C) human pancreatic cancer cells do not 
harbor KrasG12D mutation as mentioned earlier, and iExosomes treatment did not 
suppress wild-type Kras, KrasG12V or KrasG12C expression, respectively (R Fig. 
6D-F). Proliferation was also unaffected by sh/siKrasG12D iExosomes treatment in 
these cells (R Fig. 6G-I). 
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 R Fig 6: iExosomes induce apoptosis and suppress proliferation (A) MTT assay of Panc-1 
cells (n=5 partitions of indicated treatments with 3 or 6 wells for each partition of treatment) with 
the listed treatments over the course of five days. Statistical analyses were performed at the 
endpoint. (B) Representative immunostaining micrographs (scale bar: 100µm) for TUNEL in Panc-
1 cells (n=3 distinct wells of cells) exposed to the listed treatments and associated quantification. 
Puromycin was used as positive control. (0) indicates no cells were detected positive for TUNEL. 
Control: untreated, Control Exo: non-electroporated (no siRNA cargo) exosomes. (C) Flow 
cytometry analyses and quantification of apoptosis in Panc-1 cells treated with either siKrasG12D 
iExo or siScrbl iExo. Three different treatments were used to treat n=3 distinct wells of cells.  (D) 
Real time PCR analyses of wild-type KRAS transcript levels in BxPC-3 cells (n=3 independent 
experiments) treated for 3 hours with siKrasG12D, shKrasG12D, siScrbl, shScrbl containing exosomes 
(iExo), or non-electroporated exosomes (empty cargo, control Exo).  
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 These results indicated that we could successfully electroporate and load 
KrasG12D RNAi into exosomes with a high efficiency, and that the majority of RNAi 
was located inside the exosomes. In addition, treatment of pancreatic cancer cell 
lines harboring a KrasG12D mutation in vitro resulted in a significant 
downregulation of the G12D allele, decreased proliferation and increased 
apoptosis. Finally, these results also indicated that the iExosomes treatment in 
vitro was specific only towards the G12D allele. 
 
 
 
 
 
 
 
 
 
 R Fig 6 contd (E) Real time PCR analyses of KRASG12V transcript levels in Capan-1 cells (n=3 
independent experiments) treated for 3 hours with siKrasG12D, siScrbl, containing exosomes (iExo), 
or non-electroporated exosomes (empty cargo, control Exo). (F) Real time PCR analyses of 
KRASG12C transcript levels in MIA PaCa-2 cells (n=3 independent experiments) treated for 3 hours 
with siKrasG12D, siScrbl, containing exosomes (iExo), or non-electroporated exosomes (empty 
cargo, control Exo). (G) MTT assay of BxPC-3 cells (n=5 partitions of treatment given to 3 wells 
each) over the course of five days with the listed treatments. (H) MTT assay of Capan-1 cells (n=3 
partitions of treatment given to 10 wells each) over the course of five days with the listed 
treatments. (I) MTT assay of MIA PaCa-2 cells (n=3 partitions of treatment given to 10 wells each) 
over the course of five days with the listed treatments. The data is presented as the mean +/- 
SEM. One-way ANOVA comparing experimental groups to control group was used to determine 
statistical significance. **** p<0.0001, ns: not significant. 
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Chapter 4: iExosomes restrain growth of Panc-1 orthotopic tumors 
 After observing extremely encouraging results in vitro, our focus shifted to 
treating mice with pancreatic tumors. In view of this, we explored the capacity of 
iExosomes to silence KrasG12D expression in human pancreatic orthotopic 
tumors. Luciferase expressing Panc-1 human pancreatic cancer cells were 
implanted orthotopically in nude mice (R Fig. 7A). Ten days after implantation of 
cancer cells, all mice presented with detectable tumors by bioluminescence 
imaging. The mice were randomized and subjected to repeated i.p. 
administration with 108 iExosomes or iLiposomes on average every 48 hours. 
This dosage of exosomes represents approximately 0.15 to 0.20 µg of exosomal 
protein per injection. In previous studies, 5 to 10 µg of exosomal proteins were 
delivered per injection into tumor bearing mice163,164. Cohorts of mice were also 
injected with PBS vehicle, non-electroporated exosomes (control Exo) or 
exosomes and liposomes with scrambled RNAi constructs. Accumulation of 
iExosomes payload (AF647 tagged siRNA) was readily detected in the pancreas 
(R Fig. 7B). Post treatment of iExosomes every other day, the tumors of mice 
administered with PBS, control exosomes or si/sh Scramble iExosomes grew at 
an exponential rate (R Fig. 7C-D). Conversely, the tumors of mice treated with 
iExosomes were significantly reduced even after 20 days post treatment, and 
continued to maintain a baseline level until experimental endpoint of 200 days 
(post tumor implantation) (R Fig. 7C-D). Tumor growth was blunted in mice 
treated with iLiposomes, however to a much lesser extent than mice treated with 
iExosomes (R Fig. 7C-D). Histopathological analyses at the end point showed 
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advanced pancreatic tumors in all the control mice, in contrast to mostly normal 
pancreas parenchyma in the iExosomes treated mice (R Fig. 7D).
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progression timeline with experimental treatment points. Treatment was started on day 10, and continued 
every other day. (B) Representative confocal micrographs (scale bar: 100µm, inset displays digital zoom) 
of healthy mouse pancreas 24 hours following i.p. injection with Alexa-Fluor 647-tagged siRNA containing 
exosomes. Nuclear staining: SYTOX green. Arrowheads point to accumulation of label. (C) Representative 
images of luciferase activity in mice with orthotopic Panc-1 tumors at day 7 and day 77 post cancer cell 
injection and comparative analysis of averaged radiance of bioluminescence at day 77. (D) Relative 
radiance of bioluminescent Panc-1 orthotopic tumors over time. Experimental groups started with PBS: 
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Exo, sh and si Scramble and shKrasG12D iLipo) groups). Representative H&E of the pancreas (scale bar: 
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statistical significance. * p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001, ns: not significant 
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 The survival of iExosomes treated mice was significantly increased, 
wherein the control mice had a median survival of around 80-110 days, while all 
but one (died due to non tumor related issues) iExosomes treated mice were all 
alive at 200 days post tumor implantation (R Fig. 8A). Relative pancreas mass 
(expressed as a percent of pancreas mass compared to body mass at 
experimental endpoint) was also significantly reduced in the iExosomes treated 
mice as compared to controls (R Fig. 8B). Histopathological analyses of the 
tumors at end point showed advanced pancreatic tumors in all the control mice 
(R Fig. 8C).  Further delving histologically, immunolabeling of tumors for p-ERK 
(R Fig. 8D) and p-AKT (R Fig. 8E). revealed significantly suppressed expression, 
therefore pointing to attenuation of oncogenic Kras signaling in tumors of mice 
treated with iExosomes. Furthermore, real time PCR analysis of the tumors 
revealed reduced KrasG12D expression levels in treated mice as compared to 
controls (R Fig. 8F).   
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 Thereafter, to evaluate how long the efficacy of iExosomes treatment 
would last, in a separate cohort of nude mice orthotopically implanted with Panc-
1 cells, iExosomes treatment was initiated at Day 10, and after initial tumor 
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R Fig 8: iExosomes restrain Panc-1 orthotopic tumor growth (A) Kaplan-Meier curve indicating 
survival of mice in the listed experimental groups. Log-rank Mantel-Cox test, PBS: n=7, Control Exo: 
n=6, shKrasG12D iExo: n=7, shKrasG12D iLipo: n=4, shScramble iExo: n=5, siScramble iExo: n=5. (B) 
Relative pancreas mass (as a percent of body mass) in the indicated experimental groups upon 
euthanasia (PBS, n=5:  Day 62-130, Control exos, n=5:  Day 30-132, shKrasG12D iExo, n=6: Day 200, 
shKrasG12D iLipo, n=4: Day 68-137, shScramble iExo, n=5: Day 56-108, siScramble iExo, n=5: Day 68-
109, and normal healthy mice, n=5). (C) Representative H&E of the Panc-1 orthotopic pancreas is 
shown at the indicated experimental endpoints (siScramble iExo: day 109, shScramble iExo: day 108, 
siKrasG12D iLipo: day 108, scale bar: 100µm). (D) Representative micrographs (scale bar: 100µm) of 
tumors immunolabeled for phosphorylated AKT (p-AKT) and quantification of percent p-AKT stained 
area in pancreas tumors, Control Exo, n=4; shKrasG12D iExo, n=6 mice. Unpaired two-tailed t-test was 
used to determine significance. (E) Representative p-ERK immunolabeling (scale bar: 100µm) and 
quantification of percent p-ERK staining in pancreas tumors in the experimental groups. Unpaired two-
tailed t-test, Control Exo: n=4 mice, shKrasG12D iExo: n=6 mice. (F) Real time qPCR analysis of 
KrasG12D transcript levels in tumors of mice with orthotopic Panc-1 tumors treated with either Control 
Exo (n=5 mice, arbitrarily set to 1) or shKrasG12D iExo (n=6 mice), unpaired two-tailed t test. The data 
is presented as the mean +/- SEM. Unless stated otherwise, one-way ANOVA was used to determine 
statistical significance. * p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001, ns: not significant. 
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reduction, was suspended on Day 35 post tumor induction. iExosomes treatment 
suspension after initial tumor reduction showed sustained suppression effects on 
tumor growth that lasted over 10 days following the last treatment with 
iExosomes (R Fig. 9A). In this experiment, all control mice (siScrbl iExo) 
succumbed to pancreatic cancer, whereas the siKrasG12D iExo treated mice 
(treatment window: from day 10 to day 35, post cancer cell injection) were all 
alive (day 87). At this point in time, siKrasG12D iExosomes treatment was re-
initiated in this cohort of mice (R Fig. 9A-B).  Resuming siKrasG12D iExosomes 
treatment controlled the growth of these advanced tumors (R Fig. 9A-B).  
Despite continuous treatment at an advanced disease state, the mice responded 
with partial tumor growth control but ultimately succumbed (R Fig. 9A-B). To 
infer whether treatment with iExosomes is specific towards only the G12D allele, 
nude mice were orthotopically implanted with BXPC-3 (KrasWT) cells and 
iExosomes treatment initiated on day 14-post tumor induction. ). In contrast to 
the sustained anti-tumor effects of iExosomes treatment of mice with Panc-1 
orthotopic tumors, iExosomes did not impact orthotopic BxPC-3 tumor growth (R 
Fig. 9C-D) nor impact the overall survival of these mice (R Fig. 9E). 
Histopathological analyses of the tumors at end point showed advanced 
pancreatic tumors in all the groups, including iExosomes treated mice, confirming 
the specificity of the treatment towards the G12D allele (R Fig. 9F). 
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 Additionally, to evaluate more controls in vivo, we also tested the 
therapeutic efficacy of proteinase K (PK) + RNAse A (RN) treated iExosomes 
and RNAse A treated exosomes in Panc-1 orthotopic tumor bearing mice. Loss 
of surface proteins on exosomes with PK treatment, validated by flow cytometry 
(R Fig. 10A), significantly suppressed the anti-tumor efficacy of iExosomes, 
whereas RNAse A treatment alone did not have any impact on the anti-tumor 
efficacy of iExosomes (R Fig. 10B-D). A single injection of iExosomes followed 
by iLiposomes treatment did not yield a sustained, robust anti-tumor response 
when compared to continuous iExosomes treatment (R Fig. 10B-D). KrasG12D 
siRNA electroporated without exosomes and exosomes mixed with KrasG12D 
siRNA (no electroporation) also failed to offer a robust, sustained anti-tumor 
response when compared to iExosomes (R Fig. 10B-D). The partial response 
observed when treating mice with iExosomes mixed with KrasG12D siRNA, in 
contrast to naked (electroporated) siRNA, may reflect the siRNA uptake into 
exosomes154, albeit to a lesser efficiency than when electroporated (R Fig. 10B-
D). 
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 Therefore, these results indicated that iExosomes treatment was 
effective in an in vivo orthotopic model of pancreatic cancer. Treatment of Panc-1 
orthotopic mice lead to a significant decrease in tumor burden, better 
histopathology of the pancreas, as well as an increase in the lifespan of the mice. 
Even though treatment was suspended in another cohort, iExosomes showed 
sustained suppression of the tumor for about 10 days. Thereafter, once treatment 
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BJ fibroblasts, n=3 independent experiments. (B) Relative radiance of bioluminescent Panc-1 
orthotopic tumors in nu/nu mice over time, n=6 mice per group. Treatment was started on day 10-
post tumor cell induction. (C) Comparative analysis of measured radiance of bioluminescence at day 
45-post tumor cell induction, n=6 mice per group. (D) Kaplan-Meier curve comparison indicating the 
survival of mice in the indicated experimental groups in Panc-1 nu/nu mice. Log-rank Mantel-Cox 
test, n=6 in each group. The data is presented as the mean +/- SEM. Unless stated otherwise, one-
way ANOVA was used to determine statistical significance. . * p<0.05, ** p< 0.01, *** p<0.001, **** 
p<0.0001, ns: not significant. 
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was re-initiated at a significantly later stage, iExosomes still displayed partial 
tumor growth control. iExosomes treatment did not show any efficacy in an 
orthotopic BXPC-3 model, confirming specificity towards only the G12D allele. 
Finally, treatment of iExosomes with RNAse prior to injection in mice did not 
change the efficacy, confirming that majority of the RNAi cargo is within the 
exosomes. Proteinase K treatment of iExosomes prior to injection significantly 
inhibited their efficacy, suggesting the importance of various proteins on the 
surface in either evading immune surveillance or binding to cell membranes and 
entering cells to release their cargo.  
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Chapter 5: iExosomes suppress pancreatic cancer progression in KTC 
GEMM 
 A majority of the progress made in the understanding the biology, 
discovering the functions of genes and pathways, as well as testing out the 
efficacy of new drugs, in PDAC, has occurred due to the use of genetically 
engineered mouse models (GEMMs). Due to their mutational signature, GEMMs 
are able to recapitulate histopathologically what is found in the clinic in patients. 
Another property of pancreatic cancer is the vast desmoplasia, which is the 
fibrous inflammatory reaction that is found within the tumor. The stroma can 
make up upto 90% of the tumor and plays a role in tumor development, 
progression and chemotherapeutic response165. Most orthotopic models of 
pancreatic cancer cannot properly recapitulate this desmoplasia within a tumor, 
but GEMMs can.  
 Therefore to address the clinical potential of iExosomes in the 
treatment of advanced pancreatic cancer, we treated the rapidly progressing and 
highly aggressive Ptf1acre/+;LSL-KRasG12D/+;Tgfbr2Lox/Lox mice (KTC mice)161 with 
iExosomes. The type II TGF-β receptor (Tgfbr2) gene is deleted or mutated in a 
subset of pancreatic cancers and it has been shown that inactivation or impaired 
TGF- β signaling has contributed to PDAC cells being highly invasive and 
metastatic166. These mice have been shown to display pancreatic intraepithelial 
neoplasia (PanIN) at around 4 weeks of age, invasive ductal adenocarcinoma at 
around 5 weeks of age, and die at around 7 weeks of age. Therefore, due to the 
aggressive nature, the consistency in terms of tumor onset, progression and 
   96 
death, as well as the histopathology that recapitulates what is found in the clinic, 
we evaluated the efficacy of iExosomes treatment in this model. 
 Mice were injected every other day, intra peritoneally with control 
exosomes or iExosomes starting on day 33 (late treatment start) when mice 
present with PDAC (R Fig. 11A). This properly recapitulates what is observed in 
the clinic, where symptoms are latent, and patients have invasive ductal 
adenocarcinoma. Additionally, to evaluate the efficacy of IExosomes in KTC mice 
with relatively small tumors at an early stage, mice were injected every other day 
starting on day 18 (early treatment) (R Fig. 11A). Post i.p. injection of 
iExosomes, accumulation of Alexa-Fluor 647 labeled siRNA was detected in the 
tumors of KTC mice (R Fig. 11B). KTC mice treated with iExosomes from day 33 
(late treatment) showed a significant increase in their lifespans. Mice treated with 
control exo had a median survival of around 43 days, whereas shKrasG12D iExo 
mice had a median survival of 49 days and siKrasG12D iExo had a median survival 
of 64 days (R Fig. 11C). The increased overall survival was associated with a 
significant decrease in tumor burden in iExosomes-treated mice when compared 
to control mice at experimental endpoint (R Fig. 11D). Histopathological analysis 
of iExosomes-treated mice revealed a relative increase in early PanIN stage 
lesions, in contrast to complete conversion of the pancreas into PanIN and PDAC 
lesions with invasive features in control mice. The pancreas of iExosomes-
treated mice at 60 days (experimental endpoint) also presented with decreased 
invasive adenocarcinoma as compared to the control mice (R Fig. 11E). 
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Representative micrographs (scale bar: 100µm, inset displays digital zoom) of pancreas tumor 
section from KTC mice depicting accumulation of internalized Alexa-Fluor 647-tagged siRNA from 
exosomes. Nuclei are labeled with SYTOX Green. Arrowheads point to accumulation of Alexa-Fluor 
647 signal. (C) Kaplan-Meier curve indicating the survival of mice in the listed experimental groups. 
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non-electroporated exosomes (Control Exo), and associated quantification of the relative 
percentages in histological phenotypes, n=4 mice per group.  The data is presented as the mean +/- 
SEM. Unless stated otherwise, unpaired two-tailed t test was used to determine statistical 
significance. * p<0.05, **** p<0.0001. 
 
   98 
 Early treatment of KTC mice (day 18) with iExosomes resulted in a 
significant increase in survival as well. The median survival of mice treated with 
control exosomes was 42.5 days, while the median survival of mice treated with 
iExosomes was 70 days, suggesting an advantage of treating mice at an earlier 
stage with smaller tumor burdens (R Fig. 12A) The increased overall survival in 
the early treatment cohort was associated with a significant decrease in tumor 
burden in iExosomes-treated mice when compared to control mice at 
experimental endpoint (R Fig. 12B). In previous studies employing two 
genetically engineered mouse models of pancreatic cancer161,167-169, treatment 
with gemcitabine did not lead to significant decrease in tumor growth or lead to 
an increase in overall survival of tumor bearing mice. We observed similar results 
in this study (R Fig. 12C), confirming the efficacy of iExosomes in the treatment 
of KTC mice. To address the potential impact of immune response in the efficacy 
of human iExosomes in KTC mice, we isolated fibroblasts from the ear of 
C57Bl/6 mice and purified exosomes from these primary cell cultures and 
generated iExosomes. A similar improvement in survival, tumor burden, and 
histopathology was noted when using mouse fibroblast-derived iExosomes, 
compared with BJ fibroblast-derived iExosomes (R Fig. 12D-E). 
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 To evaluate the molecular changes of iExosomes treatment in detail, 
mice were treated with either control exosomes or iExosomes at day 33, every 
other day until day 44, which is when they were sacrificed. A histological analysis 
of these aged matched mice revealed a significant increase in normal 
parenchyma in the iExosomes treated mice. There was also a relative increase in 
early PanIN stage lesions, in contrast to complete conversion of the pancreas 
into PanIN and PDAC lesions with invasive features in control mice (R Fig. 13A). 
Better histopathology with significantly less invasive ductal adenocarcinoma 
therefore correlated with a decreased tumor burden (R Fig. 13B). Real time 
qPCR analysis of the pancreas tumors revealed significantly downregulated 
KrasG12D expression in the iExosomes treated cohort (R Fig. 13C). 
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 Additionally, treatment with iExosomes significantly diminished 
pancreas desmoplastic reaction, by having four times as less fibrotic area, as 
compared to control exosomes treated mice. A significantly decreased tumor 
burden in the iExosomes treated cohort corresponded to an increase in 
apoptosis (as shown by TUNEL staining) and a decrease in proliferating cells (as 
shown by Ki-67 staining). iExosomes treated mice also showed attenuation of 
phosphorylated ERK expression in CK-19 ductal cells. A significant decrease in 
phosphorylated AKT was also observed in the treatment cohort, while α SMA 
expression was strongly reduced as well. Finally, due to iExosomes targeting 
oncogenic Kras, total Kras protein expression was also highly downregulated in 
treated mice (R Fig. 14) 
 
 
 
 
 
 
R Fig 13: iExosomes suppress KTC tumors (A) Representative micrographs (scale bar: 100µm, 
inset scale bar: 50 µm) of H&E stained tumors from 44 days-old KTC mice treated with siKrasG12D 
containing exos or non-electroporated control exos, and quantification of the relative percentages 
in histological phenotypes, n=3 mice per group. (B) Tumor burden (relative mass of pancreas to 
body mass) in the indicated experimental groups at 44 days of age, n=3 mice per group. (C) Real 
time qPCR analysis of KrasG12D transcript levels in tumors of KTC mice treated with Control Exo or 
siKrasG12D iExo, n=3 mice per group.  The data is presented as the mean +/- SEM. Unless stated 
otherwise, unpaired two-tailed t test was used to determine statistical significance. * p<0.05, ** 
p<0.01, *** p<0.001. 
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R Fig 14: Immunolabeling of KTC tumors Representative micrographs (scale bar: 50µm) of 
pancreas processed for Masson Trichrome staining (MTS) and immunolabeling for apoptosis 
marker TUNEL, proliferation marker Ki-67, and phosphorylated-ERK and CK-19 co-stain, 
phosphorylated AKT, αSMA and Kras of 44 days-old KTC mice in the indicated experimental 
groups, and corresponding quantifications, n=3 mice.  The data is presented as the mean +/- 
SEM. Unless stated otherwise, unpaired two-tailed t test was used to determine statistical 
significance. * p<0.05, ** p<0.01, **** p<0.0001. 
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Chapter 6: CD47 on exosomes suppress their clearance by monocytes 
 
 iExosomes treatment in both mice orthotopically implanted with Panc-1 
cells, as well as in KTC GEMM displayed significant efficacy in terms of 
increasing the lifespan of the mice, decreasing tumor burden as well as 
attenuating KrasG12D expression, and subsequently expression of downstream 
pathways as well. In the orthotopic Panc-1 model, iExosomes treatment was 
significantly more effective than liposomes in increasing the lifespan, decreasing 
the tumor burden and attenuating the expression of downstream pathways. We 
therefore sought to explain the mechanisms behind why iExosomes were 
significantly better drug delivery vehicles, as compared to liposomes. 
 Initially, to ascertain the biodistribution properties of fibroblast exosomes in 
vivo, fibroblast exosomes were labeled with PKH67, a lipid membrane dye. 
These exosomes were then injected intra-peritoneally into immunocompetent 
C57Bl/6 mice, and 3 hours post injection, the organs harvested for 
immunofluorescence analysis of PKH67 positive exosomes within the different 
organs. We analyzed the liver, lung, pancreas, spleen, kidney, GI tract and the 
brain. Three hours post injection of PKH67 labeled exosomes, we observed that 
a majority of the injected exosomes were found localized in the liver, lung, spleen 
and pancreas, whereas the brain, kidney and G.I. Tract were less enriched (R 
Fig. 15) 
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R Fig 15: Biodistribution of BJ exosomes Representative micrographs and quantification of the 
brain, GI tract, kidney, liver, lung, pancreas and spleen of immunocompetent C57BL/6 injected i.p. 
with PKH67 labeled BJ fibroblast exosomes (n=3 mice). White box shows digital zoom inset. 
Yellow arrowheads point to accumulation of PKH67 label. Untreated mice were used as control 
(NC: negative control). 
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 Furthermore, as a comparison drug delivery vehicle, liposomes were used 
(see methods for details on liposomes).  Fibroblast exosomes and liposomes 
both were electroporated with AF647 tagged siRNA, and injected intra-
peritoneally into immunocompetent C57Bl/6 mice. Six hours post injection, the 
pancreas were harvested, digested, and analyzed by flow cytometry for the 
presence of AF647 positive cells. We noted enhanced accumulation of AF647 
siRNA in cells of the pancreas of mice treated with exosomes (8.0% of cells) 
compared to liposomes (2.8% of all cells), suggesting that exosomes are more 
efficient in entering the pancreas and delivering their cargo, as compared to 
liposomes (R Fig. 16A). Additionally, twenty-four hours post-injection, about 5% 
of cells in normal pancreas still retain AF647 positivity with iExosomes injection, 
as compared to about 1% of cells with iLiposomes (R Fig. 16B). 
A property of efficient drug delivery vehicles is the ability to stay in the 
circulation for longer91. Therefore, to assess whether exosomes had a longer 
circulation time in vivo as compared to liposomes, both exosomes and liposomes 
were elctroporated with AF647 tagged siRNA, after which they were injected 
intra-peritoneally into either immunocompetent C57Bl/6 mice or 
immunocompromised nu/nu mice. Twenty-four hours post injection, the mice 
were retro-orbitally bled, and iExosomes or iLiposomes, circulating exosomes 
were isolated from the plasma of mice and subsequently AF647 positive 
exosomes or liposomes were detected by flow cytometry employing exosomes 
bound beads. In contrast to a minimal signal from iLiposomes, a higher 
expression of AF647 positive iExosomes were detected in the mouse circulation, 
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24 hours post injection. Similar results were observed when either C57Bl/6 or 
nude mice were studied (R Fig. 16C). Additionally, we also confirmed by flow 
cytometry, that both exosomes and liposomes have the same binding efficiency 
to the aldehyde sulfate beads used throughout the experiment (R Fig. 16D). 
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Therefore, we hypothesized the presence of certain proteins on the 
surface of exosomes that gave them an advantage over liposomes by surviving 
in the circulation for longer, and therefore being able to release more cargo in the 
tissue or organ of interest. As stated above, CD47 is a widely expressed integrin 
associated transmembrane protein, that functions in part to protect cells from 
phagocytosis. It is the ligand for signal regulatory protein alpha (SIRPα), which is 
expressed on phagocytic cells such as circulating monocytes and tissue 
macrophages, as well as dendritic cells. This CD47-SIRPα binding initiates the 
‘don’t eat me’ signal that inhibits phagocytosis133. Therefore, since CD47 may 
play a role in increasing the half-life of exosomes in the circulation in vivo, we 
evaluated the presence and role of CD47 on fibroblast exosomes.  
 By flow cytometry employing exosomes bound to beads, CD47 was 
detected on fibroblast exosomes. To confirm that exosomes specifically were 
R Fig 16: Circulation time of iExo vs iLipo (A) Flow cytometry analyses of digested pancreas of 
immunocompetent C57BL/6 mice injected i.p. with siKrasG12D Exos (n=5 mice), siKrasG12D Lipos 
(n=5 mice), and PBS (untreated, n=3 mice). The mice (C57BL/6) were analyzed 6 hours post 
injection. (B) Flow cytometry analyses of digested pancreas of immunocompetent C57BL/6 mice 
injected i.p. with siKrasG12D Exos, siKrasG12D Lipos, and PBS. The mice (C57BL/6) were analyzed 
24 hours post injection. (C) Representative dot plot for the flow cytometry analyses and 
quantification of AF647-tagged RNAi containing exosomes and liposomes isolated from the plasma 
of immunocompetent C57BL/6 mice (n=3) and Nude (Nu/nu) mice (n=3), at 24 hours post i.p. 
injection. Labeled exosomes/liposomes were detected using AF647 detection in the 
exosomes/liposomes, following binding to 4µm beads. Numbers in inset represent the percent 
positive beads. (D) Flow cytometry analyses and quantification of the comparison of the binding 
efficiency of either exosomes or liposomes to aldehyde sulfate beads, n=3 distinct batches of 
exosomes and liposomes were used. The data is presented as the mean ± SEM. Unless otherwise 
stated, one-way ANOVA was used to determine statistical significance. *** p<0.001, **** p<0.0001. 
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being detected and analyzed, CD63 was used as a control, and was highly 
expressed on fibroblast exosomes. In addition, CD47 was over expressed in 
fibroblast cells, and exosomes isolated from those cells displayed slightly higher 
expression of CD47. Conversely, exosomes derived from ear fibroblasts isolated 
from CD47 knockout mice were negative for CD47 (R Fig. 17A). As liposomes 
do not express any transmembrane proteins, they were negative for the 
expression of both CD47 and CD63 (R Fig. 17B). To explore whether CD47 
proteins on the surface would increase the circulation time of exosomes, 
fibroblast exosomes, CD47 knockout exosomes (CD47 ko) or CD47 over 
expressing exosomes (CD47h9gh iExo) were electroporated with AF647 tagged 
siRNA and injected intra peritoneally in immunocompetent C57Bl/6 mice. Three 
hours post injection, the mice were retro orbitally bled, and circulating exosomes 
were isolated from the plasma of mice and subsequently AF647 positive 
exosomes were detected by flow cytometry employing exosomes bound beads. 
Three hours post i.p. injection, exosomes were readily detected in the circulation, 
and CD47 k/o exosomes showed diminished retention in the circulation. CD47high 
iExo conversely displayed a higher retention in the circulation (R Fig. 17C). 
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 Generally, efficient phagocytosis by circulating monocytes and 
other cells removes dying/dead cells, cell debris and foreign particles. In order to 
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R Fig 17: CD47 expression on BJ exosomes (A) Flow cytometry analyses and quantification of 
CD63 and CD47 on exosomes from BJ fibroblast, BJ fibroblast with CD47 over-expression (BJ, 
CD47high), CD47 knockout (CD47 k/o) and C57BL/6 WT mouse ear fibroblasts. (B) Flow cytometry 
analyses and quantification of exosomal proteins CD63 and CD47 in liposomes. (C) Flow 
cytometry analysis of AF647 tagged siRNA containing exosomes in the circulation of mice (n=6 
mice per group), 3 hours post i.p. injection of exosomes derived from BJ fibroblasts, CD47 k/o 
fibroblasts, and BJ fibroblasts overexpressing CD47. Labeled exosomes were detected using 
AF647 detection in the exosomes, following binding to 4 µm beads.  The data is presented as the 
mean ± SEM. Unless otherwise stated, one-way ANOVA was used to determine statistical 
significance. * p<0.05, **** p<0.0001. 
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determine whether iExosomes and iLiposomes were being uptaken by 
phagocytes in the circulation, immunocompetent C57Bl/6 mice were injected with 
either iExosomes or iLiposomes containing AF647 tagged siRNA, and then retro-
orbitally bled 3 hours post injection. This was then analyzed for the total number 
of CD11b+ monocytes by flow cytometry. The total number of CD11b+ monocytes 
in the blood was significantly higher in liposomes injected mice, as compared to 
exosomes injected mice, suggesting that liposomes may mobilize significantly 
higher number of circulating monocytes when compared to exosomes (R Fig. 
18A). To determine whether such mobilization impacts the efficiency of 
phagocytosis, we evaluated over time the frequency of circulating monocytes 
containing AF647 labeled siRNA following injections of iExosomes or 
iLiposomes. While control mouse blood (untreated) did not show AF647 positivity 
in CD11b+ monocytes, 18.73% and 9.36% of AF647+ monocytes were detected 
in the blood of C57Bl/6 mice administered with iLiposomes or mouse ear 
fibroblasts-derived iExosomes, respectively (R Fig. 18B). Enhanced uptake of 
the AF647 label by circulating monocytes was thus noted when C57Bl/6 mice 
were treated with liposomes compared to exosomes (R Fig. 18B). When CD47 
k/o exosomes were used, 15.45% of AF647+ monocytes were detected in the 
circulation (R Fig. 18B), supporting that the presence of CD47 on exosomes 
limits their phagocytosis by circulating monocytes. We also assayed AF647+ 
circulating monocytes from mice injected with iExosomes (from BJ human 
fibroblasts) and iExosomes incubated with anti-CD47 B6H12 and 2D3 
neutralizing antibodies, or IgG control antibodies. Anti-CD47 B6H12 prevents 
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CD47/SIRP inhibition of phagocytosis whereas anti-CD47 2D3 does not limit 
phagocytosis133. In contrast to control mice (exosomes, exosomes + IgG, 
exosomes + anti-CD47 2D3 antibodies), anti-CD47 B6H12 antibodies 
significantly increased the monocyte accumulation of AF647  (R Fig. 18B). The 
monocyte clearance of iExosomes was diminished when CD47High iExosomes 
were injected in comparison to iExosomes with baseline CD47 expression (R 
Fig. 18B). These results suggest that circulating monocytes engulf liposomes 
rapidly compared to exosomes, and that the presence of CD47 on the surface of 
exosomes activates the “don’t eat me” signal, and extends their circulation time 
in vivo. 
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 R Fig 19 A depicts the gating strategy for all phagocytosis flow cytometry 
assays, from gating the lymphocyte population, to single cells, to live cells, and 
finally quantifying the AF647 positive population from CD11b+ cells. We also 
sought to evaluate the binding efficiency of both 2D3 and B6H12 CD47 
antibodies to make sure the experiment was well controlled for, and notably, the 
binding of anti-CD47 2D3 and anti-CD47 B6H12 antibodies to exosomes was 
similar (R Fig. 19B). In addition, to confirm that phagocytosis of 
iExosomes/iLiposomes was indeed CD47-SIRPα based, the CD11b AF647 
positive population was evaluated for CD172 (SIRPα) positivity. Around 98% of 
CD11b AF647 positive population was positive for CD172, confirming that 98% of 
monocytes engulfing iExosomes/iLiposomes were positive for SIRP-α (R Fig. 
19C). Finally, and very interestingly, the number of exosomes, quantified by 
R Fig 18: CD47 driven phagocytosis analysis (A) Flow cytometry analysis of the measure of 
percent CD11b+ cells in the circulation, 3 hours following i.p. injection of liposomes (n=7 mice) or 
exosomes (n=7 mice). Untreated mice (n=4) were used as control.   (B) Flow cytometry analyses 
and quantification of the percentage of Alexa 647+/CD11b+ monocytes in the blood of 
immunocompetent adult C57BL/6 mice 3 hours post i.p. injection. For all conditions, Exosomes 
denotes siKrasG12D iExo. One way ANOVA was used to compare untreated mice (Non treated, 
n=12) and mice treated with siKrasG12D iLipo (Liposomes, n=9), IgG+siKrasG12D iExo (n=9 mice), anti-
CD47 (B6H12)+siKrasG12D iExo (n=8 mice) and anti-CD47 (2D3)+siKrasG12D iExo (n=6 mice). 
Unpaired two-tailed t test was used to compare mice treated with siKrasG12D iExo (n=13 mice) and 
iExosomes isolated from BJ fibroblast cells overexpressing CD47 (CD47high iExo, n=7). Unpaired 
two-tailed t test was used to compare mice treated with iExosomes isolated from C57BL/6 mouse 
fibroblasts (mo WT Exosomes, n=9) and iExosomes isolated from CD47 knockout mouse fibroblasts 
(mo CD47 k/o exosomes, n=9). The data is presented as the mean +/- SEM. Unless otherwise 
stated, one-way ANOVA was used to determine statistical significance. * p<0.05, ** p< 0.01, *** 
p<0.001, **** p<0.0001.  
 
   114 
NanoSightTM, was significantly lower in the circulation of CD47 k/o mice 
compared to age-matched controls (R Fig. 19D). 
 
 
 
 
 
 
 
  
We therefore confirmed that iExosomes, when injected intra peritoneally in 
vivo go efficiently to the pancreas. When compared to liposomes, we showed 
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R Fig 19: CD47 driven phagocytosis analysis (A) Schematic representation of the CD47-
phagocytosis flow cytometry gating strategy for quantifying AF647+ monocytes/macrophages, as 
shown in R Fig 18B. (B) Flow cytometry analyses and quantification of the comparison of the 
binding efficiency of CD47 neutralizing antibodies (B6H12 and 2D3) to exosomes. Incubation of 
exosomes with the antibodies was carried out for 1 hour at RT, 1 hour at 37°C, or overnight at 
4°C, n=3 distinct batches of exosomes. (C) Flow cytometry analyses of SIRP-α (CD172a) 
expression from Alexa 647+/CD11b+ monocytes in the blood of immunocompetent adult C57BL/6 
mice 3 hours post i.p. injection. (D) Quantification of NanoSightTM analysis of the number of 
exosomes/mL in the plasma of WT C57BL/6 mice (n=5) vs. CD47 knockout mice (n=7). The data 
is presented as the mean +/- SEM. Unless stated otherwise, unpaired two-tailed t test was used to 
determine statistical significance. * p<0.05, ** p<0.01, **** p<0.0001. 
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that exosomes also enter the pancreas more efficiently.  We also showed that 
iExosomes have a significant advantage over other nanoparticles such as 
liposomes by surviving in the circulation for longer in vivo. This is in part due to 
the presence of CD47, which is found on the surface of BJ fibroblast exosomes. 
It is the ligand for signal regulatory protein alpha (SIRPα), which is expressed on 
phagocytic cells such as circulating monocytes and tissue macrophages, as well 
as dendritic cells. This CD47-SIRPα binding initiates the ‘don’t eat me’ signal that 
inhibits phagocytosis132. Finally, we show that circulating monocytes engulf 
liposomes rapidly compared to exosomes, and that the presence of CD47 on the 
surface of exosomes activates the “don’t eat me” signal, and therefore extends 
their circulation time in vivo. 
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Chapter 7: Macropinocytosis and surface proteins promote iExosomes 
uptake into tumor cells 
  
 Macropinocytosis has been shown to be a regulated form of endocytosis, 
which mediates the uptake of various nutrients, antigens and molecules146. The 
contents are usually internalized into cells via large, heterogenous vesicles called 
macropinosomes148.  In addition, endocytosis has been shown to be an important 
pathway for the uptake of exosomes by cells, in part due to exosomal 
tetraspanins such as CD9, CD63, and CD81 being ligands for endocytosis 
pathways9. Ras has been implicated in intensifying macropinocytosis, and 
therefore we sought to explore whether increased accumulation of iExosomes is 
mediated by oncogenic Ras induced macropinocytosis. 
 After intra peritoneal injection of PKH67 labeled exosomes in Panc-1 
orthotopic tumor bearing mice, an accumulation of PKH67 labeled exosomes 
was predominantly detected in established Panc-1 cancer cells of the tumors 3 
hours after the injection, with significantly less efficient accumulation in normal 
pancreatic cells (R Fig. 20A). In this regard, due to a higher accumulation of 
exosomes in tumor tissue, we evaluated the role of macropinocytosis in the 
uptake of exosomes, since oncogenic Ras cells have been shown to induce 
increased macropinocytosis. Macropinosomes were stained with high molecular 
weight dextran, and Panc-1 cells, which have a mutant Kras allele (G12D) 
displayed significantly higher macropinocytosis as compared to BxPC-3 cells, 
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which have a WT Kras allele (R Fig. 20B). EIPA (5-(N-ethyl-N-isopropyl) 
amiloride has been shown to inhibit macropinosome formation without affecting 
other endocytic pathways148. Therefore, treatment of BxPC-3 cells with EIPA 
resulted in a decrease in the number of macropinosomes, as well as a very slight 
decrease in the uptake of exosomes (R Fig. 20D). However, since the amount of 
macropinosomes was significantly more in Panc-1 cells, treatment with EIPA 
resulted in a significant dose dependent attenuation of macropinosomes (R Fig. 
20C). This attenuation of macropinosomes also resulted in a significant decrease 
in PKH67 labeled exosomes inside the cells, confirming that entry of exosomes 
into cells is in part dependent on the process of macropinocytosis (R Fig. 20C). 
In contrast however, baseline liposomal entry into cells was significantly lower as 
compared to exosomes, and liposomes uptake in Panc-1 cells was unchanged 
when macropinocytosis was inhibited, suggesting that macropinocytosis may not 
be a major pathway in liposomes entry into cells (R Fig. 20E). 
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 As we observed in R Fig 10, the efficacy of iExosomes drastically 
decreases when iExosomes are pre treated with proteinase K, to remove all 
surface proteins. In addition, previous studies have revealed the importance of 
surface proteins on exosomes for binding to cell membranes and entering cells. 
Therefore, to evaluate the entry efficiency of iExosomes, they were pre treated 
with either proteinase K or trypsin prior to adding to Panc-1 cells. Treatment with 
both resulted in significantly low AF647 accumulation inside the cells, and 
thereby confirming that the efficacy of entry of exosomes into cells is inhibited by 
removal of surface proteins (R Fig. 21A). This appeared to be independent of 
CD47 expression, as similar downregulation in CM-DiL labeled exosomes uptake 
in Panc-1 and BxPC-3 cells was noted when WT or CD47 k/o exosomes were 
used (R Fig. 21B-C). However, due to the monocyte CD47-SIRP phagocytosis 
mechanism in vivo, decreased AF647+ foci in pancreas tumors are noted when 
mice are treated with CD47 k/o iExosomes compared to iExosomes (R Fig. 
R Fig 20: Macropinocytosis increases exosomal localization in cells (A) Confocal micrographs 
(scale bar: 100µm) of increased (preferential) entry of exosomes labeled with PKH67 into tumor 
tissue, as compared to normal pancreas tissue. Labeled exosomes were injected i.p. into nude mice 
orthotopically implanted with Panc-1 cells. DAPI staining (white) identifies nuclei. Red arrows point 
to PKH67 positive cells. (B) Representative images and quantification of macropinocytic uptake in 
Panc-1 or BxPC-3 cells, unpaired two-tailed t test. (C) Representative images and quantification of 
macropinocytic and exosomes uptake in Panc-1 cells treated with vehicle (DMSO) or EIPA at the 
indicated concentrations, one-way ANOVA comparing treated groups to non-treated group (0 mM 
EIPA). (D) Representative images and quantification of macropinocytic and exosomes uptake in 
BxPC-3 cells treated with vehicle (DMSO) or EIPA at the indicated concentrations, unpaired two-
tailed t test. (E) Representative images and quantification of macropinocytic and liposomes uptake, 
unpaired two-tailed t test.  In B-E (scale bar: 50µm): TMR-dextran (red) is a marker for 
macropinosomes and PKH67 (green) is a marker for liposomes. DAPI staining (blue) identifies 
nuclei.   The data is presented as the mean +/- SEM. Unless otherwise stated, one-way ANOVA was 
used to determine statistical significance. * p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001, ns: not 
significant 
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21D), in agreement with the decreased retention of CD47 k/o iExosomes in 
circulation compared to iExosomes (R Fig.17C). 
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 As a confirmation of the previously stated results, detailed characterization 
of the pancreas of tumor bearing mice (26 days old Ptf1acre/+;LSL-
KRasG12D/+;Tgfbr2Lox/Lox mice (KTC mice)) revealed that while accumulation of 
AF647+ foci is observed in normal acini, ducts, endocrine islet and aSMA+ CAFs, 
tumor cells emerged with increased accumulation of AF647+ foci (R Fig 22). 
 
 
 
 
 
Acini Ducts Islets aSMA+ CAFs Tumor cells 
AF647+ Total AF647+ Total AF647+ Total AF647+ Total AF647+ Total 
11 62 1 3 0 1 7 36 25 33 
9 52 0 2 0 0 4 52 3 9 
17 140 2 15 2 3 4 16 15 19 
Endocrine islet Acinus Duct TumorCAFs
AF
64
7/
α
SM
A/
DA
PI
R Fig 21: Surface proteins on exosomes are vital for cellular entry (A) Representative 
micrographs (scale bar: 100µm) and relative quantification of AF647 RNAi-tagged 
exosomes/liposomes uptake in Panc-1 cells, n=3 independent experiments. Exosomes/liposomes 
were pre-treated with PBS (control), proteinase K, or trypsin prior to incubation with Panc-1 cells.  
Sytox green staining (green) identifies nuclei. The fluorescent images are overlaid onto brightfield 
capture of the cells. (B) Representative micrographs (scale bar: 100µm) and relative quantification 
of CM-DiL tagged CD47 k/o vs. WT exosomes uptake in Panc-1 cells. Exosomes were pre-treated 
with PBS (control) or proteinase K (Prot K) prior to incubation with cells.  DAPI (blue) identifies 
nuclei, n=3 independent experiments. (C) Representative micrographs (scale bar: 100µm) and 
relative quantification of CM-DiL tagged CD47 k/o vs. WT exosomes uptake in BxPC-3 cells. 
Exosomes were pre-treated with PBS (control) or proteinase K prior to incubation with cells.  DAPI 
(blue) identifies nuclei. (D) Quantification and representative images (scale bar: 100µm) of 
pancreas tissue of C57BL/6 mice injected i.p with AF647 tagged siRNA containing exosomes 
derived from either BJ fibroblast or CD47 k/o Fibroblasts, n=3 mice. DAPI staining (blue) identifies 
nuclei, arrowheads point to accumulation of label. Unpaired two-tailed t test.  The data is presented 
as the mean +/- SEM. Unless otherwise stated, one-way ANOVA was used to determine statistical 
significance. * p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001.  
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 Collectively, these results revealed an important role of macropinocytosis 
in increased accumulation of exosomes in pancreatic cancer cells displaying 
oncogenic Ras mutations. This, in part, may also explain why in tumor bearing 
mice, there is a high accumulation of exosomes in tumor tissue, as compared to 
neighboring normal parenchyma. We also revealed the importance of surface 
proteins on exosomes for entering cells. Removal of surface proteins on 
exosomes by proteinase K or trypsin treatment resulted in a significant decrease 
in the entry efficacy of iExosomes. We also confirmed that CD47 does not play a 
major role in exosomes binding to and entering cells. However, in vivo, the 
efficacy of entry of CD47 knockout exosomes is significantly reduced due to an 
increased engulfment by phagocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
R Fig 22: Exosomal localization in pancreatic tumors (A) Quantification and representative 
pictures (scale bar: 100µm) of pancreas structure (endocrine islets, acinus, duct, cancer associated 
fibroblasts (CAFs) and tumor cells) in 26 days old KTC mice that have been injected with 
exosomes electroporated with AF647 labeled siRNA, n=3 mice. Red squares define the area in 
which pancreas structure is located. The table lists the number of cells with AF647+ foci and the 
total number of cells per defined cell type, each row lists results from distinct mice. 
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Chapter 8: iExosomes significantly increase survival of KPC GEMM 
 
 The KPC (Pdx1cre/+;LSL-KRasG12D/+;LSL-Trp53R172H/+) genetically 
engineered mouse model is a very well established model in pancreatic cancer 
research. These mice develop pre malignant lesions (PanINs) that ultimately 
progress to invasive ductal adenocarcinoma with a 100% penetrance170. Unlike 
the KTC mouse model, the onset of tumor and tumor progression is considerably 
variable. However, these mice display extensive stroma and tumor morphology 
similar to what is observed in humans in the clinic. In addition, metastases is 
observed in the majority of these mice, with about 80% of mice displaying 
metastases to the liver and lung, the same sites observed in humans. These 
mice have also been observed to be notoriously resistant to chemotherapy, and 
therefore are great models for testing new drugs169. 
 Treatment of KPC mice was started when the mice reached 100 days of 
age, and continued every other day till death (R Fig. 23A). Due to the variability 
of the model, the mice were subjected to MRI to determine baseline tumor size, 
and subsequently grouped into siKrasG12D iExo or siScrbl iExo groups. Treatment 
was initiated when the tumors were 200mm3 in size (R Fig. 23B). Similar to KTC 
mice, iExosomes in KPC mice significantly enhanced survival of mice, with 132.5 
days in median survival for siScrbl iExo treated mice vs. 210 days in median 
survival for siKrasG12D iExo treated mice (R Fig. 23C). Tumor weights of control 
(scramble) treated mice (R Fig. 23D). In addition, the histopathology of the 
tumors in iExosomes treated mice was vastly improved, where tumors displayed 
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significantly more normal parenchyma, while siScramble iExo treated mice 
tumors were significantly more poorly differentiated (R Fig. 23E). 
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 Taken together, we can confirm that iExosomes show significant efficacy 
in the KPC mouse model. Compared to the previously described KTC mouse 
model, the KPC model is more variable in terms of tumor onset and progression, 
and slower, however is the most commonly used mouse model in pancreatic 
cancer due to tumor morphology that recapitulates what is observed in the clinic. 
This model has been notorious for being resistant to chemotherapy, and even 
then, iExosomes therapy significantly increased the lifespan of the mice. Treated 
mice had favorable tumor histopathology as compared to scramble controls, and 
smaller tumor burden at end point. 
 
 
 
 
 
R Fig 23: iExosomes suppress KPC tumors (A) Schematic representation of tumor progression 
timeline with experimental treatment points in Pdx1cre/+;LSL-KRasG12D/+;LSL-Trp53R172H/+ (KPC) 
mice. Treatment with BJ fibroblast derived exosomes containing KrasG12D RNAi was started on 
day 100 and treatment subsequently continued every other day. The control group was treated 
with the same concentration of siRNA scramble BJ exosomes (siScrbl iExo). (B) Tumor volume (in 
mm3 by MRI quantification) of mice in the indicated experimental groups at baseline (prior to 
treatment start). siKrasG12D iExo: n=6, siScrbl iExo: n=6. (C) Kaplan-Meier curve comparison 
indicating the survival of mice in the indicated experimental groups in KPC mice. Log-rank Mantel-
Cox test, n=6 in each group. (D) Tumor weight (g: grams) at the experimental end point. siScrbl 
iExo: n=6 mice, siKrasG12D iExo: n=6 mice. (E) Representative micrographs (scale bar: 100µm) of 
H&E stained tumors of KPC mice at the experimental end point and treated with BJ fibroblast 
derived siKrasG12D iExo or siScrbl iExo, n=6 mice per group. The data is presented as the mean ± 
SEM. Unless stated otherwise, unpaired two-tailed t test was used to determine statistical 
significance. * p<0.05.  
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Chapter 9: iExosomes inhibit advanced metastatic disease and increase 
overall survival in 689 KPC mice 
 
 Next, we evaluated the efficacy of iExosomes therapy in C57Bl/6 mice 
orthotopically implanted with KPC689 cells with advanced disease. As mentioned 
earlier, the KPC mouse model is relatively variable in terms of tumor onset and 
progression. Therefore, to get a consistent tumor onset specifically with KPC 
cells, KPC 689 cancer cell line was established from the pancreas of 
Pdx1cre/+;LSL-KRasG12D/+;LSL-Trp53R172H/+ mice (KPC) mice151. Mice that have an 
advanced disease present with either lung or liver metastases, as well as spleen 
invasion, with 100% penetrance.  
 These cells present with a KrasG12D mutation, and therefore, as a 
confirmation for treatment efficacy, KPC689 cells were treated with iExosomes in 
vitro, and KrasG12D transcript levels in KPC689 cells treated with siKrasG12D iExo 
were significantly reduced compared to control (untreated KPC689 cells in vitro) 
and KPC689 cells treated with siScrbl iExo (R Fig. 24B). Mice were 
orthotopically implanted with half a million KPC689 cells, and were monitored by 
magnetic resonance imaging (MRI) and regular abdominal examination until the 
tumor reached an advanced stage. Baseline MRI was performed at day 20-post 
tumor cell injection in C57Bl/6 mice, and treatment was started at day 32-post 
induction, when the tumor was at a significantly advanced stage (R Fig. 24A). 
Mice were treated with either siKrasG12D iExo or siScramble iExo every other day, 
and treatment of these advanced tumors significantly reduced primary tumor 
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burden in the iExosomes cohort, as measured by MRI (R Fig. 24C-D). Both 
tumor volumes and tumor weight were reduced in siKrasG12D iExo treated group 
compared to siScrbl iExo treated group, by 41.79% and 41.85%, respectively, 
despite a significantly greater tumor burden in siKrasG12D iExo treated group at 
baseline compared to siScrbl iExo treated group (control) (R Fig. 24E-F). The 
median survival was also significantly increased, with iExosomes treated mice 
having a median survival of 39 days post treatment start), while scramble 
controls had a median survival of 19 days post treatment start (R Fig. 24G).  
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Gross images taken of aged matched mice revealed significant decrease 
in tumor burden in mice treated with iExosomes as compared to scramble 
controls (R Fig. 25A). As stated earlier, due to the aggressiveness of this model, 
mice that presented with advanced disease had liver, lung and spleen invasion 
with almost 100% penetrance. However, iExosomes treatment resulted in a 
decrease in the number of macro metastatic nodules observed. Even though 
treatment was started at a late stage (day 32 post tumor cell induction), 
metastasis (lung, liver and splenic nodules) was significantly suppressed in 
siKrasG12D iExo treated mice (R Fig. 25B). More ever, repeated iExosomes 
treatment in this model did not result in a decrease in the overall weight of the 
mice, hinting about the lack of toxicity involved with iExosomes (R Fig. 25C). 
 
R Fig 24: iExosomes suppress KPC689 tumors (A) Schematic representation of tumor 
progression timeline with experimental treatment points in KPC689 mice. Baseline MRI was 
performed on day 20-post tumor cell induction, treatment with siKrasG12D iExo and siScramble iExo 
was initiated on day 32. Post treatment MRI was performed on day 48-post tumor cell induction. 
(B) Real time PCR analyses of KrasG12D transcript levels in KPC689 cells treated for 3 hours with 
siKrasG12D and siScrbl containing exosomes (iExo) (n=3 independent experiments). The fold 
change is represented relative to the expression of untreated KPC cells (Control), which was 
arbitrarily set to 1. One-way ANOVA was used for statistical comparison. (C-D) Magnetic 
Resonance Imaging (MRI) of KPC orthotopic tumors in mice treated with either siKrasG12D iExo, 
n=9 mice per group (C) and representative axial images of both groups (mean ± standard 
deviation) (D). Baseline MRI was performed at day 20 post tumor cell injection in C57BL/6 mice, 
treatment was started at day 32 post induction, and a second MRI was performed at day 48 post 
tumor induction. (E) Tumor volume as measured by MRI of siKrasG12D iExo (n=9) or siScrbl iExo 
(n=9) at baseline (Day 20 post tumor induction) and post-treatment (Day 48 post tumor induction). 
One-way ANOVA was used for statistical comparison. Note that at Day 48 post tumor induction, 
siScrbl iExo is n=8 as one mouse died prior to the second imaging session. (F) Tumor weight (g: 
grams) at the experimental end point. siScrbl iExo: n=9 mice, siKrasG12D iExo: n=8 mice (one 
mouse euthanized for age matched analysis was excluded as the tumor weight does not reflect 
the tumor burden at moribund stage). (G) Kaplan-Meier curve indicating the survival of mice post 
treatment start in the listed experimental groups. Log-rank Mantel-Cox test. siScrbl iExo group: 
n=9 mice.  In the siKrasG12D iExo group: n=9 mice at the start of the experiment, however one 
mouse was euthanized and the survival curve thus shows n=8 mice. The data is presented as the 
mean ± SEM. Unless stated otherwise, unpaired two-tailed t test was used to determine statistical 
significance. * p<0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001.  
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R Fig 25: IExosomes suppress KPC689 metastases (A) Schematic representation of tumor 
progression timeline with experimental treatment points in Pdx1cre/+;LSL-KRasG12D/+;LSL-
Trp53R172H/+ (KPC) mice. Treatment with BJ fibroblast derived exosomes containing KrasG12D RNAi 
was started on day 100 and treatment subsequently continued every other day. The control group 
was treated with the same concentration of siRNA scramble BJ exosomes (siScrbl iExo). (B) 
Tumor volume (in mm3 by MRI quantification) of mice in the indicated experimental groups at 
baseline (prior to treatment start). siKrasG12D iExo: n=6, siScrbl iExo: n=6. (C) Kaplan-Meier curve 
comparison indicating the survival of mice in the indicated experimental groups in KPC mice. Log-
rank Mantel-Cox test, n=6 in each group. (D) Tumor weight (g: grams) at the experimental end 
point. siScrbl iExo: n=6 mice, siKrasG12D iExo: n=6 mice. (E) Representative micrographs (scale 
bar: 100µm) of H&E stained tumors of KPC mice at the experimental end point and treated with BJ 
fibroblast derived siKrasG12D iExo or siScrbl iExo, n=6 mice per group. The data is presented as 
the mean ± SEM. Unless stated otherwise, unpaired two-tailed t test was used to determine 
statistical significance. * p<0.05.  
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In addition, nude mice were also injected with KPC689 cells orthotopically 
and treated with iExosomes in an attempt to define whether the 
immunocompromised background would offer superior anti-tumor responses to 
iExosomes. Repeated injection of human BJ fibroblast derived iExosomes would 
elicit a humoral response in immunocompetent mice. The tumor growth kinetics 
of KPC689 cells in nude mice was however much more aggressive than in 
immunocompetent background, rendering the comparative analyses of 
iExosomes efficacy impossible. Even then however, nude mice with KPC689 
tumors injected with iExosomes did present with a significant decrease in tumor 
burden and increased survival when treated with iExosomes (R Fig. 26 A-C). 
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 Therefore, iExosomes treatment resulted in a significant improvement in 
the lifespan of mice with an extremely aggressive tumor (KPC689). Treatment in 
these mice was started at a late stage (day 32-post tumor induction), when the 
mice presented with a significantly large tumor. Treatment with iExosomes 
resulted in a severe growth attenuation of the tumors, and favorable 
histopathology of the tumors. In addition, iExosomes treatment of these mice 
resulted in a decrease in macro-metastatic nodules in the liver, spleen and lungs. 
Detailed histology of metastasis in all these organs is yet to be performed. 
Finally, the experiment was repeated with KPC689 cells in nude mice in an 
attempt to define whether the immunocompromised background would offer 
superior anti-tumor responses to iExosomes. The kinetics of tumor take however 
was drastically different, but iExosomes did show similar efficacy in nude mice 
implanted with KPC689 cells as well. 
 
 
 
 
 
R Fig 26: iExosomes suppress KPC689 (nu/nu) tumors (A) Relative radiance of 
bioluminescent KPC689 orthotopic tumors in nu/nu mice over time, n=8 mice per group. 
Treatment was initiated on day 16-post tumor implantation. (B) Tumor weights (g: grams) of the 
mice in the indicated groups at end point, n=8 mice per group. (C) Kaplan-Meier curve comparison 
indicating the survival of mice in the indicated experimental groups in KPC689 nu/nu mice.  Log-
rank Mantel-Cox test, n=8 in each group. The data is presented as the mean ± SEM. Unless 
otherwise stated, unpaired two-tailed t test was used to determine statistical significance. ** p< 
0.01. 
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Chapter 10: CD47 is important for the anti-tumor efficacy of iExosomes in 
vivo 
  
 We have previously shown (in R Fig. 21 B-D) that entry of exosomes in 
vitro into cells is independent of CD47, however the due to the monocyte CD47-
SIRP phagocytosis mechanism in vivo, the efficacy of entry into the pancreas 
reduces drastically when CD47 is removed from the surface of iExosomes. The 
efficacy of CD47 on exosomes in vivo, in a tumor-bearing model therefore still 
needs to be analyzed.  
 Therefore as an initial experiment, luciferase transfected Panc-1 cells 
were implanted in the pancreas of nude mice. When tumors were visible by IVIS 
imaging, the mice were randomized and treated. In addition to the previously 
used treatment cohorts (PBS, Control Exo, siKrasG12D iExo/iLipo), iExosomes 
and iLiposomes were also treated with an anti-CD47 blocking antibody133, as well 
as the blocking CD47 antibody being injected directly, which has been shown to 
have anti tumor benefits133. Anti-CD47 blocking monoclonal antibodies inhibit the 
interaction between CD47 and SIRPα, thereby allowing prophagocytic signals to 
dominate, and induce phagocytosis by monocytes and macrophages133. 
 Subsequently, once tumors were established in mice, iExosomes and 
iLiposomes were administered with and without incubation with anti-CD47 
neutralizing/blocking antibodies. The efficacy of iLiposomes was unaltered with 
and without anti-CD47 antibodies incubation, since liposomes do not contain 
CD47, nor any other proteins on their surface (R Fig. 27A-C). The efficacy of 
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iExosomes was however significantly inhibited with neutralization of CD47-SIRPα 
‘don’t eat me’ signal while iExosomes by themselves showed the same efficacy 
as seen in previous experiments (R Fig. 27A-C). Anti-CD47 antibodies by 
themselves did not show significant anti-tumor efficacy (R Fig. 27A-C). These 
results therefore prove the importance of CD47 on the surface of exosomes in 
terms of treatment efficacy.  
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R Fig 27: CD47 is vital for anti-tumor efficacy of iExosomes (A) Relative radiance of 
bioluminescent Panc-1 orthotopic tumors over time, n=3 mice per group. (B) Comparative analysis 
of measured radiance of bioluminescence at day 42 (experimental end point), n=3 mice per group. 
One-way ANOVA was used and experimental groups compared to the PBS control group. (C) 
Representative images of luciferase activity of orthotopic Panc-1 tumors over time, n=3 mice per 
group. Quantitative analyses are shown in A-B. The data is presented as the mean ± SEM. * 
p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001, ns: not significant. 
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 In addition, the importance of CD47 on exosomes was also evaluated by 
using CD47 knockout exosomes in the treatment of KPC689 mice, an 
immunocompetent model. These cells were also engineered to express GFP and 
luciferase, and therefore the tumor growth kinetics could be monitored by IVIS 
imagining. Liposomes containing KrasG12D targeting siRNA were also used as a 
comparative control. As compared to the previous KPC689 experiment in 
C57Bl/6 mice, treatment was started on day 16-post tumor induction (early), as 
opposed to day 32 (late) in the previous cohort. This was to discern whether 
treatment at a comparatively early stage would have an added benefit in terms of 
tumor burden and survival. Therefore, treatment with iExosomes resulted in a 
significant attenuation of tumor growth, as compared to scramble controls. CD47 
knockout iExosomes and iLiposomes however failed to significantly suppress 
tumor growth when compared to iExosomes with KrasG12D siRNA (R Fig. 28A). 
The trend observed toward anti-tumor control with CD47 k/o iExosomes did 
translate into a significant increase in survival (median survival, 50.5 days) 
compared to Scrbl siRNA containing iExosomes (median survival, 42days), albeit 
not nearly as profound as when iExosomes were used (median survival, 
82.5days; R Fig. 28B). As compared to iExosomes with KrasG12D siRNA, CD47 
knockout iExosomes as well as iLiposomes failed to effectively suppress tumor 
growth (R Fig. 28C). Interestingly as well, the number of surface lung nodules at 
the time of euthanasia were significantly lower in the iExosomes treated mice, as 
compared to scramble controls as well as CD47 knockout iExosomes and 
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iLiposomes (R Fig. 28D). A detailed histological analysis of metastases in these 
mice is currently being performed.  
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R Fig 28: iExosomes suppress KPC689 (early) tumors (A) Relative radiance of bioluminescent 
KPC689 orthotopic tumors in C57BL/6 mice over time, n=8 mice per group. Treatment was 
initiated on day 16-post tumor implantation. (B) Tumor weights (g: grams) of the mice in the 
indicated groups at end point, n=8 mice per group. (C) Kaplan-Meier curve comparison indicating 
the survival of mice in the indicated experimental groups in KPC689 orthotopic tumors in C57BL/6 
mice. Log-rank Mantel-Cox test, n=8 mice per group. (D) Number of surface lung nodules of the 
KPC689 early experimental mice in the indicated groups at end point, n=8 mice per group. The 
data is presented as the mean ± SEM. Unless otherwise stated, one-way ANOVA was used to 
determine statistical significance. * p<0.05, ** p< 0.01, *** p<0.001, **** p<0.0001. 
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We could therefore conclude from these experiments, that CD47 is highly 
important for the efficacy of iExosomes delivery of siRNA in vivo. In both nude 
(immunocompromised) and C57Bl/6 (immunocompetent) tumor models, CD47 
knockout iExosomes showed significantly less anti-tumor efficacy, as compared 
to iExosomes. This, in part is due to these exosomes being phagocytosed to a 
higher extent due to the absence of CD47 SIRPα  interaction, and therefore 
being unable to enter pancreas tumor cells and release their cargo.  
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Chapter 11: Toxicity analysis of iExosomes treatment in vivo 
 Toxicity with any new drug is a highly important aspect to evaluate. 
Gemcitabine, which is the most commonly used drug in the treatment of 
pancreatic cancer in the clinic, either in combination, or by itself, is a 
chemotherapeutic agent. These drugs have been known to extensively affect 
multiple organ systems and induce overt toxicity. Gemcitabine for example has 
been known to be associated with multiple pulmonary toxicities, wherein the 
symptoms tend to be extremely rapid, and potentially deadly171. Therefore, a 
strict biochemical, physiological and molecular evaluation of the effects of any 
drug on an organism is a necessity.  
 Therefore, in order to eventually develop iExosomes therapy into a 
clinically applicable form, various toxicity tests are needed to evaluate the effect 
of exosomes, as well as their cargo, in pre-clinical models. Therefore, in this 
regard, three basic tests; blood urea nitrogen (BUN), aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT) were performed on healthy mice, as 
well as mice across multiple experimental cohorts treated with either iExosomes 
or control exosomes/PBS/scramble siRNA. The BUN test is used to measure the 
quantity of urea nitrogen in the blood, to discern and evaluate kidney and 
sometimes even liver function. The AST test primarily checks for liver damage by 
measuring the amount of this enzyme in the blood. High-levels of AST are 
notably associated with hepatitis and liver injury and damage.  The ALT test is 
also used to evaluate liver damage and injury, and is usually evaluated in 
conjunction with the AST test. Liver injury usually results in ALT being released 
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into the blood, and therefore high levels of ALT are also a sign of liver damage 
and injury.  
 We therefore tested mice in multiple cohorts in 689KPC and Panc-1 
orthotopic models, as well in the genetically engineered KTC model for these 
toxicity tests. Exosomes, injected with either empty, with scramble or with 
KrasG12D siRNA did not induce any overt increase in BUN levels, as compared to 
healthy controls (R Fig. 29A). Levels of AST and ALT were increased in control 
cohorts due to tumor burden, but were reduced in treatment mice, possibly due 
to lower liver damage due to tumor burden, confirming that the siRNA cargo 
targeting KrasG12D does not induce any overt liver toxicity whatsoever (R Fig. 
29B-C). This was expected, since we have previously shown the siRNA to be 
specific to only the G12D mutant transcript that is found in only tumor cells. 
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 In addition, mice from multiple cohorts with multiple treatments were 
weighed before starting treatment, as well as at the time of death/euthanasia. 
This was to gauge whether mice lost weight due to any treatment cytotoxicity. 
We found that there was no significant change whatsoever in the body weights of 
mice, pre and post treatment of siKrasG12D iExosomes, or control 
exosomes/scramble iExosomes (R Fig. 30).  
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R Fig 30: Change in body weight analyses of iExosomes treatment Change in the percentage 
of mouse body weights, pre- and post-treatment, in the listed groups and cohorts. The cohorts 
used for these analyses were the Panc-1 nu/nu long-term treatment, KTC late treatment, KTC 
early treatment, 689 KPC early treatment and KPC treatment. 
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More ever, to evaluate whether the KrasG12D specific siRNA was having an 
effect on the total Kras protein expression in other organs, we evaluated the 
expression of it in KTC mice treated with siKrasG12D iExosomes over a prolonged 
period of time (KTC early cohort). A change in the expression of total Kras 
protein in control (non electroporated) exosomes treated mice versus siKrasG12D 
iExosomes treated mice would point to cytotoxicity due to siKrasG12D not being 
specific towards only the G12D transcript. However, as expected, there was no 
change in the total Kras protein expression in the evaluated organs (liver, lung, 
spleen, kidney, heart), confirming again, that siKrasG12D iExosomes treatment 
does not induce any overt cytotoxicity due to specifically targeting only the 
mutant allele of Kras (R Fig. 31). 
To discern the possible side effects and cytotoxicity of prolonged 
exosomes injection, we injected healthy C57Bl/6 mice with either a 100 million 
exosomes (the dose used for treatment), or PBS every other day for a total of 
120 days. These mice were then euthanized, and an exhaustive panel of toxicity 
tests was performed on both groups to discover if prolonged injection of just 
exosomes by themselves caused cytotoxicity in immunocompetent mice.  
 
 
R Fig 31: Immunolabeling of Kras in multiple organs Representative pictures (scale bar: 
100µm) and quantification (for Kras immunostaining) of hematoxylin and eosin, and Kras 
immunostaining of KTC (early) mice treated with siKrasG12D iExo, control Exo or PBS, in the liver, 
lung, spleen, kidney and heart. Three to five mice were evaluated per organ studied. One-way 
ANOVA was used. 
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 As seen in the above figure, there was no significant difference in all the 
tests (Albumin, Alkaline phosphatase, ALT, AST, BUN, Globulin, Total protein, 
White blood cell count, and Red blood cell count) between mice injected with 
saline, and mice injected with empty fibroblast exosomes (R Fig. 32). Therefore, 
we could confidently conclude that injecting exosomes (100 million/injection) for a 
prolonged period of time (120days) did not induce any additional and overt 
toxicity in healthy C57Bl/6 mice. 
 
 
 
 
 
 
 
 
 
 
 
 
R Fig 32: Toxicity analyses of naked BJ exosomes treatment Cytotoxicity tests (Albumin, 
Alkaline phosphatase, ALT, AST, BUN, Globulin, Total protein, White blood cell count and Red 
blood cell count) of C57Bl/6 mice injected i.p.(every other day) with either saline or empty 
fibroblast exosomes for 120 days. PBS: n=3, Empty exosomes: n=4. The data is presented as the 
mean ± SEM. Unpaired two-tailed t-test was used to determine statistical significance. 
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Chapter 12: iExosomes in combination with anti PD-L1 antibody suppress 
pancreatic cancer progression in KTC GEMM 
  
 Immunotherapy has been successful in various pre clinical models; 
however, the efficacy has not been as significant and drastic in pancreatic 
cancer. Therefore, to study if a combination of iExosomes and immunotherapy 
would display added survival or anti tumor benefits, we combined iExosomes 
treatment in KTC mice with anti PD-L1 antibody. Anti PD-L1 monoclonal antibody 
binds to its receptor PD-1, thereby blocking its activation, and potentially 
enhancing the T-cell mediated immune response to various neoplasms and also 
reversing T-cell inactivation. We therefore started combination treatment with 
200µg of anti PD-L1 antibody and 100 million iExosomes on day 33. Three doses 
of anti PD-L1 was given every other day along with iExosomes, after which PD-
L1 treatment was suspended, and iExosomes treatment was continued till death.  
 Combination treatment of scramble iExosomes and anti PD-L1 resulted in 
a median survival of 43 days, which is consistent with the median survival of 
previous control cohorts of KTC mice, suggesting that anti PD-L1 by itself did not 
display any anti-tumoral efficacy in this model. Combination therapy of siKrasG12D 
iExosomes with PD-L1 antibody resulted in a significant increase in the lifespan 
of these mice, with the median survival being 66 days (R Fig. 33A). However, as 
compared to a previously done study of iExosomes treatment in KTC mice 
started at day 33 (median survival: 64 days), the increase in the lifespan of mice 
was extremely minimal at 2 days (R Fig. 33A). Therefore, combination treatment 
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with PDL-1 did not confer a significant survival increase in KTC mice. We did 
observe a significant decrease in tumor burden at the time of death in siKrasG12D 
IExosomes+PD-L1 mice, as compared to scramble controls (R Fig. 33B). We 
also stained the tumor for PDL-1 to confirm that PD-L1 was indeed 
downregulated in the treated mice. As expected, PD-L1 was significantly 
downregulated in siScramble IExo+PD-L1 and siKrasG12D iExo+PD-L1 mice, as 
compared to PBS controls (R Fig. 33C). 
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 However, despite these results, an in depth analysis of iExosomes 
combination with immunotherapy is required. Future experiments to analyze this 
will involve using different doses of immunotherapy monoclonal antibodies, as 
well as looking at various other models of pancreatic cancer, specifically those 
that have a high expression of PD-L1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
R Fig 33: iExosomes+anti PD-L1 suppress KTC tumors (A) Kaplan-Meier curve comparison 
indicating the survival of mice in the indicated experimental groups in KTC mice. Log-rank Mantel-
Cox test, siScramble iExo+PDL-1, n=3, siKrasG12D iExo+PDL-1, n=4. (B) Tumor weights (g: 
grams) of the mice in the indicated groups at end point, siScramble iExo+PDL-1, n=3, siKrasG12D 
iExo+PDL-1, n=4, unpaired two-tailed t-test. (C) Representative pictures (scale bar: 100µm) and 
quantification (for PD-L1 immunostaining) of KTC mice treated with siScramble iExo+PDL-1, n=3, 
siKrasG12D iExo+PDL-1, n=4, or PBS, n=5. The data is presented as the mean ± SEM.  One-way 
ANOVA was used. 
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Chapter 13: iExosomes increase the lifespan and induce regression of 
pancreatic cancer patient derived xenografts (PDX) in mice  
 
 Patient derived xenografts (PDX) mimic the heterogeneity found in tumors 
in the clinic. Cell lines used for pre-clinical trials usually represent the most 
aggressive forms of the cancer, and therefore are not completely representative 
of the heterogeneous population of cells found in human tumors172. A major issue 
put forward against these cells lines is their poor predictive value with regards to 
clinical outcomes172. Therefore, to discern whether iExosomes treatment could 
be effective in PDXs, tumors derived from patients were first sequenced for 
KrasG12D positivity. Subsequently, these tumors were passaged in mice, and 
maintained their ‘donor characteristics’. These tumors were then implanted in the 
head of the pancreas of nu/nu mice. Tumors were then imaged regularly, by both 
ultrasound and MRI. Once the average size of all tumors reached 200mm3, the 
mice were randomized into siKrasG12D iExo treatment group, and siScramble iExo 
treatment group, and were injected with the aforementioned treatments every 
other day.  
 Treatments were initiated on day 62-post tumor implantation, when the 
average tumor size was 200 mm3, as measured by both ultrasound and MRI (R 
Fig. 34B). The mice were injected every other day, until day 304-post tumor 
implantation, when all the scramble mice had died and more than half of the 
iExosomes treated mice were still alive. Post treatment suspension, the mice 
were allowed to live on for survival analysis (R Fig. 34A). Treatment with 
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iExosomes initially resulted in a stagnation of tumor growth, as seen in the first 
MRI analysis post treatment start (PTS) at day 30-post tumor implantation. 
However, MRI analysis at day 81, and subsequently day 228 PTS revealed a 
significant regression in tumor burden, with the final MRI analysis at day 228 PTS 
showing minimal tumor burden in iExosomes treated mice. Scramble iExosomes 
treated mice tumor burden continued to increase over time (R Fig. 34C-D). This 
significant decrease in tumor burden corresponded with an increase in the 
lifespan of iExosomes treated mice, as compared to scramble control (R Fig. 
34E). At the time of death, iExosomes treated mice had a significantly smaller 
tumor burden as compared to mice treated with scramble exosomes (R Fig. 
34F). Off note, two siKrasG12D iExo treated mice that were euthanized on day 254 
and 257 PTS were moribund due to old age, and had minimal tumor burden. MRI 
analyses revealed the regression in tumor burden of iExosomes treated mice, as 
compared to scramble controls, and histologically, the tumors of siKrasG12D iExo 
treated mice had significantly more normal parenchyma as well as well 
differentiated tumor areas, as compared to scramble treated mice, that displayed 
minimal to none normal parenchyma and distinct poorly differentiated tumor 
areas (R Fig. 34G). 
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R Fig 34: iExosomes suppress PDX tumors (A) Schematic representation of PDX treatment 
timeline with either siKrasG12D iExo or siScrbl iExo. Treatment was started day 62 post tumor 
implantation, and continued every other day till day 242, after which treatment was suspended. (B) 
Baseline tumor volume as measured by MRI pre-treatment start. (C) Tumor volume as measured 
by MRI of siKrasG12D iExo (n=7) or siScrbl iExo (n=7) at baseline (Day 62 post tumor induction) 
and post-treatment (Day 30, 81, 228 post treatment start). (D) Separate representation of tumor 
regression of mice treated with siKrasG12D iExo (n=7), as measured by MRI at day 0, 30, 81 and 
228 post treatment start (PTS). (E) Kaplan-Meier curve indicating the survival of PDX mice post 
treatment start (PTS) in the listed treatment groups. siKrasG12D iExo (n=7) and siScrbl iExo (n=7), 
Log-rank Mantel-Cox test. (F) Tumor weight (g: grams) at the experimental end point of PDX mice. 
siKrasG12D iExo (n=7) and siScrbl iExo (n=7). Unpaired two-tailed t-test. (G) Representative axial 
as well as hematoxylin and eosin images of both siKrasG12D iExo and siScrbl iExo treated groups. 
The data is presented as the mean ± SEM. * p<0.05. 
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Chapter 14: MSC iExosomes specifically target KrasG12D expression, induce 
apoptosis and suppress KPC 689 pancreatic cancer tumors 
 As demonstrated in all previous experiments, human BJ fibroblast 
exosomes have been utilized for in vivo pre-clinical trials. However, in the clinic, 
mesenchymal stem cell (MSC) exosomes have already been utilized for the 
treatment of various diseases. Clinical grade mesenchymal cells-derived 
exosomes were prepared and utilized for the treatment of patients with graft vs. 
host disease (GVHD), which resulted in a clinical response173. Additionally, an 
important consideration when using exosomes in therapeutics is the source of 
exosomes101. Dendritic cell (DC) exosomes, for example, have already been 
tested in the clinic for its potential as a vaccine against cancer or infectious 
diseases. A concern however, is their immunogenic potential, and therefore, their 
use would require them to be immune compatible with the host. Therefore, an 
ideal source would be non-immunogenic exosomes, such as MSCs101. Since 
MSC exosomes are already GMP grade approved, we utilized MSC iExosomes 
in pre-clinical trials, to test their anti-tumor efficacy both in vitro and in vivo.  
 MSC exosomes were obtained from mesenchymal stem cells isolated 
from donors. Flow cytometry analyses for exosomal markers CD63, CD81 and 
CD9, as well as for CD47 were performed on these exosomes, which were 
positive for all the mentioned markers (R Fig. 35A). We next explored whether 
MSC iExosomes could inhibit KrasG12D expression, as well as pancreatic cancer 
cell proliferation. In contrast to non treated Panc-1 cells, or Panc-1 cells treated 
with either non electroporated (Control Exo) MSC exosomes or MSC exosomes 
   152 
electroporated with scramble siRNA, MSC iExosomes containing siRNA targeting 
KrasG12D significantly reduced KrasG12D mRNA levels in Panc-1 human pancreatic 
cells, and MSC iExosomes mediated KrasG12D suppression was almost identical 
to the suppression observed with BJ fibroblast exosomes (R Fig. 35B). 
Subsequently, the amount of apoptosis induced by MSC iExosomes in Panc-1 
cells was also identical to what was observed and repeated with BJ fibroblast 
iExosomes (R Fig. 35C). 
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 After MSC iExosomes demonstrated identical efficacy as compared to BJ 
fibroblast iExosomes, in regards to exosomal markers, inhibition of KrasG12D 
mRNA transcript, and Panc-1 cancer cell apoptosis, we evaluated the efficacy of 
MSC iExosomes in vivo, by treating the aggressive KPC689 orthotopic model 
with MSC, as well as BJ iExosomes. Treatment was started on day 32-post 
tumor induction, when the mice displayed palpable aggressive tumors. Similar to 
previous in vivo experimental methods, treatment was initiated and continued 
every other day till death. Due to the severe aggressiveness of the tumors, mice 
treated with MSC empty exosomes (Control Exo) had a median survival of 41 
days-post tumor cell induction, whereas mice treated with MSC iExosomes had a 
median survival of 81 days, and with BJ iExosmes, a median survival of 75 days 
(R Fig. 36A). Tumor burden was also significantly decreased in both iExosomes 
(MSC and BJ) groups as compared to controls (R Fig. 36B). Interestingly, the 
number of macroscopic lung nodules was significantly lower in both iExosomes 
treated groups. Spleen, liver, kidney and diaphragm invasion was also 
significantly decreased in the iExosomes treated cohorts (R Fig. 36C). 
 
R Fig 35: Efficacy of MSC iExosomes in vitro (A) Flow cytometry analyses of CD81, CD63, 
CD9 and CD47 of exosomes derived from MSCs. (B) Real time PCR analyses of KRASG12D 
transcript levels in Panc-1 cells (n=3 independent experiments) treated for 3 hours with siKrasG12D 
iExo, siScramble containing exosomes (iExo) or non-electroporated exosomes (empty cargo, 
control Exo). BJ and MSC exosomes were compared for each group. The fold change is 
represented relative to the expression of untreated Panc-1 cells (Untreated), arbitrarily set to 1. 
(C) Quantification of flow cytometry analyses of apoptosis in Panc-1 cells treated with either 
siKrasG12D iExo, siScramble containing exosomes (iExo) or non-electroporated exosomes (empty 
cargo, control Exo). BJ and MSC exosomes were compared for each group. The data is presented 
as the mean ± SEM. Unless otherwise stated, one-way ANOVA was used to determine statistical 
significance. **** p<0.0001. (These experiments were performed with the help of Mayela Mendt 
PhD) 
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R Fig 36: MSC IExosomes suppress KPC689 tumors (A) Kaplan-Meier curve comparison 
indicating the survival of mice in the indicated experimental groups in KPC689 mice. Log-rank 
Mantel-Cox test, MSC Control Exo: n=4, BJ iExo: n=6, MSC iExo: n=6. (B) Tumor weights (g: 
grams) of the mice in the indicated groups at end point. (C) Number of surface lung nodules of the 
KPC689 experimental mice in the indicated groups at end point, as well as a tabular 
representation of cancer cell invasion in the lung, spleen, liver, diaphragm and kidney, in the 
indicated groups at end point. The data is presented as the mean ± SEM. Unless otherwise 
stated, one-way ANOVA was used to determine statistical significance. 
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 With a view to translate iExosomes therapy into the clinic with 
mesenchymal stem cell exosomes, we sought to evaluate the efficacy of MSC 
iExosomes treatment, both in vitro and in vivo. MSC exosomes express the 
exosome markers CD81, CD63 and CD9, while also expressing CD47. 
Expression of all markers is similar to what is observed with BJ fibroblast 
exosomes. Treatment efficacy with MSC iExosomes in vitro was almost identical 
to what is observed with BJ iExosomes, in terms of downregulation of KrasG12D 
mRNA expression and Panc-1 cancer cell apoptosis. In the treatment of KPC689 
orthotopic mice in vivo, the efficacy of MSC iExosomes was very similar, albeit 
even slightly better than BJ IExosomes, in terms of survival, decrease in tumor 
burden and a reduction in lung metastatic nodules.  
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Summary of Results: 
 The mutant form of the GTPase KRAS is a key driver of pancreatic 
cancer, but despite efforts to target it, it remains a challenging therapeutic target. 
Exosomes, extracellular vesicles generated by all cells, are naturally present in 
the blood. Here we demonstrate that enhanced retention of exosomes in 
circulation, compared to liposomes, is due to CD47 mediated protection of 
exosomes from phagocytosis by monocytes and macrophages. Binding of 
exosomal CD47 to SIRPα initiated the ‘don’t eat me’ response, thereby allowing 
injected exosomes to remain in the circulation longer. Exosomes derived from 
normal fibroblast-like mesenchymal cells were engineered to carry siRNA or 
shRNA specific to oncogenic KRASG12D (iExosomes), a common mutation in 
pancreatic cancer. Compared to liposomes, iExosomes target oncogenic Kras 
with an enhanced efficacy that is dependent on CD47, and is facilitated by 
macropinocytosis. iExosomes treatment suppressed cancer in multiple xenograft 
and genetically engineered mouse models. Treatment increased the lifespan 
considerably in all models, and importantly was specific only towards the G12D 
allele. This allelic specificity, along with exosomes being a natural cell product, 
lead to minimal pharmacokinetic toxicity in all mouse models. Significantly, 
iExosomes treatment also induced regression of patient derived xenografts 
(PDX), which were sequenced for the G12D allele. MSC iExosomes also 
demonstrated identical efficacy, as compared to BJ iExosomes. Our results, 
therefore, inform on a novel approach for direct and specific targeting of 
oncogenic Kras in tumors using iExosomes.  
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Chapter 15: Summary and Discussion 
 
 Decades of research to establish a link between genetic alterations and 
cancer have led to the identification of many genes with mutations, deletions and 
rearrangements that contribute to the initiation and progression of cancer. Among 
them, mutations in the Kras gene are considered key events responsible for the 
initiation of cancer in the pancreas, lung and colon, among others25,174.  
Oncogenic KRAS mutations (G12D, G12V and G12C) have emerged as 
sufficient drivers of pancreas cancer and are associated with activation of 
downstream effectors such as MEK, Akt and Erk, among others28,29,34,43,45,174-176. 
Efforts have therefore been made to target the downstream effector pathways to 
target tumor cells. However, more often than not, targeting one specific pathway 
leads to another pathway becoming hyperactive, thereby promoting various 
escape and resistance mechanisms. Targeting multiple pathways at once also 
increasingly builds up toxicity associated with the drugs. Therefore, many such 
compelling cell biological, molecular and genetic studies have established a 
sound rationale for targeting Ras for the treatment of cancer90,177,178. But Ras has 
remained largely undruggable, partly due to its complicated structure and 
biochemistry46. A few studies showed some efficacy with methodologies 
developed to target oncogenic Kras using siRNA molecules88,90,156,179, but these 
approaches may have been limited by lack of specificity and inefficient delivery. 
Therefore, there is a need to translate efficient knockdown of oncogenic Kras 
from in vitro models to pre-clinical and clinical settings by developing new drug 
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delivery systems that can efficiently deliver the RNAi cargo to the tumor cells of 
interest. Nonetheless, a recent clinical study demonstrated that siG12D-
LODERTM (siRNA against KrasG12D in the biodegradable polymeric matrix Local 
Drug EluteR or LODERTM) were well tolerated and showed potential efficacy in 
pre-clinical sub cutaneous and orthotopic mouse models, and subsequently in 
patients with locally advanced pancreas cancer180. An issue however with this 
technology is that the treatment is restricted to only localized sites of tumors, and 
will not work in patients with advanced disease and subsequently metastases. 
Therefore, there is a need for an efficient RNAi delivery system. 
 
Exosomes as a drug delivery system: 
Exosomes are natural by products of cells, and are released by all cells in 
the body. Our study suggests that exosomes can serve as an optimal delivery 
system to deliver drugs to target oncogenic Ras as a viable treatment option for 
patients.  In this study, we report that a dosage of iExosomes (approximately 108 
exosomes or 0.15-0.20 μg of exosomal protein per injection) can control 
advanced PDAC in mouse models of pancreas adenocarcinoma. Importantly, 
approximately 0.5 to 1.6 mg of clinical grade mesenchymal cells-derived 
exosomes were readily prepared and multiple doses administered (every 2-3 
days) to a patient with graft vs. host disease (GVHD), resulting in a clinical 
response173. Therefore, an anticipated production of clinical grade iExosomes for 
the treatment of patients with PDAC is feasible.  
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Our experimental results suggest that exosomes exhibit a superior ability 
to deliver RNAi molecules and suppress tumor growth when compared to 
liposomes. Unlike liposomes, exosomes contain natural plasma membrane-like 
phospholipids (with phosphatidylserine and cholesterol on the cytosolic side) 
associated with membrane-anchored proteins. The phospholipid bilayer of 
exosomes may contribute to their diminished clearance from the circulation, 
possibly due to reduced interaction with opsonins, and coagulation and 
complement factors recognized by monocyte/macrophage for phagocytosis181-183. 
Our results also support that the presence of CD47 on exosomes allows for 
evasion from phagocytosis by the circulating monocytes. Increased half-life in the 
circulation further enables exosomes to reach more parenchymal cells in the 
pancreas. Mice that are deficient of CD47 circulate approximately half the 
number of exosomes than wild-type mice. These experiments suggest CD47 
plays a role of survival of exosomes in the blood, it also suggests that other 
proteins might also function to enhance the lifespan of exosomes in the 
circulation, giving exosomes a natural advantage over other synthetically made 
nanoparticles. 
 Additionally, our experiments show that CD47 does not play a significant 
role in the entry of exosomes into pancreatic cells. These nano vesicles contain 
multiple tetraspanins and transmembrane proteins that likely enhance 
endocytosis, thus enhancing the delivery of their internal content99,162. 
Additionally, the increased number of exosomes reaching the pancreas may gain 
further advantage to enter oncogenic Kras-associated cancer cells as a result of 
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enhanced macropinocytosis, and our results indicating enhanced uptake of 
exosomes in oncogenic Kras expressing cancer cells in association with 
increased macropinocytosis concurs with previous findings9,148. Our results also 
support an efficient uptake of iExosomes despite the stroma dense features of 
pancreas tumors. Previous studies have revealed stroma to be detrimental to the 
delivery of drugs to pancreatic tumor cells184. Whether exosomes entering cells 
via this mechanism (macropinocytosis) protect themselves from lysosome 
dependent degradation of their content needs further exploration.  
 
Efficacy of exosomes as a drug delivery system in pancreatic cancer: 
 Our studies revealed the efficacy of iExosomes treatment in pancreatic 
cancer. By establishing exosomes as a drug delivery system, we packaged 
oncogenic Kras specific RNAi into the exosomes to deliver to tumor cells. By 
utilizing the orthotopic Panc-1 model in nude mice, we established that 
exosomes were an efficient delivery system in vivo. A study of iExosomes 
treatment in the orthotopic BxPC-3 model revealed the specificity of the G12D 
targeting RNAi. This was especially important considering that the exosomes 
were not targeted, and therefore travel to other sites and organs besides the 
pancreas. However, due to the RNAi being specific only towards the oncogenic 
allele of Kras, exosomal release of it into other cells did not cause any toxicity. 
This is especially important considering the overwhelming interest of targeted 
therapies, and minimizing drug cytotoxicity in pre-clinical and clinical trials. 
iExosomes therapy was also effective in significantly increasing the lifespan and 
   161 
attenuating the rate of growth of tumor in spontaneous and aggressive 
genetically engineered mouse models. These models are known to be replicative 
of the histology observed in human pancreatic cancers, and subsequently a vast 
improvement in the histopathology of GEMM tumors was also observed with 
iExosomes treatment. By utilizing the highly aggressive and metastatic KPC689 
orthotopic model, we confirmed the anti-tumor efficacy of iExosomes on late 
stage tumors as well.  
In addition, the metastatic and invasion readout in the lungs, liver and 
spleen in iExosomes treated mice was significantly lower as compared to 
controls. This was an encouraging result, since in addition to targeting the 
primary tumor; iExosomes can also be designed to target metastatic secondary 
tumors as well. Especially in pancreatic cancer, the route of injections could be 
potentially changed, or even an additional different route added to target the 
highly metastatic sites such as the liver and lung. However, further exhaustive 
testing of the efficacy of iExosomes treatment for secondary metastatic tumors in 
pre-clinical models is needed. 
Finally, to have a representation of the heterogeneity of mutations and 
cells found in human pancreatic tumors, patient derived xenografts sequenced 
for KrasG12D (and implanted in nu/nu mice) were treated with iExosomes. 
Encouragingly, iExosomes treatment induced a high tumor regression in this 
model, and significantly increased the lifespan of these mice. These mice also 
showed minimal to no signs of cytotoxicity from more than 120 doses of 
iExosomes. 
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Comparison of iExosomes as a monotherapy, versus other anti cancer agents in 
pancreatic cancer: 
 The KPC (Pdx1cre/+;LSL-KRasG12D/+;LSL-Trp53R172H/+) genetically 
engineered mouse model is a very well established model in pancreatic cancer 
research. It is also the most frequently used pre-clinical model in the pancreatic 
cancer field due to its tumor histology recapitulating what is observed in the 
clinic, as well as being notoriously resistant to Gemcitabine. We therefore 
compared the median survival post treatment start (PTS) of iExosomes in KPC 
mice versus other published agents that have been sanctioned for clinical trials. 
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 Due to the variability of tumor onset of this model, most treatments are 
started when the tumors reach around 200mm3. The Evans and Tuveson group 
have shown that Gemcitabine alone increases the median survival of KPC mice 
by only 15 days PTS, as compared to non-treated KPC mice167,169. Gemcitabine 
in combination with IPI-926, an inhibitor of stromal tissue that targets the 
Hedgehog signaling pathway increased the median survival by 28 days PTS169. 
Gemcitabine in combination with Calcipotriol, a vitamin D receptor ligand, 
increased survival by 32 days167. Anti CD40 monoclonal antibody, in combination 
with Gemcitabine, Nab Paclitaxel and anti PD-1 increased the overall median 
survival by 45 days185, while t-cell therapy by the Hingorani group increased 
survival by 97 days186. All these agents are, or have been in the clinical trial 
phase. Encouragingly, iExosomes treatment, just as a monotherapy, increased 
the overall median survival of KPC mice by 110 days, which is significantly longer 
than all the aforementioned treatments. Therefore, even though this is a very 
rough comparison estimate, we believe our study and treatment can potentially 
increase the overall median survival of patients suffering from pancreatic cancer. 
 Additionally, combining iExosomes with either immunotherapy or 
chemotherapy, to potentially induce further and faster regression of tumors, will 
need to be studied extensively. iExosomes treatment in combination with anti 
PD-L1 monoclonal antibody did not seemingly increase the overall survival of 
mice, as compared to just iExosomes monotherapy. However, multiple factors 
such as the dosage of PD-L1, or combining with anti CTLA-4 or anti PD-1 will 
need to be studied further, to get a proper understanding of iExosomes therapy 
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combination with immunotherapy. Furthermore, since Gemcitabine is the current 
standard of treatment in pancreatic cancer, combining iExosomes targeting 
oncogenic Kras with Gemcitabine may potentially lead to better anti-tumor 
effects, as compared to the anti-tumor affects of both drugs alone. Its has been 
shown that inhibiting downstream pathways of oncogenic Ras such as the 
MEK/ERK pathway leads to sensitizing tumor cells to Gemcitabine, thereby 
increasing its efficacy187. Subsequently, targeting oncogenic Kras by iExosomes, 
and not just individual downstream pathways, may even possibly sensitize tumor 
cells further to Gemcitabine. Therefore, such combination therapies along with 
iExosomes need to be studied exhaustively.  
 
Targeting multiple other mutations and types of cancers by iExosomes: 
 Based on the same hypothesis we have put forward and studied, it is 
indeed possible to target the G12D mutation in other forms of cancer. For 
example, around 45% of colorectal cancers have a mutation in the G12D allele; 
while around 20% of all Non-small cell lung carcinoma’s (NSCLC) have a 
KrasG12D mutation7. Therefore it is imperative to evaluate the efficacy of 
iExosomes targeting KrasG12D in pre-clinical models of the aforementioned 
cancers. Dosage and/or route of injection may have to be changed based on 
initial results in pre-clinical models of these types of tumors.   
In addition, it is highly possible to edit the cargo of exosomes based on the 
mutations being targeted. As mentioned earlier, Kras is the most frequently 
mutated isoform in all cancer, wherein around 22% of all tumor types have a 
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mutation in Kras54. Therefore, it is indeed possible to design and target other 
Kras mutant alleles such as G12V (second most frequent Kras mutation in 
pancreatic cancer) or G12C (most frequent Kras mutation in NSCLC). 
Subsequently, these can either be used as a monotherapy, or in combination 
with KrasG12D targeting iExosomes to account for the heterogeneity of mutations 
found in the clinic. Also, importantly, it may additionally be possible to target 
mutations other than Kras, such as c-Myc, that are increasingly prevalent in other 
types of cancers.  
 
Scaling up for clinical trials: 
 Currently, isolation of exosomes is based on cell culture techniques and 
methods, wherein the dose of exosomes being injected per mouse per day is 108 
exosomes. Additionally, human BJ fibroblast exosomes are currently being 
utilized for in vivo pre-clinical trials. However, in the clinic, mesenchymal stem 
cell (MSC) exosomes have already been vastly studied and utilized for the 
treatment of various diseases. As stated above, about 0.5 to 1.6 mg per dose of 
clinical grade mesenchymal cells-derived exosomes were prepared and utilized 
for the treatment of patients with graft vs. host disease (GVHD), which resulted in 
a clinical response. Multiple doses of these exosomes were administered 
repeatedly (every 2-3 days)173. Since there is already experience in the field in 
using MSC exosomes, in addition to already being GMP grade approved, using 
MSC exosomes for packaging KrasG12D siRNA, in view of human clinical trials, is 
the next step forward. 
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 Therefore, to scale-up iExosomes for human clinical trials, each dose 
would have to be at around 5x1011 exosomes per injection. In our hands, a large 
cell culture flask of MSC’s generates around 1010 exosomes, which is sufficient 
for pre-clinical trials using mouse models, but not acceptable for human trials. 
Cell culture bioreactors however, have a production scale of 2000 liters (as 
compared to 25mL from one flask), and therefore the capability of isolating MSC 
exosomes is increased exponentially. We are therefore able to isolate 3-4x1012 
MSC exosomes in one round with a bioreactor. Subsequently, using multiple 
rounds of a bioreactor will generate an adequate amount of exosomes for the 
purpose of clinical trials. Additionally, large-scale electroporation devices, 
capable of electroporating large volumes, are being tested for their siRNA 
loading efficiency. 
 
 
Collectively, our studies have offered an insight into the therapeutic 
potential of exosomes in the specific targeting of oncogenic Kras in pancreatic 
cancer. While we focused specifically on pancreatic cancer, the methods and 
technology we have studied and developed makes it possible to use exosomes 
as a delivery system for a multitude of mutations, cancers and disorders. 
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